Document:

exv10w44

Exhibit 10.44

AMENDED AND RESTATED LICENSE AGREEMENT (2008)

This amended and restated agreement is between Biomira Management Inc., a Delaware corporation with
offices located at Seattle, Washington (“ONCOTHYREON”), and Merck KGaA, a German corporation with
offices located at Darmstadt, Germany (“MERCK”) and is effective as of December 18, 2008.

WHEREAS Biomira B.V. and MERCK entered into an amended and restated collaboration agreement
effective as of May 7, 2001 (the “2001 COLLABORATION AGREEMENT”) in relation to, inter alia, the
development of BLP25;

AND WHEREAS Biomira International Inc. and MERCK entered into an amended and restated supply
agreement effective as of May 7, 2001 (the “2001 SUPPLY AGREEMENT”) in relation to, inter alia, the
manufacture and supply by Biomira International Inc. to MERCK of BLP25;

AND WHEREAS the 2001 COLLABORATION AGREEMENT was further amended and restated by the parties
thereto by agreement effective as of March 1, 2006 (the “2006 COLLABORATION AGREEMENT”);

AND WHEREAS the 2001 SUPPLY AGREEMENT was further amended and restated by the parties thereto by
agreement effective as of March 1, 2006 (the “2006 SUPPLY AGREEMENT”);

AND WHEREAS on December 7, 2007, the respective rights and obligations of Biomira B.V. and Biomira
International Inc. under the 2006 COLLABORATION AGREEMENT and the 2006 SUPPLY AGREEMENT were
transferred and assigned to ONCOTHYREON;

AND WHEREAS ONCOTHYREON and MERCK now wish to combine and amend and restate the 2006 COLLABORATION
AGREEMENT and the 2006 SUPPLY AGREEMENT as a single amended and restated license agreement, all
upon the terms and subject to the conditions set forth in this AGREEMENT;

AND WHEREAS, ONCOTHYREON (and certain AFFILIATES of ONCOTHYREON) and EMD Serono Canada, Inc. (an
AFFILIATE of MERCK), in conjunction with entering into this AGREEMENT, have entered into an asset
purchase agreement (the “ASSET PURCHASE AGREEMENT”) pursuant to which ONCOTHYREON and the specified
AFFILIATES of ONCOTHYREON have sold certain assets relating to BLP25 to EMD Serono Canada, Inc.;

NOW, THEREFORE, in consideration of the premises and covenants contained herein and other good and
valuable consideration, the receipt and sufficiency of which is hereby agreed to by the parties,
and intending to be legally bound hereby, the parties hereto agree as follows:

ARTICLE 1

DEFINITIONS

Section 1.1 Meaning

Whenever a term is written in this AGREEMENT with all capital letters it shall have the following
meaning:

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

2

	 	1.1.1	 	“ADVERSE EVENT” means, with respect to PRODUCT in a particular country in the
TERRITORY, the occurrence of an adverse event with respect to PRODUCT as defined by
applicable law or regulation in such country;
	 
	 	1.1.2	 	“AFFILIATES” means any business entity that directly or indirectly controls,
is controlled by, or is under common control with either party to this AGREEMENT. A
business entity shall be deemed to “control” another business entity if it owns,
directly or indirectly, more than fifty (50%) percent of the outstanding voting
securities, capital stock, or other comparable equity or ownership interest of such
business entity. If the laws of the jurisdiction in which such business entity
operates prohibit ownership by a party of more than fifty percent (50%), control shall
be deemed to exist at the maximum level of ownership allowed by such jurisdiction;
	 
	 	1.1.3	 	“AGREEMENT” means this amended and restated license agreement, together with
all schedules and appendices hereto and any amendments to or restatements of this
amended and restated license agreement;
	 
	 	1.1.4	 	“ASSET PURCHASE AGREEMENT” has the meaning attributed to that term in the
seventh recital to this AGREEMENT;
	 
	 	1.1.5	 	“BLP25” means ONCOTHYREON’s immunotherapeutic vaccine composed of a 25-amino
acid sequence of the MUC1 cancer mucin, which vaccine is combined with the adjuvant
monophosphoryl Lipid A and is encapsulated in a liposomal delivery system, together
with (i) any IMPROVEMENTS thereto (such as liposomal IL-2 in a kit, synthetic Lipid A,
or new delivery formats such as unit dose liquid formulations and unit dose syringes)
owned by ONCOTHYREON or licensed in by ONCOTHYREON during the term of this AGREEMENT
with the right to sublicense in the manner contemplated by this AGREEMENT and (ii) any
PRODRUG thereof;
	 
	 	1.1.6	 	“BGLP40” means any variant of ONCOTHYREON’s (or its AFFILIATES’)
immunotherapeutic vaccine composed of two tandem repeats of the MUC1 cancer mucin,
whether or not glycosylated, and whether or not lapidated, which vaccine is combined
with an adjuvant and is encapsulated/incorporated in a liposomal delivery system,
together with any improvements thereto owned by ONCOTHYREON (or its AFFILIATES) or
licensed in by ONCOTHYREON (or its AFFILIATES);
	 
	 	1.1.7	 	“CLINICAL DEVELOPMENT” means all activities required for MARKET APPROVAL of
PRODUCT in the TERRITORY (including without limitation non-clinical and clinical
trials, including but not limited to, toxicology and absorption, distribution,
metabolism and elimination studies), as well as all clinical activities desirable for
optimized marketing of PRODUCT in the TERRITORY (including without limitation Phase
IIIb and Phase IV studies);

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

3

	 	1.1.8	 	“COMPETITIVE PRODUCT” means, with respect to PRODUCT in a particular country
in the ROW TERRITORY, a cancer vaccine developed, marketed and SOLD by a third party
(which, for greater certainty, shall exclude an AFFILIATE of a party to this AGREEMENT)
for the treatment and/or prevention of cancer that elicits a MUC1 specific immune
response (but excluding for greater certainty gene therapy products) and which has an
adverse impact on SALES of PRODUCT in such country;
	 
	 	1.1.9	 	“CONFIDENTIAL INFORMATION” has the meaning attributed to that term in section
8.1 of this AGREEMENT;
	 
	 	1.1.10	 	“CORE PATENT COUNTRIES” shall mean the countries listed in appendix 1;
	 
	 	1.1.11	 	“CORIXA LICENSE” means that certain adjuvant license agreement dated as of October
20, 2004 with Corixa Corporation, together with all schedules thereto and any
amendments to or restatements of such adjuvant license agreement;
	 
	 	1.1.12	 	“DANA-FARBER LICENSE” means that certain license agreement dated November 22, 1996
with the Dana-Farber Cancer Institute, Inc., together with all schedules thereto and
any amendments to or restatements of such license agreement;
	 
	 	1.1.13	 	“DEVELOPMENT PLAN” shall mean the development plans contemplated in section 3.1 of
this AGREEMENT;
	 
	 	1.1.14	 	“DISTRIBUTOR” means, with respect to PRODUCT in a particular country in the
TERRITORY, a third party retained to market, promote and/or sell PRODUCT in such
country, but excluding for greater certainty wholesalers and any such third party in
circumstances where the laws of such country require the use of such third party to
market, promote and/or sell PRODUCT in such country;
	 
	 	1.1.15	 	“DOMAIN NAMES” has the meaning attributed to that term in section 5.12.6 of this
AGREEMENT.
	 
	 	1.1.16	 	“EFFECTIVE DATE” shall mean December 18, 2008, or such other date as ONCOTHYREON and
MERCK may agree upon in writing;
	 
	 	1.1.17	 	“END USER” shall mean, with respect to PRODUCT, any person at arm’s length with MERCK
and its AFFILIATES that acquires PRODUCT in final form for end use, including
physicians and hospitals but excluding DISTRIBUTORS and other agents;
	 
	 	1.1.18	 	“FIELD” shall mean the use of BLP25 for the prevention and/or treatment of cancers in
humans;
	 
	 	1.1.19	 	“ICRT LICENSE” means that certain amended and restated license agreement dated
November 14, 2000 with Imperial Cancer Research Technology Limited

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

4

	 	 	 	(now Cancer Research Technology Limited), together with all schedules thereto and
any amendments to or restatements of such license agreement;
	 
	 	1.1.20	 	“IFRS” means international financial reporting standards, consistently applied;
	 
	 	1.1.21	 	“IMPROVEMENTS” means, collectively, all inventions, discoveries, improvements or
other technology in the FIELD and all processes or uses relating thereto, whether or
not patentable, that arise after the ORIGINAL EFFECTIVE DATE as a result of conduct
under this AGREEMENT and relate directly to BLP25. For clarity, IMPROVEMENTS shall not
include any inventions, discoveries, improvements or other technology that ONCOTHYREON,
develops or acquires to the extent covering any active compound that is separate and
clearly distinct from BLP25, notwithstanding the fact that such active compound may be
useful as part of a combination therapy with BLP25. For further clarity, BGLP40 shall
be deemed not to be an IMPROVEMENT;
	 
	 	1.1.22	 	“INDICATION” means a specific health care indication (e.g., non-small cell lung
cancer) for which PRODUCT is, as indicated on the label for the PRODUCT, specified for
the treatment and/or prevention thereof;
	 
	 	1.1.23	 	“JOINT IMPROVEMENT PATENT RIGHTS” has the meaning attributed to that term in section
10.1.1 of this AGREEMENT;
	 
	 	1.1.24	 	“JOINT IMPROVEMENTS” has the meaning attributed to that term in section 9.1 of this
AGREEMENT;
	 
	 	1.1.25	 	“LAUNCH” shall mean, with respect to PRODUCT in a particular country in the
TERRITORY, the date of the first arms’ length sale of PRODUCT in such country after
receipt of MARKET APPROVAL for PRODUCT in such country;
	 
	 	1.1.26	 	“MAJOR MARKET” shall mean any one of Germany, France, United Kingdom, Italy, Spain or
Japan, and “MAJOR MARKETS” shall mean all of such countries;
	 
	 	1.1.27	 	“MARKET APPROVAL” shall mean, with respect to PRODUCT in a particular country in the
TERRITORY, the date upon which the last of all governmental or regulatory approvals
required for the sale of PRODUCT in that country has been granted, including price
approval for the PRODUCT (if required);
	 
	 	1.1.28	 	“MARKETING PLAN” shall mean the marketing plans contemplated in section 3.1 of this
AGREEMENT;
	 
	 	1.1.29	 	“MERCK COST OF GOODS” includes, but is not limited to, with respect to PRODUCT in the
TERRITORY, reasonable direct material, labour and subcontracted costs incurred by or on
behalf of MERCK in connection with the procurement of raw materials, manufacture,
vialing, testing, stability, releasing and shipment of PRODUCT, as well as the
reasonable indirect costs of administration, salary, support, depreciation, facility
rental, facility repair and

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

5

	 	 	 	maintenance, facility utilities, insurance and facility property taxes attributable
to PRODUCT;
	 
	 	1.1.30	 	“MERCK IMPROVEMENTS” has the meaning attributed to that term in section 9.3 of this
AGREEMENT;
	 
	 	1.1.31	 	“MERCK MANUFACTURING ACTIVITIES” has the meaning attributed to that term in section
9.10 of this AGREEMENT;
	 
	 	1.1.32	 	“MERCK OFFER” has the meaning attributed to that term in section 2.7.2 of this
AGREEMENT;
	 
	 	1.1.33	 	“MUC1” means cancer associated mucin-1;
	 
	 	1.1.34	 	“NA TERRITORY” shall mean, collectively, Canada (including Quebec) and its
territories and the United States of America and its territories;
	 
	 	1.1.35	 	“NEGOTIATION PERIOD” has the meaning attributed to that term in section 2.7.2 of this
AGREEMENT;
	 
	 	1.1.36	 	“NET SALES” shall mean, with respect to PRODUCT in a particular country, the sum of
the gross amounts invoiced for all SALES (directly or indirectly) by MERCK, its
AFFILIATES and their respective sublicensees, DISTRIBUTORS, assignees and transferees
of PRODUCT to END USERS, less the following deductions from such invoiced amounts which
are actually incurred in accordance with IFRS:

	 	1.1.36.1	 	credits or allowances actually granted for spoiled or damaged PRODUCT or
with respect to returned or rejected PRODUCT, and for retroactive price
adjustments;
	 
	 	1.1.36.2	 	normal and customary trade, cash and quantity discounts, allowances,
rebates and credits actually allowed, including allowances, adjustments,
reimbursements, discounts, chargebacks and rebates given to healthcare
organizations and any governmental or quasi-governmental body or agency,
whether during the actual SALES/royalty period or not;
	 
	 	1.1.36.3	 	sales, value added or similar taxes measured by the billing amount, when
included in billing;
	 
	 	1.1.36.4	 	freight, postage, shipping, and insurance charges related to delivery of
PRODUCT from the applicable MERCK/distributor warehouse measured by the billing
amount, when included in billing; and
	 
	 	1.1.36.5	 	import and export duties actually paid.

Any refund or reimbursement of any of the foregoing amounts previously deducted from
NET SALES shall be appropriately credited upon receipt thereof.

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

6

If PRODUCT is SOLD in combination with another product or products (for greater
certainty the use of adjuvant or other such PRODUCT enhancer stipulated to be mixed
with PRODUCT shall not be considered to be “another product” for purposes of this
section 1.1.36), “NET SALES” under such circumstances shall be calculated by
multiplying the “NET SALES” of the combination by the fraction A/(A + B), in which A
is the amount invoiced for PRODUCT when SOLD separately, and B is the total amount
invoiced for any other product or products in combination when SOLD separately;

	 	1.1.37	 	“ONCOTHYREON IMPROVEMENTS” has the meaning attributed to that term in section 9.2 of
this AGREEMENT;

	 	1.1.38	 	“ONCOTHYREON KNOW-HOW” means all proprietary information and data in the FIELD
including but not limited to compounds, formulae, protocols, methods, techniques and
results of experimentation and testing, which, except for published patent applications
which are also included within this definition, is generally not known to the public,
and which are owned by ONCOTHYREON or licensed in by ONCOTHYREON with the right to
sublicense in the manner contemplated by this AGREEMENT, and which directly relate to
research, CLINICAL DEVELOPMENT, use and/or sale of PRODUCT and/or the manufacture of
PRODUCT. For greater certainty, ONCOTHYREON KNOW-HOW shall include ONCOTHYREON
IMPROVEMENTS and IMPROVEMENTS licensed in by ONCOTHYREON with the right to sublicense
in the manner contemplated by this AGREEMENT, which arise or occur after the ORIGINAL
EFFECTIVE DATE and which fall within the ambit of the preceding sentence.
Notwithstanding the foregoing, ONCOTHYREON KNOW-HOW shall not include any subsequently
developed or acquired ONCOTHYREON KNOW-HOW to the extent covering any active compound
that is separate and clearly distinct from PRODUCT, notwithstanding the fact that such
active compound may be useful as part of a combination therapy with PRODUCT;

	 	1.1.39	 	“ONCOTHYREON PATENT RIGHTS” means all rights in the FIELD owned by ONCOTHYREON or
licensed in by ONCOTHYREON with the right to sublicense in the manner contemplated by
this AGREEMENT in any of the following patents: any patent issuing on any patent
application identified in appendix 2, as well as any patent issuing from any continuing
applications of the patents listed in appendix 3, such applications including any
divisions, continuations, and continuation-in-part applications, as well as any patents
issuing on any reissue and/or reexamination application, and including any patent term
restoration or extension (i.e. supplemental protection certificates) of any such
patents. ONCOTHYREON PATENT RIGHTS also includes all rights in the FIELD owned by
ONCOTHYREON or licensed in by ONCOTHYREON with the right to sublicense in the manner
contemplated by this AGREEMENT in any foreign patents which correspond to those
described in the preceding sentence and in any patents that claim ONCOTHYREON
IMPROVEMENTS, JOINT IMPROVEMENTS and/or IMPROVEMENTS. Notwithstanding the foregoing,
ONCOTHYREON PATENT RIGHTS shall not include any subsequently

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

7

	 	 	 	developed or acquired ONCOTHYREON PATENT RIGHTS to the extent covering any active
compound that is separate and clearly distinct from PRODUCT, notwithstanding the
fact that such active compound may be useful as part of a combination therapy with
PRODUCT;

	 	1.1.40	 	“ONCOTHYREON TECHNOLOGY” means all ONCOTHYREON PATENT RIGHTS and/or ONCOTHYREON
KNOW-HOW in the FIELD;
	 
	 	1.1.41	 	“ORIGINAL EFFECTIVE DATE” means May 7, 2001;
	 
	 	1.1.42	 	“PRODRUG” means a chemical precursor of PRODUCT which is to be cleaved in a human
being directly into PRODUCT and/or a metabolic intermediate thereof, but excluding for
greater certainty, antigen processing;
	 
	 	1.1.43	 	“PRODUCT” shall mean BLP25;
	 
	 	1.1.44	 	“RIGHTS” has the meaning attributed to that term in section 2.7.2 of this AGREEMENT;
	 
	 	1.1.45	 	“ROW TERRITORY” shall mean all countries in the world except the NA TERRITORY;
	 
	 	1.1.46	 	“SALE” includes, with respect to PRODUCT, the sale thereof to an END USER, and “SOLD”
and “SELL” have a corresponding meaning;
	 
	 	1.1.47	 	“SALES REPORT” has the meaning attributed to that term in section 7.2 of this
AGREEMENT;
	 
	 	1.1.48	 	“SELECTED DOMAIN NAMES” has the meaning attributed to that term in section 5.12.5 of
this AGREEMENT;
	 
	 	1.1.49	 	“SELECTED TRADEMARK” has the meaning attributed to that term in section 5.12.1 of
this AGREEMENT;
	 
	 	1.1.50	 	“TERRITORY” shall mean, collectively, the NA TERRITORY and the ROW TERRITORY;
	 
	 	1.1.51	 	“THIRD PARTY LICENSES” means, collectively, the ICRT LICENSE, the DANA-FARBER
LICENSE, the U of A LICENSE, the CORIXA LICENSE and any other third party license or
sublicense of any technology included as part of the ONCOTHYREON TECHNOLOGY;
	 
	 	1.1.52	 	“TRADEMARK” means the trademarks and logos initially selected for BLP25 pursuant to
section 5.12 of this AGREEMENT, being the trademarks STIMUVAX, [+];
	 
	 	1.1.53	 	“TRADEMARK DOMAIN NAMES” has the meaning attributed to that term in section 5.12.5 of
this AGREEMENT;

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

8

	 	1.1.54	 	“TRANSFER NOTICE” has the meaning attributed to that term in section 2.7.2 of this
AGREEMENT;
	 
	 	1.1.55	 	“TRANSFER PERIOD” has the meaning attributed to that term in section 2.7.2 of this
AGREEMENT;
	 
	 	1.1.56	 	“U of A LICENSE” means that certain license dated December 1, 2001 with the
University of Alberta in relation to the Samuels MUC1 liposomal formulation patents,
together with all schedules thereto and any amendments to or restatements of such
license agreement; and
	 
	 	1.1.57	 	“VALID CLAIM” means, with respect to PRODUCT in a particular country in the
TERRITORY, a claim of an issued and unexpired patent included within the ONCOTHYREON
PATENT RIGHTS which has not been held unenforceable, unpatentable or invalid by a
decision of a court or other governmental agency of competent jurisdiction,
unappealable or unappealed within the time allowed for appeal, and which has not been
admitted to be invalid or unenforceable through reissue, disclaimer or otherwise.

ARTICLE 2

LICENSE GRANT

Section 2.1 ONCOTHYREON License Grant

Subject to the terms and conditions of this AGREEMENT and only for the purpose of MERCK fulfilling
its obligations and exercising its rights under this AGREEMENT, ONCOTHYREON hereby grants to MERCK
a license (or in the case of ONCOTHYREON TECHNOLOGY that ONCOTHYREON has licensed from a third
party, a sublicense) under the ONCOTHYREON TECHNOLOGY to make, use, import, develop, market and
SELL and have made, used, imported, developed, marketed and SOLD PRODUCT in the FIELD in the NA
TERRITORY and the ROW TERRITORY. Such license shall, except to the extent otherwise provided in
this AGREEMENT or otherwise required by applicable law or regulation (as, for example, in the
European Union under applicable competition law), be exclusive for the FIELD in the NA TERRITORY
and in the ROW TERRITORY, subject to the rights of ONCOTHYREON under this AGREEMENT.

MERCK shall have the right to grant sublicenses (including the right to appoint DISTRIBUTORS of
PRODUCT in the TERRITORY, including AFFILIATES of MERCK) under the licenses obtained under this
AGREEMENT without the prior written consent of ONCOTHYREON provided however, that MERCK, when doing
so, complies with the provisions of the THIRD PARTY LICENSES. MERCK shall be responsible for the
acts and omissions of its DISTRIBUTORS, AFFILIATES, sublicensees and contract manufacturers and
such acts and omissions shall be regarded for purposes of this AGREEMENT as the acts and omissions
of MERCK. ONCOTHYREON agrees not to, and shall cause its wholly owned AFFILIATES not to assert
against MERCK or its sublicensees any patent not included in the ONCOTHYREON PATENT RIGHTS that is
or might be infringed by reason of MERCK or its sublicensees exercise of the licenses granted to
MERCK under this section 2.1. Further, ONCOTHYREON covenants and agrees that for so long as MERCK
has exclusive rights to all

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

9

of the ONCOTHYREON TECHNOLOGY under this AGREEMENT, ONCOTHYREON shall not grant to any third party
rights to the ONCOTHYREON TECHNOLOGY which would permit such third party to make, use, import,
develop, market or SELL or have made, have used, imported, developed, marketed or SOLD PRODUCT for
the treatment of disease in humans.

Section 2.2 Term of Grant

The licenses granted in section 2.1 of this AGREEMENT shall remain in force and effect on a
country-by-country basis until the later of (a) the expiration or termination of the last to expire
or terminate of VALID CLAIMS that cover PRODUCT in such country, and (b) the date which is the
fifteenth (15th) anniversary of the LAUNCH of PRODUCT in any country in the TERRITORY.
Upon the expiration of any such license grant as aforesaid, MERCK shall thereafter, subject to
complying with any applicable provisions of the THIRD PARTY LICENSES (including the payment of any
and all royalties and other amounts required to be paid thereunder), have a paid up, royalty free,
non-exclusive license under the ONCOTHYREON TECHNOLOGY to make, use, import, develop, market and
SELL, and have made, used, imported, developed, marketed and SOLD PRODUCT in such country in the
FIELD.

Section 2.3 Third Party Licenses

With respect to the THIRD PARTY LICENSES to the extent not waived in writing by the licensor under
such THIRD PARTY LICENSES, ONCOTHYREON and MERCK hereby incorporate by reference in this AGREEMENT
any provisions specified in such THIRD PARTY LICENSES to be included in sublicenses of the subject
matter of such THIRD PARTY LICENSES and to make such other amendments to this AGREEMENT as may be
required in connection with the sublicensing of such THIRD PARTY LICENSES by ONCOTHYREON to MERCK.
MERCK also agrees to cooperate with ONCOTHYREON and its AFFILIATES in fully complying in a timely
manner with the terms of such THIRD PARTY LICENSES and, without limiting the generality of the
foregoing, MERCK shall provide to ONCOTHYREON or its designated AFFILIATE in a timely manner or
assist ONCOTHYREON or its designated AFFILIATE in preparing in a timely manner any and all reports,
data, confirmations, approvals and other information that may be required by ONCOTHYREON or its
designated AFFILIATE in connection therewith. ONCOTHYREON shall provide MERCK with examples of
applicable reports previously utilized by ONCOTHYREON and/or its AFFILIATES for such purposes in
order to assist MERCK in preparing the necessary reports.

Section 2.4 Bankruptcy or Insolvency

All rights and licenses granted to MERCK under this article 2 are, and shall be deemed to be, for
purposes of applicable bankruptcy law (including section 365(n) of the United States Bankruptcy
Code), licenses of rights to “intellectual property” (including as such term is defined under
section 101(35A) of the United States Bankruptcy Code). The parties agree that MERCK, as a
licensee of such rights under this AGREEMENT, shall retain and may fully exercise all of its rights
and elections under such applicable bankruptcy law, including but not limited to MERCK’s rights to
continue to exercise all rights licensed hereunder.

Section 2.5 Combination Products

ONCOTHYREON shall not prohibit MERCK from combining for use in the FIELD PRODUCT licensed under
this AGREEMENT with any other product.

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

10

Section 2.6 Covenant Not to Sue or Challenge

MERCK (on behalf of itself and its AFFILIATES and their respective sublicensees) agrees not to in
any way challenge or contest (including by way of an allegation of misuse or non-infringement), nor
assist any other person to challenge or contest, the validity or enforceability of any of the
ONCOTHYREON TECHNOLOGY including, without limitation, the ONCOTHYREON PATENT RIGHTS.

Section 2.7 Exclusivity

	 	2.7.1	 	[+]
	 
	 	2.7.2	 	[+] [Redaction continues for two pages]
	 
	 	2.7.3	 	[+]

ARTICLE 3

REPORTING AND PLANS

Section 3.1 Reporting

On or before March 31, 2009 for the 2009 calendar year, and on or before January 1 for each
subsequent calendar year during the TERM until first commercial SALE of PRODUCT has been made,
MERCK shall provide ONCOTHYREON with a written development plan (the “DEVELOPMENT PLAN”) for
PRODUCT which plan shall outline the CLINICAL DEVELOPMENT activities that MERCK plans to perform in
such calendar year, as well as its manufacturing activities. Upon request of ONCOTHYREON, but no
more than once per calendar quarter, MERCK shall provide ONCOTHYREON with a succinct written update
(i.e. one or two pages) of any material change to the DEVELOPMENT PLAN as well as the progress made
with respect to the CLINICAL DEVELOPMENT, including updates on the status of each ongoing clinical
trial (including the number of patients) and regulatory filings. Upon first commercial SALE of
PRODUCT, the DEVELOPMENT PLAN shall no longer be provided to ONCOTHYREON. In lieu of the
DEVELOPMENT PLAN, MERCK shall provide ONCOTHYREON with a marketing plan (the “MARKETING PLAN”)
which plan shall outline the marketing activities that MERCK plans to perform in the then current
calendar year, as well as its manufacturing activities. Upon request of ONCOTHYREON, but no more
than once per calendar quarter, MERCK shall provide ONCOTHYREON with a succinct written update
(i.e. one or two pages) of any material change to the MARKETING PLAN as well as the progress made
with respect to the marketing of PRODUCT, including updates on the status of each ongoing clinical
trial (including the number of patients) and regulatory filings. Notwithstanding the foregoing,
MERCK shall promptly following any change or event which may be material to ONCOTHYREON in relation
to the subject matter of this AGREEMENT advise ONCOTHYREON together with full particulars thereof.
Such reports and information shall be received by ONCOTHYREON subject to the obligations of Article
8.

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

11

ARTICLE 4

DEVELOPMENT AND MARKET APPROVAL

— NA TERRITORY AND ROW TERRITORY

Section 4.1 CLINICAL DEVELOPMENT Studies and Costs

MERCK will be responsible, and have sole decision making authority, for conducting, or having
conducted, all development (including CLINICAL DEVELOPMENT) and MARKET APPROVAL (including the
preparation, submission and prosecution of all regulatory authority filings and applications
required to obtain all necessary MARKET APPROVALS to SELL PRODUCT in, among others, the NA
TERRITORY and the MAJOR MARKETS in the ROW TERRITORY) tasks necessary and/or desirable for CLINICAL
DEVELOPMENT of PRODUCT in the NA TERRITORY and the ROW TERRITORY. Without limiting the generality
of the foregoing, MERCK agrees to undertake the Phase III clinical trial of BLP25 in Stage III a/b
non-small cell lung cancer described in the protocol set forth in appendix 4. MERCK will bear all
costs in relation to all of the foregoing.

Section 4.2 Regulatory Filings 

MERCK will, at MERCK’s expense, use commercially reasonable efforts to diligently pursue the
preparation, submission and prosecution and maintenance of all regulatory authority filings and
applications required to obtain and maintain all necessary and/or desirable MARKET APPROVALS to
sell PRODUCT in each of the NA TERRITORY, the MAJOR MARKETS in the ROW TERRITORY and in such other
countries in the ROW TERRITORY in which MERCK, using reasonable business judgment, determines to
sell PRODUCT, all in a prudent and skilful manner in accordance with all applicable laws and
regulations. To the extent not already assigned to MERCK, ONCOTHYREON shall promptly assign to
MERCK all applications and filings held by ONCOTHYREON with any regulatory authority relating to
the development, manufacture and commercialization of PRODUCT. MERCK shall keep ONCOTHYREON
informed in respect of the matters which are the subject of this section 4.2 in the manner
specified in Section 3, provided, however, that the final decision on the specifics of the
preparation, submission and prosecution and maintenance of such regulatory filings and applications
shall be made by MERCK. Upon the written request of MERCK, ONCOTHYREON, shall, or shall direct its
AFFILIATE to, either withdraw or transfer to MERCK any drug master file submitted by ONCOTHYREON or
any of its AFFILIATES in relation to the PRODUCT to any regulatory authority in the TERRITORY. For
clarity, any contact to regulatory authorities anywhere in the TERRITORY that relate to the PRODUCT
shall be MERCK’s or its AFFILIATES’ or sublicensees’ responsibility, and any contact made by any
such authority to ONCOTHYREON or any of its AFFILIATES in relation to the PRODUCT shall be referred
promptly by ONCOTHYREON or its AFFILIATE to MERCK.

Section 4.3 MARKET APPROVAL Owner

MERCK shall be the record owner of all MARKET APPROVALS required for SALE of PRODUCT in the NA
TERRITORY and the ROW TERRITORY. Forthwith upon the expiration or termination of this AGREEMENT
with respect to PRODUCT in a particular country in the ROW TERRITORY or the NA TERRITORY, or if any
of the licenses granted by ONCOTHYREON to MERCK in this AGREEMENT become non-exclusive, MERCK shall
in a timely manner comply with section 11.6 of this AGREEMENT in relation to PRODUCT in such
country.

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

12

Section 4.4 Know-How Documentation

In an effort to support the transfer by ONCOTHYREON to MERCK of the ONCOTHYREON KNOW-HOW,
ONCOTHYREON agrees (to the extent legally permitted to do so) to make available to MERCK and its
designated AFFILIATE (with the right to print or photocopy documents at MERCK’s cost) for a period
of two (2) years following the EFFECTIVE DATE, (a) all ONCOTHYREON KNOW-HOW, including (to the
extent falling within the definition of ONCOTHYREON KNOW-HOW) any preclinical data, clinical data,
assays and associated materials, protocols, plans, reports, procedures (including standard
operating procedures), and any other similar information, that is necessary or useful (acting
reasonably) to develop, manufacture, test, release, seek regulatory approval for, or commercialize
BLP25, all to the extent in ONCOTHYREON’s possession or control, (b) copies of all material
communications specifically in relation to BLP25 with regulatory authorities in the possession or
control of ONCOTHYREON, (c) copies of all material communications with third parties related
specifically to the development and manufacture of BLP25 (e.g. communication with contract
manufacturing organizations, vendors, contractors) in the possession or control of ONCOTHYREON, and
(d) copies of all material documents that ONCOTHYREON or its AFFILIATES received from third parties
related specifically to the development and manufacture of BLP25 (e.g. standard operating
procedures, regulatory filing documents, batch records, certificates received from contract
manufacturing organizations, vendors, contractors), in the possession or control of ONCOTHYREON.

ARTICLE 5

PRODUCT MARKETING — NA TERRITORY AND ROW TERRITORY

Section 5.1 Costs and Expenses

MERCK shall bear all costs and expenses associated with the manufacturing, promoting, marketing,
distributing and SALE of PRODUCT in the TERRITORY.

Section 5.2 Sales Force Training

MERCK shall be responsible for developing or having developed (in accordance with all applicable
legal and regulatory requirements) training programs and materials concerning promotion of PRODUCT
in the TERRITORY. MERCK shall also be responsible for developing or having developed (in
accordance with all applicable legal and regulatory requirements) training programs and materials
concerning technical aspects of PRODUCT.

Section 5.3 Costs of Sales Representatives and Specialty Personnel

MERCK shall be responsible for all costs and expenses related to its sales representatives (whether
employees or contracted) in the TERRITORY. MERCK shall be responsible for all costs and expenses
related to “specialty” personnel (including managed care representatives, professional relations,
patient advocacy, reimbursement, specialty sales, and the like) in the TERRITORY.

Section 5.4 Distribution

MERCK shall have the sole responsibility for distribution of PRODUCT in the TERRITORY. In
fulfilling its obligations with respect to the distribution of PRODUCT in the TERRITORY, MERCK
shall use commercially reasonable efforts consistent with accepted pharmaceutical practices. All
costs incurred in relation to such distribution shall be borne by MERCK.

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

13

Section 5.5 Label Content

MERCK shall be responsible for ensuring that the label and product insert for any PRODUCT SOLD in
the TERRITORY shall comply with all legal, governmental and regulatory requirements. Insofar as it
is not contrary to law or regulation in any particular country in the TERRITORY, the box and
package insert, and the label to the extent that space permits, shall include prominent reference
to MERCK (or, if applicable, any AFFILIATE of MERCK designated by MERCK) as marketer and
manufacturer of the PRODUCT and to ONCOTHYREON or its designated AFFILIATE as licensor. Any
trademark or other content as may be from time to time required pursuant to the CORIXA LICENSE
shall be marked on every PRODUCT label and/or insert in the manner required under the CORIXA
LICENSE.

Section 5.6 Product Price

MERCK shall determine the SALES price for PRODUCT SOLD in the TERRITORY.

Section 5.7 Booking Sales

MERCK shall book all SALES of PRODUCT in the TERRITORY.

Section 5.8 Advertising and Promotion

MERCK shall be responsible for determining the sales strategy for SALE of PRODUCT in the TERRITORY,
and shall create, or have created all materials for advertising and promotion of PRODUCT in the
TERRITORY. All costs and expenses incurred in relation to such advertising and promotion shall be
borne by MERCK.

Section 5.9 Customer Complaints and Medical Inquiries

MERCK (or its designated AFFILIATE) shall be responsible for handling all customer complaints and
inquiries regarding PRODUCT in the TERRITORY. All complaints and inquiries received by ONCOTHYREON
or its agents shall be promptly referred to MERCK for response according to applicable law. MERCK
shall use commercially reasonable efforts to handle such matters in a timely, prudent and skilful
manner, in compliance with applicable laws, regulations, rules, policies and regulatory
requirements and in accord with MERCK’s standard operating procedures. MERCK shall keep
ONCOTHYREON informed in a timely manner with respect to MERCK’s activities in regard to customer
complaints and inquiries for PRODUCT. All costs incurred in responding to customer complaints and
inquiries shall be borne by MERCK.

Section 5.10 Adverse Event Reporting

MERCK (or its designated AFFILIATE) shall be responsible for reporting all ADVERSE EVENTS regarding
PRODUCT to the appropriate regulatory authorities in the TERRITORY. All information received by
ONCOTHYREON or its agents shall be promptly transferred according to applicable law to MERCK for
handling. MERCK shall handle such matter in a timely, prudent and skilful manner, in compliance
with all applicable laws, rules, policies, regulations and regulatory requirements, and in accord
with MERCK’s standard operating procedures. MERCK shall keep ONCOTHYREON informed in a timely
manner with respect to MERCK’s activities with respect to ADVERSE EVENT reporting for PRODUCT. All
costs incurred in responding to and reporting ADVERSE EVENTS regarding PRODUCT in the TERRITORY
shall be borne by MERCK.

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

14

Section 5.11 PRODUCT Recall

MERCK (or its designated AFFILIATE) shall be responsible for initiating and implementing all
PRODUCT recalls required by controlling regulatory agencies and for all voluntary PRODUCT market
withdrawals in the TERRITORY. MERCK shall handle such matters in a timely, prudent and skilful
manner, in compliance with all applicable laws, rules, policies, regulations and regulatory
requirements, and in accord with MERCK’s standard operating procedures. MERCK shall keep
ONCOTHYREON informed in a timely manner with respect to MERCK’s activities in regard to recalls and
market withdrawals. All costs incurred in responding to recalls and market withdrawals shall be
borne by MERCK.

Section 5.12 Trademarks and Branding

	 	5.12.1	 	Ownership and Filing. PRODUCT shall be marketed and sold in the TERRITORY
under the applicable trademark selected by MERCK (the “SELECTED TRADEMARK”) which
SELECTED TRADEMARK can be a TRADEMARK or any other trademark selected by MERCK.
ONCOTHYREON acknowledges that MERCK shall be the owner of the TRADEMARKS in the
TERRITORY. ONCOTHYREON shall not knowingly do or cause to be done any act or thing
contesting, challenging or, in any way, impairing or intending to impair any part of
MERCK’s right, title or interest in the TRADEMARKS for the duration of this AGREEMENT.
Further, ONCOTHYREON shall not use or register in the TERRITORY any trademark which is
similar or identical to any of the TRADEMARKS on similar or identical goods or services
to those which are the subject of this AGREEMENT for the duration of this AGREEMENT.
MERCK shall diligently pursue the filing, maintenance and defence of the TRADEMARKS and
the SELECTED TRADEMARKS in the TERRITORY. All trademark-related costs (including,
without limitation, legal, third party, branding, filing, maintenance and other such
costs) of developing, prosecuting, registering, maintaining and defending the
TRADEMARKS and the SELECTED TRADEMARKS shall be borne by MERCK as of March 1, 2006.
	 
	 	5.12.2	 	Trademark License. MERCK hereby grants, in the event that ONCOTHYREON or an
AFFILIATE of ONCOTHYREON obtains the right to manufacture and/or SELL PRODUCT under
this AGREEMENT, to ONCOTHYREON and its designated AFFILIATES a royalty free,
non-exclusive license to use, display, reproduce and publish the TRADEMARKS and/or the
SELECTED TRADEMARKS in connection with the manufacture, use, marketing, promotion,
distribution and SALE of PRODUCT in any countries in the TERRITORY where ONCOTHYREON or
an AFFILIATE of ONCOTHYREON has the right to manufacture and/or SELL PRODUCT under this
AGREEMENT for so long as such right to manufacture and/or SELL exists under this
AGREEMENT. In addition to the foregoing, ONCOTHYREON shall have the right to use the
TRADEMARKS and/or the SELECTED TRADEMARKS in connection with corporate disclosure and
corporate information dissemination. ONCOTHYREON and its designated AFFILIATES shall
have no right to grant sublicenses under such license without the prior written consent
of MERCK (such consent not to be unreasonably withheld). Any goodwill arising from the
use of the TRADEMARKS and/or the SELECTED TRADEMARKS by ONCOTHYREON

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

15

	 	 	 	or its designated AFFILIATES shall inure to the benefit of MERCK. Further, such use
shall be in accordance with the applicable laws in the relevant jurisdiction, as
well as with any reasonable requirements of any brand guide that may be provided by
MERCK from time to time. When using any of the TRADEMARKS and/or the SELECTED
TRADEMARKS under license, ONCOTHYREON and its designated AFFILIATES shall use the
identifiers Ô or â, as appropriate.
	 
	 	5.12.3	 	Assignment. MERCK shall, at MERCK’s cost, arrange for assignment of the
trademarks [+] from ONCOTHYREON or its AFFILIATES to MERCK. Until such assignment is
completed, ONCOTHYREON shall, at MERCK’s cost, provide reasonable cooperation and
assistance with respect to such assignment, including but not limited to providing
documents in ONCOTHYREON’s possession (including its AFFILIATES and external law firm)
and signatures as requested by the relevant trademark offices. A list of currently
identified trademark registrations and applications for [+] are included in appendix 5.
MERCK confirms that ONCOTHYREON and its AFFILIATES are released from all other
obligations under the STIMUVAX letter agreement dated December 21, 2004 including,
without limitation, the 40,000 Euro payment.
	 
	 	5.12.4	 	Trademark Infringement. For countries in which the TRADEMARKS and/or
SELECTED TRADEMARKS are used under license by ONCOTHYREON and/or its AFFILIATES,
ONCOTHYREON shall:

	 	5.12.4.1	 	promptly report to MERCK particulars of any use by any other party of a
trademark, trade name or mode of advertising which comes to ONCOTHYREON’s or
its designated AFFILIATES’ attention and which might qualify as an infringement
of the TRADEMARKS and/or SELECTED TRADEMARKS or as unfair competition; and
	 
	 	5.12.4.2	 	in the event that it comes to the attention of ONCOTHYREON or its
designated AFFILIATES that any party alleges that the TRADEMARKS and/or
SELECTED TRADEMARKS are invalid or that they infringe any rights of a third
party, or that the TRADEMARKS are open to any other form of attack, ONCOTHYREON
or its designated AFFILIATES shall promptly report the matter to MERCK.

In any event described in this section ONCOTHYREON shall not take any action, either
amicably or legally, and shall let MERCK or a nominee of MERCK take any action which
MERCK, acting reasonably, deems necessary, provided, however, that nothing herein
shall prevent ONCOTHYREON from defending and/or protecting its own reasonable
interests. ONCOTHYREON or its designated AFFILIATES, upon MERCK’s reasonable
request and at MERCK’s expense, shall cooperate in any action so taken to the extent
that such cooperation is not materially adverse in interest to ONCOTHYREON and/or
its AFFILIATES.

 
 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

16

	 	5.12.5	 	Domain Names. Any domain names related to the TRADEMARKS (the “TRADEMARK
DOMAIN NAMES”) and/or the SELECTED TRADEMARKS (the “SELECTED DOMAIN NAMES”) in the
TERRITORY shall be selected by MERCK. ONCOTHYREON acknowledges that MERCK shall be the
owner of the TRADEMARK DOMAIN NAMES in the TERRITORY. ONCOTHYREON shall not knowingly
do or cause to be done any act or thing contesting, challenging or, in any way,
impairing or intending to impair any part of MERCK’s right, title or interest in the
TRADEMARK DOMAIN NAMES in the TERRITORY for the duration of this AGREEMENT. Further,
ONCOTHYREON shall not use or register in the TERRITORY any domain name which is similar
or identical to any of the domain names related to the TRADEMARKS on similar or
identical goods or services which are the subject of this AGREEMENT for the duration of
this AGREEMENT. MERCK shall be responsible for the filing, maintenance and defence of
the TRADEMARK DOMAIN NAMES and the SELECTED DOMAIN NAMES in the TERRITORY. All domain
name-related costs (including, without limitation, legal, third party, filing,
maintenance and other such costs) of prosecuting, registering, maintaining and
defending the TRADEMARK DOMAIN NAMES and the SELECTED DOMAIN NAMES or any alternate or
additional domain names shall be borne by MERCK.

	 	5.12.6	 	Domain License. MERCK hereby grants to ONCOTHYREON and its designated
AFFILIATES a royalty free, non-exclusive license to use, display, reproduce and publish
the TRADEMARK DOMAIN NAMES, the SELECTED DOMAIN NAMES or any alternate or additional
domain names under the same terms and under the same circumstances as set forth in
Section 5.12.2.

Section 5.13 General Diligence

Subject to section 14.1 and without being limited by section 5.14, MERCK shall, at MERCK’s expense,
use commercially reasonable efforts to diligently pursue the development (including CLINICAL
DEVELOPMENT), commercialization, manufacture (including commercial scale-up), registration,
promotion, marketing and SALE of PRODUCT in a prudent and skilful manner in accordance with the
DEVELOPMENT PLAN and/or the MARKETING PLAN then in effect, which plans will contain development,
manufacturing and marketing activities representing commercially reasonable efforts, and in
accordance with all applicable laws and regulations. MERCK will bear all costs with respect
thereto.

Section 5.14 Excused Performance

In addition to the terms of section 14.1, MERCK’s performance under this AGREEMENT with respect to
PRODUCT in a particular country is expressly conditioned upon the continuing absence of any safety
or efficacy or regulatory event with respect to PRODUCT in such country which materially limits,
reverses or restricts the development and/or marketing of such PRODUCT in such country. MERCK’s
obligations to develop, promote and/or SELL such PRODUCT in such country under this AGREEMENT shall
be delayed or suspended so long as any such condition exists.

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

17

Section 5.15 Japanese Market

Without derogating from section 5.13, in relation to Japan, MERCK shall, as soon as reasonable
considering the Japanese market and in any event no later than [+] after positive clinical endpoint
data (with no material toxicology issue) being available from a pivotal Phase II or Phase III trial
with respect to PRODUCT, commence discussions with the applicable Japanese regulatory authorities
with respect to initiating any required clinical trials in Japan and finalize a comprehensive
CLINICAL DEVELOPMENT plan for Japan for PRODUCT (which shall include a reasonable timeframe for
obtaining regulatory approval in Japan) and thereafter use commercially reasonable efforts to
pursue such CLINICAL DEVELOPMENT plan within the timeframes stipulated therein. Notwithstanding
any provision to the contrary in this AGREEMENT, if MERCK fails to meet the requirements of this
section 5.15 with respect to Japan, then this AGREEMENT shall cease to apply to PRODUCT in relation
to Japan and all rights related to PRODUCT in Japan shall revert to ONCOTHYREON.

ARTICLE 6

CONSIDERATION — NA TERRITORY AND ROW TERRITORY

Section 6.1 Consideration for Licenses Granted

In consideration for the licenses granted by ONCOTHYREON to MERCK under article 2, MERCK shall, in
the event that MERCK sublicenses, assigns, transfers or otherwise relinquishes all or any of its
rights and/or obligations under this AGREEMENT relating to the NA TERRITORY or any part thereof to
a third party (which term for purposes of this section 6.1 shall not include an AFFILIATE of MERCK
as long as all such rights and/or obligations remain with such AFFILIATE of MERCK, or a contract
manufacturing organization for the development, testing, release or supply of PRODUCT selected by
MERCK) and receives upfront payments, milestone payments, royalty payments or other monetary
consideration, or in-kind consideration of substantive value, in respect thereof, pay ONCOTHYREON
[+] within thirty (30) days of the effective date of such sublicense, assignment, transfer or
relinquishment, provided that no such payment will be due in connection with the transfer or sale
by MERCK of all or substantially all of its business or in the event of the merger or consolidation
of MERCK with another corporation.

Section 6.2 Consideration — Milestone and Other Payments

	 	6.2.1	 	Upfront and Manufacturing Process Transfer Milestone Payments. In
consideration for the licenses granted by ONCOTHYREON to MERCK under Article 2 and
other benefits afforded MERCK under this AGREEMENT, and in addition to the payment
provided for in section 6.1 of this AGREEMENT, the pre LAUNCH milestone payments
provided for in section 6.2.2 of this AGREEMENT, the post LAUNCH milestone payments
provided for in section 6.2.3 of this AGREEMENT and the royalty payments provided for
in section 6.3 of this AGREEMENT, MERCK shall make the payments specified in this
section 6.2.1 to ONCOTHYREON:

	 	6.2.1.1	 	Ten Million Four Hundred Fifty Two Thousand Four Hundred Two Dollars and
Fifty Eight Cents US ($10,452,402.58 US) on the Effective Date;

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

18

	 	6.2.1.2	 	the remaining manufacturing process transfer milestone payment of [+] within
thirty (30) days of the first manufacturing run of PRODUCT (by MERCK or any
AFFILIATE or sub-supplier of MERCK) after upscale of the current process to the
commercial process, provided that, notwithstanding whether or not the
manufacturing process transfer milestone specified in this section 6.2.1.2 has
been met (at all or in part), such milestone payment (to the extent not
previously paid by MERCK to ONCOTHYREON) shall be due and payable by MERCK to
ONCOTHYREON on December 31, 2009;

	 	6.2.1.3	 	MERCK shall be responsible for payment of and shall pay in a timely manner
all royalties and other amounts payable pursuant to the CORIXA LICENSE to the
extent agreed to by CORIXA, and if no such agreement is obtained, reimburse
ONCOTHYREON (or its designated AFFILIATE) for any such payments to CORIXA; and

	 	6.2.1.4	 	for clarification, each of the payments of MERCK identified in this section
6.2.1 is non-refundable to MERCK, and each of the payments identified in
Sections 6.2.1.1 and 6.2.1.2 shall be made only once.

	 	6.2.2	 	Pre LAUNCH Milestone Payments. In consideration for the licenses
granted by ONCOTHYREON to MERCK under Article 2 and other benefits afforded MERCK under
this AGREEMENT, and in addition to the payment provided for in section 6.1 of this
AGREEMENT, the upfront and other payments provided for in section 6.2.1 of this
AGREEMENT, the post LAUNCH milestone payments provided for in section 6.2.3 of this
AGREEMENT and the royalty payments provided for in section 6.3 of this AGREEMENT, MERCK
shall make the following payments to ONCOTHYREON:

	 	6.2.2.1	 	with respect to BLP25 for the first INDICATION:

	 	6.2.2.1.1	 	MERCK shall within thirty (30) days of the date of submission
of a BLA to the FDA for BLP25 for such first INDICATION, pay
ONCOTHYREON [+];
	 
	 	6.2.2.1.2	 	MERCK shall pay ONCOTHYREON [+] within [+] of the date of
submission to the applicable regulatory authority in the first MAJOR
MARKET of a BLA (or its equivalent in the jurisdiction in question)
for BLP25 for such first INDICATION;
	 
	 	6.2.2.1.3	 	MERCK shall pay ONCOTHYREON [+] within thirty (30) days of the
date of receipt of approval of the BLA submitted to the FDA for
BLP25 for such first INDICATION;
	 
	 	6.2.2.1.4	 	MERCK shall pay ONCOTHYREON [+] within thirty (30) days of the
date of receipt of approval of the BLA

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

19

	 	 	 	(or its equivalent in the jurisdiction in question)
submitted to the applicable regulatory authority in the
first MAJOR MARKET for BLP25 for such first INDICATION;

	 	6.2.2.2	 	with respect to BLP25 for the second INDICATION:

	 	6.2.2.2.1	 	MERCK shall within thirty (30) days of the date of submission
of a BLA to the FDA for BLP25 for such second INDICATION pay
ONCOTHYREON [+];
	 
	 	6.2.2.2.2	 	MERCK shall pay ONCOTHYREON [+] within thirty (30) days of the
date of submission to the applicable regulatory authority in the
first MAJOR MARKET of a BLA (or its equivalent in the jurisdiction
in question) for BLP25 for such second INDICATION;
	 
	 	6.2.2.2.3	 	MERCK shall pay ONCOTHYREON [+] within thirty (30) days of the
date of receipt of approval of the BLA submitted to the FDA for
BLP25 for such second INDICATION;
	 
	 	6.2.2.2.4	 	MERCK shall pay ONCOTHYREON [+] within thirty (30) days of the
date of receipt of approval of the BLA (or its equivalent in the
jurisdiction in question) submitted to the applicable regulatory
authority in the first MAJOR MARKET for BLP25 for such second
INDICATION;

	 	6.2.2.3	 	For clarification, each of the milestone payments of MERCK identified in
this section 6.2.2 shall be made only once for the stated milestone triggering
event. Any milestone payments made by MERCK under section 6.2.2 are
non-refundable to MERCK.

	 	6.2.3	 	Post LAUNCH Milestone Payments. In consideration for the licenses
granted by ONCOTHYREON to MERCK under Article 2 and other benefits afforded MERCK under
this AGREEMENT, and in addition to the payment provided for in section 6.1 of this
AGREEMENT, the upfront and other payments provided for in section 6.2.1 of this
AGREEMENT, the pre LAUNCH milestone payments provided for in section 6.2.2 of this
AGREEMENT and the royalty payments provided for in section 6.3 of this AGREEMENT, MERCK
shall pay to ONCOTHYREON the following post-LAUNCH milestone payments within forty-five
(45) days of the end of the applicable period specified below:

	 	6.2.3.1	 	when ROW NET SALES with respect to PRODUCT in any calendar year (following
LAUNCH of PRODUCT anywhere in the TERRITORY) equal or exceed [+], a sales
milestone payment shall be paid by MERCK to ONCOTHYREON of [+];

 
 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

20

	 	6.2.3.2	 	when ROW NET SALES with respect to PRODUCT in any calendar year (following
LAUNCH of PRODUCT anywhere in the TERRITORY) equal or exceed [+], a sales
milestone payment shall be paid by MERCK to ONCOTHYREON of [+];
	 
	 	6.2.3.3	 	when ROW NET SALES with respect to PRODUCT in any calendar year (following
LAUNCH of PRODUCT anywhere in the TERRITORY) equal or exceed [+], a sales
milestone payment shall be paid by MERCK to ONCOTHYREON of [+];
	 
	 	6.2.3.4	 	when ROW NET SALES with respect to PRODUCT in any calendar year (following
LAUNCH of PRODUCT anywhere in the TERRITORY) equal or exceed [+], a sales
milestone payment shall be paid by MERCK to ONCOTHYREON of [+]; and
	 
	 	6.2.3.5	 	when ROW NET SALES with respect to PRODUCT in any calendar year (following
LAUNCH of PRODUCT anywhere in the TERRITORY) equal or exceed [+], a sales
milestone payment shall be paid by MERCK to ONCOTHYREON of [+].

For clarification, each of MERCK’s sales milestone payments identified in this
section 6.2.3 shall be made only once for the stated sales milestone triggering
event. However, more than one sales milestone may be achieved in a particular
calendar year, in which case (if not previously paid) each such sales milestone
payments shall be made by MERCK to ONCOTHYREON. Any sales milestone payments made
by MERCK under this section 6.2.3 are non-refundable to MERCK.

Section 6.3 Royalty Payments

	 	6.3.1	 	In consideration for the licenses granted by ONCOTHYREON to MERCK under
Article 2 and other benefits afforded MERCK under this AGREEMENT, and in addition to
the payment provided for in section 6.1 of this AGREEMENT, the upfront and other
payments provided for in section 6.2.1 of this AGREEMENT, the pre LAUNCH milestones
provided for in section 6.2.2 of this AGREEMENT and the post LAUNCH milestones provided
for in section 6.2.3 of this AGREEMENT, MERCK shall make the payments specified in this
section 6.3 to ONCOTHYREON.
	 
	 	6.3.2	 	With respect to BLP25 in a particular country in the NA TERRITORY, MERCK
shall, until the later of (a) the expiration or termination of the last to expire or
terminate of VALID CLAIMS that cover PRODUCT in such country, and (b) the date which
is the fifteenth (15th) anniversary of the LAUNCH of PRODUCT in any country
in the TERRITORY, pay to ONCOTHYREON on a quarterly basis as specified in article 7 of
this AGREEMENT a royalty on NET SALES of PRODUCT in such country calculated as follows:

	 	6.3.2.1	 	MERCK shall pay ONCOTHYREON a royalty equal to [+] of NET

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

21

	 	 	 	SALES in such country in respect of PRODUCT for such portion of annual
NET SALES in the NA TERRITORY for the calendar year in question up to and
including [+] (pro-rated for stub periods); and
	 
	 	6.3.2.2	 	MERCK shall pay ONCOTHYREON a royalty equal to [+] of NET SALES in such
country in respect of PRODUCT for such portion of annual NET SALES in the NA
TERRITORY for the calendar year in question which exceed [+] (pro-rated for
stub periods).

The royalty rates specified in sections 6.3.2.1 and 6.3.2.2 above shall be reduced
to [+] and [+], respectively, in circumstances where MERCK has paid in full to
ONCOTHYREON in the manner specified in section 6.2.1.2 the remaining manufacturing
process transfer milestone payment in the amount of [+] on or before December 31,
2009.

	 	6.3.3	 	With respect to BLP25 in a particular country in the ROW TERRITORY, MERCK
shall, until the later of (a) the expiration or termination of the last to expire or
terminate of VALID CLAIMS that cover such PRODUCT in such country, and (b) the date
which is the fifteenth (15th) anniversary of the LAUNCH of such PRODUCT in
any country in the TERRITORY, pay to ONCOTHYREON on a quarterly basis as specified in
article 7 of this AGREEMENT a royalty on NET SALES of such PRODUCT in such country
calculated as follows:

	 	6.3.3.1	 	so long as, with respect to the calendar quarter in question, no COMPETITIVE
PRODUCT(S) has actual SALES (based on IMS Global Services data) in such country
which are more than [+] of the actual SALES (based on IMS Global Services data)
of MERCK, its AFFILIATES and their respective permitted sublicensees,
DISTRIBUTORS, assignees and transferees with respect to PRODUCT in such
country, then MERCK shall pay ONCOTHYREON a royalty equal to [+] of NET SALES
in such country in respect of PRODUCT for such calendar quarter (provided that
such [+] royalty rate shall be reduced to [+] in circumstances where MERCK has
paid in full to ONCOTHYREON in the manner specified in section 6.2.1.2 the
remaining manufacturing process transfer milestone payment in the amount of [+]
on or before December 31, 2009);
	 
	 	6.3.3.2	 	if, with respect to the calendar quarter in question, a COMPETITIVE
PRODUCT(S) has actual SALES (based on IMS Global Services data) in such country
which are more than [+] but no more than [+] of the actual SALES (based on IMS
Global Services data) of MERCK, its AFFILIATES and their respective permitted
sublicensees, DISTRIBUTORS, assignees and transferees with respect to PRODUCT
in such country, then MERCK shall pay ONCOTHYREON a royalty equal to [+] of NET
SALES in such country in respect of PRODUCT for such calendar quarter (provided
that such [+] royalty rate shall be

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

22

	 	 	 	reduced to [+] in circumstances where MERCK has paid in full to
ONCOTHYREON in the manner specified in section 6.2.1.2 the remaining
manufacturing process transfer milestone payment in the amount of [+] on
or before December 31, 2009);
	 
	 	6.3.3.3	 	if, with respect to the calendar quarter in question, a COMPETITIVE
PRODUCT(S) has actual SALES (based on IMS Global Services data) which are more
than [+] of the actual SALES (based on IMS Global Services data) of MERCK, its
AFFILIATES and their respective permitted sublicensees, DISTRIBUTORS, assignees
and transferees with respect to PRODUCT in such country, then MERCK shall pay
ONCOTHYREON a royalty equal to [+] of NET SALES in such country in respect of
PRODUCT for such calendar quarter (provided that such [+] royalty rate shall be
reduced to [+] in circumstances where MERCK has paid in full to ONCOTHYREON in
the manner specified in section 6.2.1.2 the remaining manufacturing process
transfer milestone payment in the amount of [+] on or before December 31,
2009).

	 	6.3.4	 	If, with respect to PRODUCT in a particular country in the TERRITORY, MERCK is
able to demonstrate that, for any reason beyond the control of MERCK and its permitted
sublicensees and distributors, the royalty rate payable by MERCK under sections 6.3.2
and 6.3.3 causes or is likely to cause a significant reduction in SALES of PRODUCT in
such country, ONCOTHYREON and MERCK shall meet and in good faith review in such
circumstances the royalty rate applicable to PRODUCT in such country.
	 
	 	6.3.5	 	It is recognized that certain third party rights licensed to ONCOTHYREON under
the THIRD PARTY LICENSES are included in ONCOTHYREON PATENT RIGHTS as indicated in
appendix 3. To the extent such THIRD PARTY LICENSES relate to the TERRITORY,
ONCOTHYREON is solely responsible for all payments due to those third parties, provided
that MERCK acknowledges and agrees that MERCK shall be responsible for the payment of
all royalties and other amounts payable pursuant to the CORIXA LICENSE.
	 
	 	6.3.6	 	No royalties under this section 6.3 shall be payable on PRODUCT used solely by
or on behalf of the parties for tests or development purposes or on transfers between
MERCK and its sublicensees who are not END USERS. Unless ONCOTHYREON and MERCK
otherwise agree in writing, no samples of any PRODUCT shall be made available by MERCK
to END USERS.
	 
	 	6.3.7	 	In establishing the royalty structure of this section 6.3, ONCOTHYREON and
MERCK recognize, and MERCK acknowledges, the substantial value of the various actions
and investments undertaken by ONCOTHYREON prior to the EFFECTIVE DATE. Such value is
significant and in addition to the value of ONCOTHYREON’s grant to MERCK of the license
pursuant to section 2.1 of this AGREEMENT, as it enables the rapid and effective
development and

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

23

	 	 	 	commercialization of PRODUCT in the TERRITORY. Therefore, ONCOTHYREON and MERCK
agree that the royalty payments calculated as a percentage of NET SALES (plus any
other payments provided for elsewhere in this AGREEMENT) provide fair compensation
to ONCOTHYREON for these additional benefits.

ARTICLE 7

ACCOUNTING RECORDS AND PROCEDURES

— NA TERRITORY AND ROW TERRITORY

Section 7.1 Royalty Payments

MERCK shall make royalty payments due ONCOTHYREON under article 6 of this AGREEMENT on a quarterly
basis, within forty-five (45) days following the end of each calendar quarter for which royalties
are due. Each royalty payment shall be accompanied by a SALES REPORT.

Section 7.2 SALES REPORTS

Within forty-five (45) days after the end of each calendar quarter following the first sale of
PRODUCT in the TERRITORY, MERCK shall provide ONCOTHYREON with a detailed report (a “SALES REPORT”)
which will set forth in reasonable detail and with reasonable supporting documentation on a
country-by-country basis (for each country in the TERRITORY):

	 	7.2.1	 	the number of units of PRODUCT sold during such calendar quarter in such
country;
	 
	 	7.2.2	 	the total billings for PRODUCT during such calendar quarter in such country
and in the TERRITORY;
	 
	 	7.2.3	 	the deductions applicable to the determination of NET SALES with respect to
PRODUCT during such calendar quarter in such country;
	 
	 	7.2.4	 	the NET SALES with respect to PRODUCT during such calendar quarter in such
country;
	 
	 	7.2.5	 	the average sales price of PRODUCT during such calendar quarter in such
country;
	 
	 	7.2.6	 	the total royalties due and the basis of the calculation thereof; and
	 
	 	7.2.7	 	such other information as ONCOTHYREON may reasonably request.

Section 7.3 Records and Audits

MERCK will keep and maintain (and, to the extent applicable, will cause its AFFILIATES and their
respective sublicensees, distributors, assignees and transferees to keep and maintain) proper and
complete records and books of account in such form and detail as is necessary for the determination
of the amounts payable by MERCK (on behalf of itself and its AFFILIATES and their respective
sublicensees, distributors, assignees and transferees) to ONCOTHYREON under this AGREEMENT. MERCK
shall at least once in each calendar year during normal business

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

24

hours upon thirty (30) days prior written notice from ONCOTHYREON make those records (and, to the
extent applicable, those of its AFFILIATES and their respective sublicensees, distributors,
assignees and transferees) available for audit by an internationally recognized accounting firm
designated by ONCOTHYREON (except one to which MERCK shall have objection, acting reasonably and
provided such accounting firm agrees to enter into a confidentiality agreement with the audited
party which provides protection for confidential information which is similar to that provided
under article 8 of this AGREEMENT) for the sole purpose of, and MERCK will only be required to
disclose information related to, verifying such payments, revenues, NET SALES, costs, expenses and
deductions and the correctness of calculations and classifications in respect thereof. MERCK shall
preserve (and, to the extent applicable, will cause its AFFILIATES and their respective
sublicensees, distributors, assignees and transferees to preserve) such records made in any
calendar year for a period of seven (7) years following the close of that calendar year. Results
of any such examination shall be made available to each of ONCOTHYREON and MERCK, but all backup
documentation and data shall be made available only to such accounting firm for use only on the
premises of the audited party. In the event that such audit discloses that the actual royalties or
other amounts payable by MERCK to ONCOTHYREON are greater than the royalties or other amounts paid
by MERCK, then MERCK shall pay to ONCOTHYREON any additional royalties and other amounts based on
the results disclosed by such audit. In the event that such audit discloses that the actual
royalties or other amounts payable by MERCK to ONCOTHYREON are less than the royalties or other
amounts paid by MERCK, then ONCOTHYREON shall reimburse MERCK for any such overpayment based on the
results disclosed by such audit. The cost of such audit shall be borne by ONCOTHYREON unless such
audit discloses that the actual royalties and other amounts payable by MERCK to ONCOTHYREON are
greater by five percent (5%) or more than the royalties and other amounts paid by MERCK, in which
case MERCK shall be responsible for payment of all reasonable costs of such audit.

Section 7.4 Payments from Germany

Unless otherwise agreed to in writing by ONCOTHYREON and MERCK, MERCK will make all payments and
reimbursements to ONCOTHYREON under this AGREEMENT from Germany.

Section 7.5 Confidentiality of Financial Reports

Except as otherwise required for purposes of or permitted under this AGREEMENT and except to the
extent disclosure by ONCOTHYREON is required by law or any applicable regulatory authority,
ONCOTHYREON agrees to hold in confidence according to article 8 all information concerning royalty
payments and financial reports, and all information learned in the course of any audit. If
ONCOTHYREON believes, acting reasonably, disclosure is required by law or any applicable regulatory
authority, ONCOTHYREON shall immediately so notify MERCK and shall provide reasonable assistance to
MERCK in maintaining MERCK’s rights at MERCK’s expense.

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

25

ARTICLE 8

CONFIDENTIALITY

Section 8.1 Definition

CONFIDENTIAL INFORMATION is any and all information of a confidential nature including without
limitation DEVELOPMENT PLANS, COMMERCIAL MANUFACTURING PLANS, MARKETING PLANS, any data and/or
information generated under this AGREEMENT, any and all data and/or other information of a
confidential nature which is proprietary to the disclosing party and not generally known (including
without limitation relating to the ONCOTHYREON TECHNOLOGY), and technological information not
limited to compound(s), composition(s), formulation(s) and/or, manufacturing information, and
including business information not limited to commercial forecasts, sales, plans, programs,
customers, assets, financial projections, and costs.

Section 8.2 Obligations

Each party agrees to hold all of the other party’s CONFIDENTIAL INFORMATION received or generated
in connection with this AGREEMENT (either prior to, on, or after the EFFECTIVE DATE) in confidence
and neither disclose it to any third party nor allow any third party access to it nor use it for
any purpose other than as specified by this AGREEMENT. Disclosure by a receiving party of
CONFIDENTIAL INFORMATION of the other party shall only be made to such of its directors, officers,
employees, agents and consultants whose duties require such disclosure and then only if the persons
to whom such CONFIDENTIAL INFORMATION is disclosed are bound by appropriate confidentiality
undertakings. The above notwithstanding, each of MERCK and ONCOTHYREON may disclose CONFIDENTIAL
INFORMATION of the other party to their respective AFFILIATES or distributors on a “need-to-know”
basis provided such persons are bound by like terms of confidentiality as those stated herein.

Section 8.3 Exceptions

These obligations of non-disclosure and non-use shall not apply to CONFIDENTIAL INFORMATION which:

	 	8.3.1	 	was, at the time of disclosure, in the possession of the receiving party (as
evidenced by its written records) and was not previously acquired from or on behalf of
the disclosing party on a confidential basis,
	 
	 	8.3.2	 	was in the public domain prior to disclosure, or became, after disclosure,
publicly known through no fault of the receiving party or any person to whom the
receiving party directly or indirectly provided such CONFIDENTIAL INFORMATION,
	 
	 	8.3.3	 	was received from a third party who rightfully made such disclosure,
	 
	 	8.3.4	 	was approved for use or release by written authorization from the disclosing
party prior to such use or release by the receiving party,
	 
	 	8.3.5	 	is required to be disclosed by operation of law, governmental regulation or
court order provided the receiving party gives the disclosing party written notice of
such required disclosure prior to making such disclosure, and the receiving party

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

26

	 	 	 	uses all reasonable effort to cooperate in securing confidential protection for such
information; or
	 
	 	8.3.6	 	is required to be disclosed to any governmental authority or regulatory
authority to the extent that such disclosure is reasonably necessary to obtain
authorizations to conduct a clinical trial with and to market commercially PRODUCTS,
provided the disclosing party is otherwise entitled to engage in such activities under
this AGREEMENT.

Any specific CONFIDENTIAL INFORMATION shall not be deemed to fall within 8.3.1, 8.3.2, 8.3.3,
8.3.4, 8.3.5 or 8.3.6 above merely because it falls within the scope of more general information
within one of these exceptions.

Section 8.4 Term of Confidentiality

These obligations of confidentiality and non-use are binding throughout the duration of this
AGREEMENT and shall remain in force for a period of ten (10) years from the date of the expiration
or termination of this AGREEMENT.

Section 8.5 Return of Information

Upon termination and upon request from the disclosing party, the receiving party agrees to promptly
return all originals and copies of CONFIDENTIAL INFORMATION received, as well as permanently delete
all electronically or otherwise stored CONFIDENTIAL INFORMATION from all systems containing such
CONFIDENTIAL INFORMATION, except as otherwise required by applicable law and/or regulation and
except that one copy may be retained by legal counsel solely as a measure of the receiving party’s
obligations under this AGREEMENT.

Section 8.6 Publicity

	 	8.6.1	 	Confidentiality. Neither party may disclose any non-public
information regarding the nature and/or occurrence of this transaction, or the nature
and/or occurrence of any event or information occurring as a result of this transaction
without the prior written consent of the other party (such consent not to be
unreasonably withheld), except that each of MERCK and ONCOTHYREON may disclose such
information to their respective AFFILIATES that are under like terms of confidentiality
as those stated herein without such consent and any such information that is required
by law or any applicable regulatory authority to be disclosed (to the extent required
to be disclosed). Where practicable, prior to any required submission of the terms of
this transaction to any governmental agency or authority, the disclosing party shall
provide the other party with a copy of such submission including, without limitation,
identification of any portions of this AGREEMENT which the disclosing party intends to
redact or intends to request the governmental agency or authority to redact, so that
the other party may review and comment on any such proposed submission. The disclosing
party shall initially redact financial terms (and such other material terms as are
appropriate in the circumstances) and will use commercially reasonable efforts to
obtain the concurrence of the governmental agency or authority to such redaction of
financial and other material terms.

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

27

	 	8.6.2	 	Press Release. The parties shall agree on a press release to announce
the execution of this Agreement, and on a Question and Answer (“Q&A”) outline for use
in responding to inquiries about this AGREEMENT. With respect to future press releases
or other public statements relating to the subject matter of this AGREEMENT, including,
but not limited to, webcast materials, press kits and Q&A’s, except to the extent
dealing with subject matter already in the public domain or as required by law or any
applicable regulatory authority (and even then to the extent practicable) and except
with respect to information already in the public domain or previously approved by the
other party, ONCOTHYREON and MERCK shall each provide to the other party a copy of any
proposed press release and the other party shall provide any comments with respect
thereto within the same period of time (which shall be specified, but shall not be less
than twenty-four (24) hours) as the party proposing to issue such press release has
permitted for its own internal review. If no comments are received by the issuing
party within the permitted review period, the press release in question shall be deemed
to have been approved by the other party. If comments are received by the issuing
party within the permitted review period, then the issuing party shall seriously and in
good faith consider such comments and, to the extent such comments are not incorporated
in such press release, only the minimum legally or regulatorily required disclosure
shall be made with respect to such matters.
	 
	 	8.6.3	 	Scientific Publications.
	 
	 	 	 	MERCK, and not ONCOTHYREON (except with respect to research which took place on or
before the EFFECTIVE DATE), shall have the right to present at symposia,
professional meetings, and to publish in academic journals or other similar
publications, accounts of its research relating to the ONCOTHYREON TECHNOLOGY, the
PRODUCT, ONCOTHYREON IMPROVEMENTS, MERCK IMPROVEMENTS and JOINT IMPROVEMENTS which
are the subject of this AGREEMENT, provided that MERCK shall have furnished a copy
of the proposed disclosure at least sixty (60) days in advance of the presentation
or publication date to ONCOTHYREON. ONCOTHYREON shall use the sixty (60) day
period to evaluate the disclosure for patentable content and to, if it so
determines, pursue patent protection with respect thereto.

ARTICLE 9

INVENTIONS AND PATENTS

Section 9.1 JOINT IMPROVEMENTS

All IMPROVEMENTS made jointly by employees or others (including, without limitation, AFFILIATES of
MERCK) acting on behalf of ONCOTHYREON and MERCK (the “JOINT IMPROVEMENTS”) shall be jointly owned
by ONCOTHYREON and MERCK (each party shall have an undivided, one-half interest). JOINT
IMPROVEMENTS shall be managed pursuant to section 9.7.

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

28

Section 9.2 ONCOTHYREON IMPROVEMENTS

IMPROVEMENTS made solely by employees or others acting on behalf of ONCOTHYREON (the “ONCOTHYREON
IMPROVEMENTS”) shall be owned solely by ONCOTHYREON, and, in the circumstances specified in the
definition of BLP25, shall be subject to the licenses granted to MERCK in article 2.
Notwithstanding any provision to the contrary in this AGREEMENT, ONCOTHYREON shall have the right,
but not the obligation, to file, prosecute and maintain patent protection for ONCOTHYREON
IMPROVEMENTS to be licensed hereunder and, MERCK shall pay, to the extent Merck was given the
opportunity to select the respective countries in which to protect the same, one hundred percent
(100%) of the filing, prosecution, maintenance and defense costs associated with such patent
applications or patents and the use of the technology represented thereby and one hundred percent
(100%) of the development (including clinical development), scale-up and other costs associated
therewith throughout the TERRITORY. ONCOTHYREON may at any time, upon written notice to MERCK,
elect not to file, or cease prosecuting, defending and/or maintaining any patent and/or patent
application forming part of the ONCOTHYREON IMPROVEMENTS and shall, if requested in writing by
MERCK within forty-five (45) days of the receipt by MERCK of the aforementioned written notice from
ONCOTHYREON, assign such invention, patent and/or patent application, either in total or on a
country-by-country basis, to MERCK and MERCK shall bear one hundred percent (100%) of the
assignment costs in connection therewith and continue to bear one hundred percent (100%) of the
filing, production, maintenance and defence costs.

Section 9.3 MERCK IMPROVEMENTS

IMPROVEMENTS made solely by employees or others (including, without limitation, AFFILIATES of
MERCK) acting on behalf (including, without limitation, pursuant to any general services or other
similar agreement) of MERCK (the “MERCK IMPROVEMENTS”) shall be owned solely by MERCK. MERCK shall
have the right to file, prosecute and maintain at its cost patent protection for MERCK
IMPROVEMENTS.

Section 9.4 Determination of Inventorship

Inventorship shall be determined in accordance with U.S. patent law.

Section 9.5 Invention Disclosure

ONCOTHYREON shall promptly disclose to MERCK and MERCK shall promptly disclose to ONCOTHYREON any
IMPROVEMENTS arising under this AGREEMENT. Each party agrees to hold such disclosure from the
other party on a confidential basis under the same terms regarding confidentiality as described in
article 8. Each party agrees to keep the other party informed of the filing and status of any
patent application or patent pertaining to this AGREEMENT and shall consider any comments or
suggestions from the other party with respect thereto.

Section 9.6 Independent Use of JOINT IMPROVEMENTS

Within the FIELD the use of JOINT IMPROVEMENTS shall only be for purposes of and pursuant to the
terms and conditions of this AGREEMENT. Outside of the FIELD the parties shall each be entitled to
use JOINT IMPROVEMENTS as such party determines, provided that prior to a party licensing any such
JOINT IMPROVEMENT to a third party such party shall consult with the other party with the aim of
jointly licensing such JOINT IMPROVEMENT to

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

29

such third party. In the absence of a joint license, neither party may license a JOINT IMPROVEMENT
to a third party without the prior written consent of the other party.

Section 9.7 Prosecution and Maintenance of Joint Patents

	 	9.7.1	 	Filing, Prosecution and Maintenance. ONCOTHYREON and MERCK shall
determine, with respect to each JOINT IMPROVEMENT, the procedure and responsibility for
filing, prosecuting and maintaining patent applications with respect to such JOINT
IMPROVEMENTS. Unless otherwise agreed in writing, all reasonable costs incurred with
respect to the filing, prosecution and maintenance of patent applications and patents
covering JOINT IMPROVEMENTS, including fees and expenses of patent counsel, shall be
borne equally by the parties. Notwithstanding that one party may be delegated
responsibility for filing, prosecuting and maintaining patent applications with respect
to a particular JOINT IMPROVEMENT, the other party must approve in writing the taking
of any material action with respect thereto including without limitation approving any
patent application prior to filing. Both ONCOTHYREON and MERCK shall have the right to
participate fully in the formation and implementation of patent strategy.
	 
	 	9.7.2	 	Cooperation. Each party shall reasonably make available to the other
party or its authorized attorneys, agents or representatives, its employees, agents or
consultants (including, without limitation, AFFILIATES of MERCK) necessary or
appropriate to enable the appropriate party to file, prosecute and maintain patent
applications and resulting patents with respect to all JOINT IMPROVEMENTS, for a period
of time sufficient for such party to obtain the assistance it needs from such
personnel. All reasonable costs incurred by either party in providing such cooperation
shall be shared equally by the parties.
	 
	 	9.7.3	 	Failure to Agree. In the case of a failure of ONCOTHYREON and MERCK
to agree upon whether or in which countries patent applications should be filed and
prosecuted for JOINT IMPROVEMENTS, the party which desires to proceed may file and
prosecute the patent applications in its own name and at its own expense, and shall
maintain such patents at its own expense. If either ONCOTHYREON or MERCK wishes to
discontinue its portion of payment for maintenance of any patent on the JOINT
IMPROVEMENTS, such party may do so with prior written notice to the other party, and
the other party may maintain such patent on the JOINT IMPROVEMENTS at its own expense.
Notwithstanding the foregoing, either party may reacquire its rights in any patents or
patent applications in any country relating to the JOINT IMPROVEMENTS by paying its
portion of any costs incurred by the other party to such other party.

Section 9.8 No Waiver

By entering into this AGREEMENT, subject to the licenses granted in this AGREEMENT, neither party
waives or forfeits any of its rights to any patent that it owns and that exists at the EFFECTIVE
DATE, or to any IMPROVEMENT that it owns either jointly or solely.

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

30

Section 9.9 Cooperation with Respect to Patents

	 	9.9.1	 	The parties acknowledge and agree that it is in their mutual interest to
cooperate with respect to the filing, prosecution and maintenance of the ONCOTHYREON
PATENT RIGHTS in the FIELD. Therefore, with respect to the ONCOTHYREON PATENT RIGHTS
in the FIELD, ONCOTHYREON agrees to keep MERCK informed on a regular basis of its
patent strategy, proposed new patent applications and the filing and status of any
patent application or patent and to consider in good faith any comments or suggestions
of MERCK with respect thereto, subject to MERCK agreeing to appropriate safeguards with
respect to the ownership of such proprietary rights. MERCK agrees to hold such
disclosure from ONCOTHYREON on a confidential basis under the same terms regarding
confidentiality as described in article 8.
	 
	 	9.9.2	 	Subject to the other provisions of this article 9, ONCOTHYREON covenants and
agrees to use reasonable commercial efforts to prosecute and, prior to the expiration
or termination thereof, defend and maintain the ONCOTHYREON PATENT RIGHTS in the CORE
PATENT COUNTRIES during the term of this AGREEMENT, provided that ONCOTHYREON may at
any time, upon written notice to MERCK, cease prosecuting, defending and/or maintaining
any patent and/or patent application forming part of the ONCOTHYREON PATENT RIGHTS and
shall, if requested in writing by MERCK within forty-five (45) days of the receipt by
MERCK of the aforementioned written notice from ONCOTHYREON, assign such patent and/or
patent application, either in total or on a country-by-country basis, to MERCK. In the
event that MERCK requests to take over any such patent or patent application as
aforesaid, MERCK shall be responsible for all costs and expenses incurred in connection
with transferring such rights to MERCK and all ongoing costs and expenses in connection
with the prosecution, defence and maintenance of such rights (including without
limitation any liability and/or amounts payable with respect thereto pursuant to
section 10.2). Notwithstanding the foregoing but always subject to the other
provisions of this article 9, MERCK shall have the right in circumstances where MERCK
has assumed such obligations as aforesaid, at MERCK’S election, to (i) charge to
ONCOTHYREON all reasonable costs and expenses incurred by MERCK or its designated
AFFILIATE in connection with the prosecution, defence and maintenance of such patent or
patent application in such CORE PATENT COUNTRY notwithstanding the assignment thereof
to MERCK, or (ii) deduct such reasonable costs and expenses incurred by MERCK or its
designated AFFILIATE in connection with the prosecution, defence and maintenance of
such patent or patent application in such CORE PATENT COUNTRY from any payment
obligations that MERCK has vis-à-vis ONCOTHYREON or its AFFILIATES under this
AGREEMENT.

Section 9.10 Merck Manufacturing Activities

Notwithstanding any other provision to the contrary in this AGREEMENT, ONCOTHYREON and MERCK agree
that any manufacturing activities pursued or undertaken by or on behalf of MERCK or any of its
AFFILIATES or their respective sublicensees, contract manufacturers, and the like, after the
EFFECTIVE DATE (the “MERCK MANUFACTURING ACTIVITIES”)

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

31

which are at variance with or different from those undertaken by ONCOTHYREON prior to the EFFECTIVE
DATE shall be the sole responsibility, and at the risk, of MERCK.

ARTICLE 10

PATENT INFRINGEMENT

Section 10.1 Infringement by Third Parties

	 	10.1.1	 	Notification. If any claims in ONCOTHYREON PATENT RIGHTS licensed to MERCK
hereunder or in patent rights covering a JOINT IMPROVEMENT (“JOINT IMPROVEMENT PATENT
RIGHTS”) are believed to be infringed by a third party in a country where PRODUCT is
being or will be sold, the party first having knowledge of such infringement shall
promptly so notify the other party in writing. Such notice shall set forth in
reasonable detail the facts of that infringement as are then known.
	 
	 	10.1.2	 	Initiating Proceedings. ONCOTHYREON shall have the primary right, but not
the obligation, to initiate, prosecute, and control any action or proceeding with
respect to such infringement. If ONCOTHYREON fails to initiate proceedings intended to
remedy such infringement within ninety (90) days of receiving written notice of such
infringement, then MERCK may bring and control any such action. If one party initiates
proceedings intended to remedy such infringement, then the other party shall be kept
fully informed with respect to such proceedings and shall be consulted in relation to
all material discussions concerning such proceedings. Further, the other party agrees
to cooperate and give reasonable assistance, including agreeing to be joined as a party
plaintiff if suit is filed. The party which brings and controls proceedings against an
alleged infringer will do so at its own expense. If the other party chooses to be
represented by counsel of its own choice in any such proceeding, then that party may be
so represented, but at its own expense.
	 
	 	10.1.3	 	Distribution of Awards. Any monetary award received as a result of
proceedings contemplated by this section 10.1 shall first be used to compensate
ONCOTHYREON and MERCK for their respective reasonable expenses incurred in connection
with such proceedings (provided that if the monetary award is not sufficient to
compensate both ONCOTHYREON and MERCK for their reasonable expenses incurred in
connection with such proceedings, then such monetary award shall be apportioned pro
rata based on the reasonable expenses of each of the parties). Any award monies
remaining after such reimbursement shall (to the extent such award monies represent
compensation for lost SALES of PRODUCT) be added to NET SALES for the calendar quarter
in which they are received and then dealt with in the manner prescribed in this
AGREEMENT for such NET SALES. Any remaining award monies which do not represent
compensation for lost sales of PRODUCT shall be shared equally by the parties.
	 
	 	10.1.4	 	Voluntary Disposition. No settlement or consent judgment or other voluntary
final disposition of a suit under this section 10.1 may be entered into by either

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

32

party without the prior consent of the other party, such consent not to be
unreasonably withheld.

Section 10.2 Claims Against ONCOTHYREON TECHNOLOGY and JOINT TECHNOLOGY

	 	10.2.1	 	Notice.

	 	10.2.1.1	 	If a third party asserts that a patent or other right owned by it is
infringed by ONCOTHYREON’s and/or MERCK’s use or sale in the manner prescribed
in this AGREEMENT of any ONCOTHYREON PATENT RIGHTS, the party first obtaining
knowledge of such claim shall immediately provide the other party with written
notice of such claim and the related facts as are then known, in reasonable
detail. ONCOTHYREON shall have the primary right, but not the obligation to,
control the defense and settlement of any such claim at its expense. If
ONCOTHYREON fails to assume the control and settlement of any such claim within
ninety (90) days of receiving written notice thereof, then MERCK may control
the defense and settlement of such action. The controlling party shall keep
the non-controlling party fully informed with respect to all matters in
relation to such claim and shall consult with the non-consulting party in
relation to all material discussions concerning such claim and the defense
thereof. The non-controlling party agrees to cooperate and provide reasonable
assistance in defending such claims. No settlement shall be entered into
without the prior written consent of ONCOTHYREON and MERCK, such consent not to
be unreasonably withheld.
	 
	 	10.2.1.2	 	If a third party asserts that a patent or other right owned by it is
infringed by the use, in the manner prescribed in this AGREEMENT, of any JOINT
IMPROVEMENTS, the party first obtaining knowledge of such claim shall
immediately provide the other party with written notice of such claim and the
related facts as are then known, in reasonable detail. Both parties shall
share in the control of the defense and settlement of any such claim. Each
party shall keep the other party fully informed with respect to all matters in
relation to such claim and shall consult with the other party in relation to
all material discussions concerning such claim and the defense thereof. The
parties agree to cooperate and provide reasonable assistance to the other in
defending such claims. No settlement shall be entered into without the prior
written consent of ONCOTHYREON and MERCK, such consent not to be unreasonably
withheld.

	 	10.2.2	 	Damages.

	 	10.2.2.1	 	Subject to section 10.2.3, after complying fully with the procedures set
forth in section 10.2.1.1, any damages or other payments that result from a
claim of infringement as specified in section 10.2.1.1 that are

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

33

	 	 	 	required to be paid as a result of reaching a settlement with a third
party in the manner prescribed in section 10.2.1.1 or as a result of a
judgment from a competent court (which is unappealable or with respect to
which the appeal period has expired), shall be:

	 	10.2.2.1.1	 	shared equally by ONCOTHYREON and MERCK to the extent such
infringement relates to the NA TERRITORY or to the ROW TERRITORY
with respect to JOINT IMPROVEMENTS;
	 
	 	10.2.2.1.2	 	paid by ONCOTHYREON to the extent such infringement relates
to the NA TERRITORY or the ROW TERRITORY with respect to
ONCOTHYREON PATENT RIGHTS other than IMPROVEMENTS, JOINT
IMPROVEMENTS or as a result of MERCK MANUFACTURING ACTIVITIES; and
	 
	 	10.2.2.1.3	 	paid by MERCK to the extent such infringement relates to
IMPROVEMENTS, MERCK MANUFACTURING ACTIVITIES or to the extent
contemplated in section 10.2.4.

	 	 	 	Finally, the reasonable costs and expenses of the parties in defending
and settling any such action shall be borne by the responsible
party(ies) as set forth above.
	 
	 	10.2.2.2	 	After complying fully with the procedures set forth in section 10.2.1.2,
any damages or other payments that result from a claim of infringement as
specified in section 10.2.1.2 that are required to be paid as a result of
reaching a settlement with a third party in the manner prescribed in section
10.2.1.2 or as a result of a judgment from a competent court (which is
unappealable or with respect to which the appeal period has expired), shall be
shared equally by ONCOTHYREON and MERCK. Finally, the reasonable costs and
expenses of the parties in defending and settling any such action shall be
shared equally by ONCOTHYREON and MERCK.

	 	10.2.3	 	Royalty Payable to Third Party.
	 
	 	 	 	In the event that MERCK, after permitting ONCOTHYREON to defend against any such
allegation of infringement in the manner provided for in this article 10, is
obligated to pay a royalty to a third party (for which ONCOTHYREON is liable
pursuant to section 10.2.2.1) because the use and sale in the manner specified in
this AGREEMENT of PRODUCT in a country in the ROW TERRITORY or the NA TERRITORY
infringes one or more patents held by a third party claiming subject matter that is
also claimed in the ONCOTHYREON PATENT RIGHTS (but excluding ONCOTHYREON
IMPROVEMENTS, MERCK

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

34

	 	 	 	IMPROVEMENTS, JOINT IMPROVEMENTS and MERCK MANUFACTURING ACTIVITIES), then MERCK may
reduce the royalties otherwise payable to ONCOTHYREON under section 6.3 of this
AGREEMENT for PRODUCT in the applicable country by fifty percent (50%) of the amount
of all such royalties, license fee and other license payments properly paid by MERCK
to such third party, provided that in no circumstances shall the royalties otherwise
payable under this AGREEMENT by MERCK to ONCOTHYREON for PRODUCT in such country be
reduced to less than sixty percent (60%) of the amount otherwise payable.
	 
	 	10.2.4	 	Subject to Section 9.9.2.
	 
	 	 	 	The provisions of this section 10.2 do not apply to any ONCOTHYREON PATENT RIGHTS
taken over by MERCK under section 9.9.2 to the extent that MERCK’s (or those of its
AFFILIATES and their respective sublicensees, DISTRIBUTORS, contract manufacturers,
assignees and/or transferees) acts or omissions have contributed to the infringement
in question or claim thereof, and in all such cases and to the extent that MERCK’s
(or those of its AFFILIATES and their respective sublicensees, DISTRIBUTORS,
contract manufacturers, assignees and/or transferees) acts or omissions have
contributed to the infringement in question or claim thereof, MERCK shall be solely
responsible for all payments, costs and expenses in connection therewith.

ARTICLE 11

TERM AND TERMINATION

Section 11.1 Term and Expiration

This AGREEMENT shall be effective as of the EFFECTIVE DATE and, unless terminated earlier pursuant
to this article 11, this AGREEMENT shall remain in force and effect on a country-by-country basis
until the later of (a) the expiration or termination of the last to expire or terminate of VALID
CLAIMS that cover PRODUCT in such country, and (b) the date which is the fifteenth
(15th) anniversary of the LAUNCH of PRODUCT in any country in the TERRITORY.

Section 11.2 Early Termination

This AGREEMENT may be terminated as follows:

	 	11.2.1	 	by mutual written agreement of ONCOTHYREON and MERCK, effective as of the time
specified in such written agreement; or
	 
	 	11.2.2	 	by either party, upon any breach of this AGREEMENT by the other party of any
obligation to make payments required hereunder, which failure to make payment is not
the subject of a legitimate, good faith dispute between the parties, provided, however,
that the party alleging such breach must first give the other party written notice
thereof, which notice must identify the breach in reasonable detail and that the party
giving such notice views such alleged breach as a basis for terminating this AGREEMENT
under this section 11.2.2 and the party receiving such notice

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

35

	 	 	 	must have failed to cure such alleged breach within forty-five (45) days after
receipt of such notice; or
	 
	 	11.2.3	 	by either party, upon any material breach of this AGREEMENT by the other party,
provided, however, that the party alleging such material breach must first give the
other party written notice thereof, which notice must identify the breach in reasonable
detail and that the party giving such notice views such alleged material breach as a
basis for terminating this AGREEMENT under this section 11.2.3 and the party receiving
such notice must have failed to cure such alleged material breach within ninety (90)
days after receipt of such notice or, such longer period of time as the party alleging
such material breach may agree to in writing as a result of the good faith efforts of
the other party to resolve such material breach in a timely manner; or
	 
	 	11.2.4	 	by either party, in the event that the other party institutes any proceedings under
any statute or otherwise relating to insolvency or bankruptcy, or should any
proceedings under any such statute or otherwise be instituted against such party and
not be dismissed or vacated within ninety (90) days of the date of commencement of such
proceedings;
	 
	 	11.2.5	 	by MERCK upon thirty (30) days prior written notice to ONCOTHYREON if, in the
exercise of MERCK’s reasonable judgment, MERCK determines that there are issues
concerning the safety or efficacy of PRODUCT which materially adversely affects
PRODUCT’s medical, economic or competitive viability, provided that if ONCOTHYREON does
not agree with such determination and notifies MERCK to that effect within ten (10)
days following receipt by ONCOTHYREON of MERCK’s written notice of termination, the
matter shall be submitted to binding arbitration before an expert or expert panel in
the field of clinical drug development, such expert or expert panel to be appointed by
ONCOTHYREON and MERCK in accordance with the procedure under section 14.7 of this
AGREEMENT.

Section 11.3 Continuing Liability

Termination of this AGREEMENT for any reason shall not release any party from any liability,
obligation or agreement which has already accrued nor affect the survival of any provision hereof
which is expressly stated to survive such termination. Termination of this AGREEMENT for any
reason shall not constitute a waiver or release of, or otherwise be deemed to prejudice or
adversely affect, any rights, remedies or claims, whether for damages or otherwise, which a party
may have hereunder or which may arise out of or in connection with such termination.

Section 11.4 Disposition of Inventory

MERCK may dispose of its inventory of PRODUCT on hand as of the effective date of termination, and
may fill any orders for PRODUCT accepted prior to the effective date of termination, for a period
of twelve (12) months after the effective date of termination, and, within thirty (30) days after
disposition of such inventory and fulfilment of such orders (and in any event within fourteen (14)
months after termination) MERCK will forward to

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

36

ONCOTHYREON a final report and pay all royalties or other amounts due for NET SALES in such period.

Section 11.5 Rights and Cooperation on Termination 

Upon the termination of this AGREEMENT in its entirety, or with respect to a particular country,
the parties shall cooperate so as to minimize the impact of such termination on both parties.
ONCOTHYREON and its AFFILIATES shall have the right to use any and all proprietary information and
data relating to the manufacture of PRODUCT and any and all preclinical and clinical trial results
and related data relating to PRODUCT that are developed by or on behalf of ONCOTHYREON and/or MERCK
(including, without limitation, MERCK’s AFFILIATES) after the ORIGINAL EFFECTIVE DATE pursuant to
this AGREEMENT (including without limitation all such results and data used or developed by MERCK
(including, without limitation, MERCK’s AFFILIATES) in support of applications for MARKET
APPROVAL), all MARKET APPROVALS shall be assigned to ONCOTHYREON or its designated AFFILIATE by
MERCK (of its applicable AFFILIATE) as soon as is reasonably practicable, and all third party
manufacturing agreements and related rights used to manufacture PRODUCT shall be assigned to
ONCOTHYREON or its designated AFFILIATE by MERCK (or its applicable AFFILIATE) as soon as is
reasonably practicable. For ONCOTHYREON requested proprietary information and data relating to the
manufacture of PRODUCT only (whether patent protected or not), ONCOTHYREON shall pay to MERCK such
reasonable compensation as is agreed to in writing by ONCOTHYREON and MERCK, acting reasonably, in
good faith and in a timely manner, and, if not agreed to by MERCK and ONCOTHYREON within forty-five
(45) days of the date of termination of this AGREEMENT, such compensation shall be determined
pursuant to section 14.7 of this AGREEMENT. To the extent required in connection with the
foregoing, MERCK hereby grants to ONCOTHYREON and its AFFILIATES an irrevocable, non-exclusive,
royalty-free (subject to the compensation to be paid by ONCOTHYREON to MERCK described above)
license to use such proprietary technology, information and data relating to the manufacture of
PRODUCT and such preclinical and clinical trial results and data in the TERRITORY. Finally, for a
period not to exceed [+] from termination, MERCK shall supply sufficient PRODUCT to ONCOTHYREON or
its designated AFFILIATE to meet such requirements at a cost equal to [+] of the MERCK COST OF
GOODS incurred by or on behalf of MERCK in connection with the manufacture of such PRODUCT and
otherwise reasonably assist ONCOTHYREON and/or its designated AFFILIATE, at ONCOTHYREON’s expense,
to manufacture or have manufactured PRODUCT.

Section 11.6 Rights and Cooperation on Expiration

Upon expiration of this AGREEMENT with respect to a particular country as provided for in section
11.1 of this AGREEMENT, or if any of the licenses granted by ONCOTHYREON to MERCK in this AGREEMENT
with respect to PRODUCT in such country become non-exclusive, MERCK shall (i) permit ONCOTHYREON or
its designated AFFILIATE to utilize all MARKET APPROVALS owned by MERCK and/or its AFFILIATES with
respect to PRODUCT in such country (ii) permit ONCOTHYREON or its designated AFFILIATE to use any
and all proprietary information and data relating to the manufacture of PRODUCT and any and all
preclinical and clinical trial results and related data relating to PRODUCT developed by or on
behalf of MERCK and its AFFILIATES, (iii) supply, for a period of not to exceed [+] from such
expiration, sufficient PRODUCT to ONCOTHYREON or its designated AFFILIATE to meet their
requirements at a cost equal to [+] of the MERCK COST OF GOODS incurred by or

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

37

on behalf of MERCK in connection with the manufacture of such PRODUCT and otherwise reasonably
assist ONCOTHYREON and/or its designated AFFILIATE, at ONCOTHYREON’s expense, to manufacture or
have manufactured PRODUCT, and (iv) take all other actions reasonably necessary to permit
ONCOTHYREON or its designated AFFILIATE to commence the manufacture, marketing and SALE of PRODUCT
in such country. Such actions may include, but shall not be limited to, the filing of duplicate
MARKET APPROVALS upon ONCOTHYREON’s request and at its sole expense, and granting ONCOTHYREON
permission to cross-reference, copy and duplicate the MARKET APPROVALS. For ONCOTHYREON requested
proprietary information and data relating to the manufacture of PRODUCT only (whether patent
protected or not), ONCOTHYREON shall pay to MERCK such reasonable compensation as is agreed to in
writing by ONCOTHYREON and MERCK, acting reasonably, in good faith and in a timely manner, and, if
not agreed to by MERCK and ONCOTHYREON within forty-five (45) days of the date of termination of
this AGREEMENT, such compensation shall be determined pursuant to section 14.7 of this AGREEMENT.
To the extent required in connection with the foregoing, MERCK hereby grants to ONCOTHYREON and its
AFFILIATES an irrevocable, non-exclusive, royalty-free (subject to the compensation to be paid by
ONCOTHYREON to MERCK described above) license to use such proprietary technology, information and
data relating to the manufacture of PRODUCT and such preclinical and clinical trial results and
data in the TERRITORY.

ARTICLE 12

REPRESENTATIONS AND WARRANTIES

Section 12.1 Corporate Existence and Power

Each party represents and warrants to the other party that, as of the EFFECTIVE DATE, (a) it is a
corporation duly organized and validly existing and in good standing, under the laws of the
jurisdiction of its incorporation; (b) it has the corporate power and authority and the legal
right to own its property and assets, to lease the property and assets it operates under lease, and
to carry on its business as it is now being conducted; and (c) it is in compliance with all
requirements of applicable law, except to the extent that any non-compliance would not have a
material adverse effect on the properties, business, financial or other condition of such party and
would not materially adversely affect such party’s ability to perform its obligations under this
AGREEMENT.

Section 12.2 Authorization and Enforcement of Obligations

Each party represents and warrants to the other party that, as of the EFFECTIVE DATE, it has the
corporate power and authority and legal right to enter into this AGREEMENT and to perform its
obligations hereunder; and that this AGREEMENT has been duly executed and delivered on behalf of
each party and, except as it may be limited by applicable law, constitutes a legal, valid, binding
obligation, according to its terms.

Section 12.3 Consents

Subject to section 2.3 of this AGREEMENT, each party represents and warrants to the other party
that, as of the EFFECTIVE DATE, all necessary consents, approvals and authorizations of all
governmental authorities and others required to be obtained by such party in connection with this
AGREEMENT have been obtained.

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

38

Section 12.4 No Conflict

Subject to section 2.3 of this AGREEMENT, each party represents and warrants to the other party
that, as of the EFFECTIVE DATE, the execution and delivery of this AGREEMENT and the performance of
such party’s obligations hereunder do not conflict with or violate any requirement of applicable
laws or regulations, and do not conflict with, or constitute a default under any contractual
obligation of such party.

Section 12.5 Authorization of Obligations

The execution, delivery and performance by each party of this AGREEMENT have been duly authorized
by all necessary corporate action and do not and will not (a) require any consent or approval of
its stockholders or, subject to section 2.3 of this AGREEMENT, any other third party that has not
been received by the EFFECTIVE DATE, (b) violate any provision of any law, rule, regulation, order,
writ, judgment, injunction, decree, determination or award presently in effect that have
applicability to it or any provision of its charter documents or (c) result in a breach of or
constitute a default under any material agreement, mortgage, lease, license, permit or other
instrument or obligation to which it is a party or by which it or its properties may be bound or
affected.

Section 12.6 ONCOTHYREON Representations 

	 	12.6.1	 	ONCOTHYREON represents and warrants to MERCK that as of the EFFECTIVE DATE (but
subject to section 2.3 and the need to obtain the consents of the licensees under the
THIRD PARTY LICENSES):

	 	12.6.1.1	 	to ONCOTHYREON’s knowledge after due inquiry, ONCOTHYREON is the sole owner
of, or the exclusive licensee or sublicensee (on the terms described in the
applicable licensee agreement) in the NA TERRITORY and the ROW TERRITORY of the
ONCOTHYREON PATENT RIGHTS and the ONCOTHYREON KNOW-HOW in existence as at the
EFFECTIVE DATE, with the right to grant to MERCK the rights granted in this
AGREEMENT, free and clear (except to the extent specified in the THIRD PARTY
LICENSES) of any liens or encumbrances which would prevent or impair the grant
of such rights;
	 
	 	12.6.1.2	 	ONCOTHYREON has not assigned or conveyed any interest in the ONCOTHYREON
PATENT RIGHTS or the ONCOTHYREON KNOW-HOW in existence as at the EFFECTIVE DATE
and licensed to MERCK under this AGREEMENT, or entered into any agreement or
made any commitment which is inconsistent with or in derogation of the rights
granted to MERCK hereunder;
	 
	 	12.6.1.3	 	as at the EFFECTIVE DATE, ONCOTHYREON has not received from any third party
any written notice to the effect that the ONCOTHYREON PATENTS or the
ONCOTHYREON KNOW-HOW infringe the proprietary rights of any such third party;

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

39

	 	12.6.1.4	 	there is no action, suit, proceeding, alternative dispute resolution,
mediation or investigation pending or, to the knowledge of ONCOTHYREON,
threatened against ONCOTHYREON relating to the ONCOTHYREON PATENT RIGHTS or the
ONCOTHYREON KNOW-HOW;
	 
	 	12.6.1.5	 	to ONCOTHYREON’s knowledge after due inquiry, no third party rights are
required in order to enable MERCK to enjoy, as currently enjoyed by MERCK as at
the EFFECTIVE DATE, the licenses granted by ONCOTHYREON to MERCK under this
AGREEMENT; and
	 
	 	12.6.1.6	 	to ONCOTHYREON’s knowledge after due inquiry, the ICRT LICENSE and the
DANA-FARBER LICENSE are in full force and effect and ONCOTHYREON has no
knowledge of any breach or action by ONCOTHYREON which might give rise to a
breach under such licenses.

Section 12.7 No Further Representations or Warranties

Except as expressly provided in this article 12 or any other provision of this AGREEMENT, or in the
Asset Purchase Agreement, neither party makes any representation or warranty of any kind to the
other party, express or implied.

Section 12.8 Survival of Representations and Warranties

The representations and warranties contained in this AGREEMENT shall survive the EFFECTIVE DATE, as
applicable, for a period of one (1) year.

ARTICLE 13

INDEMNIFICATION

Section 13.1 Indemnification by ONCOTHYREON

Subject to the terms and conditions of this AGREEMENT, ONCOTHYREON shall indemnify and hold MERCK
(and any affiliated corporation and their respective officers, directors, shareholders, employees
and agents) (collectively, the “MERCK INDEMNITEES”), free and harmless from any and all claims,
demands, liabilities, losses, actions or causes of actions, and any and all expenses associated
therewith (including, without limiting the generality of the foregoing, reasonable defense costs
and attorney’s fees), arising out of or in connection with, or that are the result of, or are
otherwise related to: (i) actions and proceedings brought by any regulatory or other authority
against any of the MERCK INDEMNITEES concerning PRODUCT, for or on account of the alleged
unapproved or unauthorized introduction by ONCOTHYREON, its AFFILIATES or their respective agents
of PRODUCT in interstate or intrastate commerce anywhere in the world; (ii) any claim, complaint,
suit, proceeding or cause of action against any of the MERCK INDEMNITEES alleging physical injury,
including death as a result of the acts or omissions of ONCOTHYREON, its AFFILIATES or their
respective employees and agents, except to the extent attributable to any one or more of the MERCK
INDEMNITEES; (iii) ONCOTHYREON’s, its AFFILIATES’ or their respective agents’ non-compliance with
any applicable laws or regulations, except to the extent attributable to any one or more of the
MERCK INDEMNITEES; (iv) any failure of ONCOTHYREON to perform, in

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

 

40

whole or in part, any of its obligations hereunder, except to the extent attributable to any one or
more of the MERCK INDEMNITEES; (v) for the period specified in section 12.8, any breach by
ONCOTHYREON of any of its representations or warranties under this AGREEMENT; or (vi) any breach by
ONCOTHYREON or its AFFILIATES of the THIRD PARTY LICENSES which materially adversely affects
MERCK’s rights under this AGREEMENT, except to the extent attributable to any one or more of the
MERCK INDEMNITEES.

Section 13.2 Indemnification by MERCK

Subject to the terms and conditions of this AGREEMENT, MERCK shall indemnify and hold ONCOTHYREON
(and any affiliated corporation and their respective officers, directors, shareholders, employees
and agents) (the “ONCOTHYREON INDEMNITEES”), free and harmless from any and all claims, demands,
liabilities, losses, actions or causes of actions, and any and all expenses associated therewith
(including, without limiting the generality of the foregoing, reasonable defense costs and
attorney’s fees), arising out of or in connection with, or that are the result of, or are otherwise
related to: (i) actions and proceedings brought by any regulatory authority against any of the
ONCOTHYREON INDEMNITEES concerning PRODUCT, for or on account of the alleged unapproved or
unauthorized introduction by MERCK, its AFFILIATES or their respective distributors, sublicensees
and agents of PRODUCT in interstate or intrastate commerce anywhere in the world; (ii) any claim,
complaint, suit, proceeding or cause of action against any of the ONCOTHYREON INDEMNITEES alleging
physical injury, including death as a result of the acts or omissions of MERCK, its AFFILIATES or
their respective employees, distributors, sublicensees and agents, except to the extent
attributable to any one or more of the ONCOTHYREON INDEMNITEES; (iii) MERCK’s, its AFFILIATES’ or
their respective distributors’, sublicensee’s or agents’ non-compliance with any applicable laws or
regulations, except to the extent attributable to any one or more of the ONCOTHYREON INDEMNITEES;
(iv) any failure of MERCK to perform, in whole or in part, any of its obligations hereunder, except
to the extent attributable to any one or more of the ONCOTHYREON INDEMNITEES; (v) MERCK’s, its
AFFILIATES’ or their respective distributors’, sublicensees’, contract manufacturers’ or agents’
manufacture, marketing and/or SALE of PRODUCT, except to the extent attributable to any one or more
of the ONCOTHYREON INDEMNITEES; or (vi) for the period specified in section 12.8, any breach by
MERCK of any of its representations or warranties under this AGREEMENT.

Section 13.3 Procedure

The indemnified party shall give prompt written notice to the indemnifying party(ies) of any suits,
claims or demands by third parties or the indemnified party which may give rise to any loss for
which indemnification may be required under this article 13; provided, however, that failure to
give such notice shall not impair the obligation of the indemnifying party to provide
indemnification hereunder except if and to the extent that such failure materially impairs the
ability of the indemnifying party to defend the applicable suit, claim or demand. The indemnifying
party shall be entitled to assume the defense and control of any suit, claim or demand of any third
party at its own cost and expense; provided, however, that the other party shall have the right to
be represented by its own counsel at its own cost in such matters. In the event that the
indemnifying party shall decline to assume control of any such suit, claim or demand, the party
entitled to indemnification shall be entitled to assume such control, conduct the defense of, and
settle such suit, claim or action, all at the sole cost and expense of the indemnifying party.
Neither the indemnifying party nor the indemnified party shall settle or

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

41

dispose of any such matter in any manner which would adversely impact the rights or interests of
the other party without the prior written consent of the indemnified party, which shall not be
unreasonably withheld. Each party shall cooperate with the other party and its counsel in the
course of the defense of any such suit, claim or demand, such cooperation to include using
reasonable efforts to provide or make available documents, information and witnesses.

ARTICLE 14

MISCELLANEOUS

Section 14.1 Force Majeure

Any delay in the performance of any of the obligations of either party (except for the payment of
money) shall not be considered a breach of this AGREEMENT and the time required for performance
shall be extended for a period equal to the period of such delay, provided that such delay has been
caused by or is the result of (including without limitation in relation to third party contractors
and suppliers) any act of God, acts of the public enemy; insurrections; riots; embargoes; labour
disputes such as strikes, lockouts or boycotts; fires; explosions; floods; earthquakes; mudslides;
or other unforeseeable causes beyond the control of the party so affected. The party so affected
shall give prompt notice to the other party of such cause, and shall take whatever reasonable steps
are necessary to relieve the effect of such cause as rapidly as reasonable.

Section 14.2 Independent Contractor

Execution of each party’s responsibilities under this AGREEMENT is solely under the direction and
control of each respective party as an independent contractor, and not as an employee or agent of
the other party.

Section 14.3 Survival

Such provisions of this AGREEMENT that, by their nature, would be expected to survive termination
of this AGREEMENT, including without limitation sections 7.3, 7.5, 11.3, 11.4, 11.5, 11.6, 14.6,
14.9 and 14.14 and articles 8 and 13 shall survive any such termination.

Section 14.4 Notice

Whenever any notice is to be given hereunder, it shall be in writing and shall be deemed received
on the day delivered, if delivered by courier on a business day, or if sent by first-class
certified or registered mail, postage prepaid, to the following addresses:

ONCOTHYREON:

Biomira Management, Inc.

2601 Fourth Avenue, Suite 500

Seattle WA 98121

United States of America

Attention: President

Facsimile: (206) 801-2101

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

42

With a copy to:

Oncothyreon Inc.

2601 Fourth Avenue, Suite 500

Seattle WA 98121

United States of America

Attention: President

Facsimile: (206) 801-2101

MERCK:

Merck KGaA

Frankfurter Strasse 250

D-64293 Darmstadt

Germany

Attention: Merck Serono Legal Department

Facsimile: +49-6151-72-2373

With a copy to

Merck Serono S.A Geneva

9 Chemin des Mines, 1202 Geneva

Switzerland

Facimile: +41224143660

Section 14.5 Waivers

No waiver of any term, provision, or condition of this AGREEMENT, whether by conduct or otherwise,
in any one or more instances, shall be deemed to be construed as a further or continuing waiver of
any such term, provision, or condition of this AGREEMENT unless reduced to writing signed by an
authorized representative of each party.

Section 14.6 Applicable Law

This agreement shall be construed under the substantive laws of England, without reference to its
conflicts of laws provisions.

Section 14.7 Dispute Resolution

Should any dispute arise between the parties concerning this AGREEMENT, the parties agree to first
attempt to resolve the dispute in good faith. If within fifteen (15) days of one party providing
written notice of such dispute to the other party such dispute is not resolved, then the parties
agree to continue to attempt to resolve the dispute in good faith through meetings between a member
of MERCK’s Executive Management Board and the President of ONCOTHYREON before resorting to any
other forum for a remedy. If resolution of the dispute is not reached between the Presidents
within twenty (20) days of either party submitting such dispute in writing to the Presidents, then
the parties shall within the next following fifteen (15) day period initiate binding arbitration in
London, England under the rules of the International Chamber of Commerce. The party desiring
arbitration shall nominate one (1) arbitrator and shall

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

43

notify the other party in writing of such nomination. Such other party shall, within ten (10) days
after receiving such notice, nominate an arbitrator and the two (2) arbitrators shall select a
third arbitrator of the arbitration tribunal to act jointly with them. The parties will act
reasonably and in good faith to select arbitrators who are objective and who are suitably qualified
by education or professional experience to deal with the matters which are the subject of the
arbitration.

Section 14.8 Assignment

The parties agree that this AGREEMENT is personal in nature and, except for transfer by ONCOTHYREON
to any of its AFFILIATES, this AGREEMENT may not be assigned or otherwise transferred, nor may any
right or obligations hereunder be assigned or transferred directly or indirectly by either party,
whether voluntary, by operation of law or otherwise, without the written consent of the other
party, such consent not to be unreasonably withheld. In connection with ONCOTHYREON determining
whether to consent to an assignment, the parties agree that ONCOTHYREON shall be deemed to be
acting reasonably if it withholds its consent in circumstances where the proposed assignee is not a
corporation of equal or greater financial resources, marketing strength and expertise (including in
the cancer area), and stature in the pharmaceutical industry as MERCK. Any purported assignment in
violation of this section 14.8 shall be void. Notwithstanding the foregoing, either party may,
without such consent, assign or novate this AGREEMENT and its rights and obligations hereunder in
connection with the transfer or sale of all or substantially all of its business, through merger,
consolidation or change in control or similar transaction after first giving the other party
written notice of such event. Pursuant to any such assignment, any permitted assignee shall assume
all rights of the assignor under this AGREEMENT, and pursuant to any such novation, any permitted
novatee shall assume all rights and obligations of the novator under this AGREEMENT.

Section 14.9 Currency

All payments to be made under this AGREEMENT shall be made in United States dollars. The currency
in which NET SALES were invoiced shall be converted to United States dollars on the date of payment
of the royalty due using the applicable commercial rate of exchange for buying US dollars with the
currency that is the average of the closing buying rates for such currency for the quarter for
which such payments are due, quoted as local currency per US $1, as established and published by
the European Central Bank.

Section 14.10 Payment of taxes

Each of ONCOTHYREON and MERCK shall be responsible for any and all taxes and other similar levies
or charges properly assessed against payments received by such party from the other party under
this AGREEMENT. If applicable laws or regulations require that taxes be withheld on such payments,
the withholding party will in a timely manner notify the other party in writing specifying the
details thereof and shall:

	 	14.10.1	 	deduct those taxes from the amount of such payment due to the receiving party,
	 
	 	14.10.2	 	pay the taxes to the proper taxing authority in a timely manner, and
	 
	 	14.10.3	 	send proof of payment to the receiving party within sixty (60) days following that
payment.

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

44

The parties agree to cooperate to reduce the amount of any such deductions and to obtain the
benefit of any tax treaty with respect to such deductions. Further, the withholding party shall
cooperate with the receiving party in obtaining for the receiving party a credit or refund for any
such taxes, levies or charges. Neither party shall be required under this concluding paragraph of
section 14.10 to act in a manner which is financially detrimental from a taxation perspective to
such party.

Section 14.11 Interest

Any late payments of any nature under this AGREEMENT shall bear interest, running from the date
such payment was due until such payment is made in full, at a rate per annum equal to the average
three (3) month US dollar LIBOR rate (as published from time to time by Reuters) plus one percent
(1%).

Section 14.12 Sublicensees

In addition to the requirements of sections 2.1 and 2.3 of this AGREEMENT, in the event MERCK
utilizes any AFFILIATE or third party to distribute PRODUCT (directly or indirectly) for MERCK in
the TERRITORY or otherwise sublicenses any of the licensed rights under this AGREEMENT, the
agreement with such AFFILIATE or third party shall include an obligation for such third party to
comply with the provisions of this AGREEMENT on the same basis as if such SALES were made by MERCK,
and MERCK shall for all purposes under this AGREEMENT treat the net sales of PRODUCT of the
sublicensee as NET SALES of MERCK.

Section 14.13 Limitation

Notwithstanding any other provision to the contrary in this AGREEMENT, other than with respect to
applicable third party product liability and patent infringement claims, the maximum aggregate
liability of ONCOTHYREON under this AGREEMENT shall not exceed the amounts paid by MERCK to
ONCOTHYREON up to the time in question under this AGREEMENT (including, for greater certainty,
payments by MERCK under this AGREEMENT with respect to shared costs, equity purchases and
milestones) and any preceding agreement between the parties relating to the PRODUCT. Neither party
shall have any liability to the other party or any other person pursuant to this AGREEMENT for any
special, indirect or consequential damages, including but not limited to loss of profits, loss of
business opportunities or loss of business investment.

Section 14.14 Severability

If any provision of this AGREEMENT is held to be illegal or unenforceable, that provision shall be
limited to the minimum extent necessary or, if necessary, eliminated, so that this AGREEMENT shall
otherwise remain enforceable and in full force and effect

Section 14.15 Integration Clause

Except for the ASSET PURCHASE AGREEMENT, this AGREEMENT is the sole agreement with respect to the
subject matter hereof, and supersedes all proposals, negotiations, conversations, discussions,
agreements (including the 2006 COLLABORATION AGREEMENT and the 2006 SUPPLY AGREEMENT) and/or
representations, whether oral or written, including any industry custom or past dealing between the
parties relating to the subject matter of this AGREEMENT. The parties agree that any and all obligations between the parties that are outside the
terms of this  AGREEMENT and that relate to the subject matter of this

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

45

 AGREEMENT that preceded the
EFFECTIVE DATE of this AGREEMENT have been satisfactorily executed or are null and void.

Section 14.16 U.S. Dollars

Unless otherwise provided, any reference in this AGREEMENT to dollars shall be to U.S. dollars.

Section 14.17 Amendment of Agreement

No change, modification, extension, termination, waiver or other amendment of this AGREEMENT or any
of the provisions contained herein, shall be valid unless made in writing and signed by a duly
authorized representative of each party.

Section 14.18 Third Parties

A person who is not a party to this AGREEMENT has no rights under the Contracts (Rights of Third
Parties) Act 1999 to enforce any term of this AGREEMENT.

Section 14.19 No Further Representations or Warranties

Each party acknowledges that it has not relied on or been induced to enter this AGREEMENT by a
representation or warranty other than those expressly set out in this AGREEMENT. A party is not
liable to the other party for a representation or warranty that is not set out in this AGREEMENT,
including any warranty implied by statute.

Section 14.20 Non-Solicitation

During the term of this AGREEMENT, without the prior written consent of the other party, neither
party shall knowingly solicit for hire any existing employee of the other party.

Section 14.21 Counterparts

This AGREEMENT may be executed in several counterparts, each of which when so executed shall be
deemed to be an original and shall have the same force and effect as an original but such
counterparts together shall constitute but one and the same instrument.

This AGREEMENT is agreed to and accepted by:

	 	 	 	 	 	 	 	 	 
	Merck KGaA	 	 	 	Biomira Management Inc.
	 
	 	 	 	 	 	 	 	 
	By:

	 	/s/ Andreas Stickler
	 	 
	 	By:
	 	/s/ Robert L. Kirkman, M.D.
	 

	 	 
	 	 	 	 	 	 
	 

	 	Title: Head of M&A
	 	 	 	 
	 	Title: President & CEO
	 

	 	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	AND
	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	By:

	 	/s/ Jens Eckhardt	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	 
	 	 	Title: Associate General Counsel	 	 	 	[IN DUPLICATE]
	 

	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	 

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

46

APPENDIX 1

CORE PATENT COUNTRIES

[+]

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

47

APPENDIX 2

ONCOTHYREON KNOW-HOW

[+] [Redaction continues for two pages]

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

48

APPENDIX 3

ONCOTHYREON PATENT RIGHTS

[+]

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

49

APPENDIX 4

PROTOCOL FOR PHASE III CLINICAL TRIAL

OF BLP25 FOR NON-SMALL CELL LUNG CANCER

[+]

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

50

APPENDIX 5

TRADEMARKS

[+] [Redaction continues for 20 pages]

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSIONexv10w45

Exhibit 10.45

ASSET PURCHASE AGREEMENT

This Agreement is dated as of the 18th day of December, 2008.

AMONG:

ONCOTHYREON CANADA INC., a Canadian corporation with offices located at Edmonton,
Alberta (“Oncothyreon Canada”)

AND:

BIOMIRA MANAGEMENT, INC., a Delaware corporation with offices located at Seattle,
Washington (“Biomira Management”)

AND:

ONCOTHYREON INC., a Delaware corporation with offices located at Seattle, Washington
(“Oncothyreon Parent”)

(Oncothyreon Canada, Biomira Management and Oncothyreon Parent hereinafter
collectively referred to as “Oncothyreon”)

AND:

MERCK KGaA, a German corporation with offices located at Darmstadt, Germany
(“Merck”)

AND:

EMD SERONO CANADA INC., an Ontario corporation with offices located at 2695 North
Sheridan Way, Suite 200, Mississauga, Ontario (“EMD”), an affiliate of Merck

     WHEREAS Merck and Biomira Management will be entering into an amended and restated license
agreement pursuant to which Biomira Management will license to Merck, inter alia, certain
manufacturing rights in relation to the manufacture of BLP25;

     AND WHEREAS Oncothyreon Canada and Biomira Management have agreed to sell certain assets
related to the manufacture of BLP25 to EMD and Merck and EMD and Merck have agreed to purchase such
assets from Oncothyreon Canada and Biomira Management, all upon the terms and subject to the
conditions set forth in this Agreement;

     AND WHEREAS EMD and Oncothyreon Canada have agreed on certain matters in respect of certain
employees of Oncothyreon Canada;

     NOW THEREFORE in consideration of the representations, warranties, covenants and agreements
set forth in this Agreement and other good and valuable consideration, the receipt and sufficiency
of which is acknowledged by the parties hereto, the parties hereto covenant and agree as follows:

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

2

ARTICLE 1

INTERPRETATION

Section 1.1 Definitions

     In this Agreement, unless otherwise provided, the following terms shall have the following
meanings:

	 	1.1.1	 	“Adjustment Date” has the meaning set out in Section 5.4;
	 
	 	1.1.2	 	“Affiliate” means any business entity that directly or indirectly controls, is
controlled by, or is under common control with either party to this Agreement. A
business entity shall be deemed to “control” another business entity if it owns,
directly or indirectly, more than fifty (50%) percent of the outstanding voting
securities, capital stock, or other comparable equity or ownership interest of such
business entity. If the laws of the jurisdiction in which such business entity
operates prohibit ownership by a party of more than fifty percent (50%), control shall
be deemed to exist at the maximum level of ownership allowed by such jurisdiction;
	 
	 	1.1.3	 	“Agreement” means this asset purchase agreement, together with any amendments
to or replacements of or substitutions for this asset purchase agreement;
	 
	 	1.1.4	 	“Applicable Law” means

	 	1.1.4.1	 	any applicable domestic or foreign law including any statute, subordinate
legislation or treaty, and
	 
	 	1.1.4.2	 	any applicable guideline, directive, rule, standard, requirement, policy,
order, judgment, injunction, award or decree of a Governmental Authority having
the force of law;

	 	1.1.5	 	“Assets” means all of Oncothyreon’s right, title and interest in and to all of
the assets that Oncothyreon uses to carry on the Purchased Business as of December18,
2008 (or in the six months prior to December18, 2008, has used to carry on the
Purchased Business subject to ordinary course of business changes, sales, replacements,
alterations, disposals, usage, breakage, and the like, during such period) including,
without limiting the generality of the foregoing: (i) the Lease; (ii) the Leased
Premises Assets; (iii) the Manufacturing Contracts; (iv) the Inventory Assets; and (v)
the Other Assets but excluding for greater certainty the Excluded Assets;
	 
	 	1.1.6	 	“Assumed Liabilities” has the meaning set out in Section 2.7;
	 
	 	1.1.7	 	“Books and Records” means: the books, records and accounts of the Purchased
Business and includes, without limitation, all material documents, data, information
and correspondence (including general correspondence in writing or

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

3

	 	 	 	electronic form) in the possession or control of Oncothyreon and to the extent not
originals, means true and complete copies of such instruments, whether on paper or
in electronic format;
	 
	 	1.1.8	 	“BLP25” means BLP25 as defined in the License Agreement;
	 
	 	1.1.9	 	“Business Day” means a day other than a Saturday, Sunday or statutory holiday
in Alberta, Canada or Ontario, Canada;
	 
	 	1.1.10	 	“Claim” means any claim, demand, assessment, action, suit, proceeding, investigation,
cause of action, notice of action, litigation, judgement, order or decree;
	 
	 	1.1.11	 	“Closing” means the completion of the purchase and sale of the Assets and the
assumption by EMD and Merck of the Assumed Liabilities and the Transferred Employees as
contemplated by this Agreement on the Closing Date;
	 
	 	1.1.12	 	“Closing Date” means the 18th day of December, 2008 or such other date as EMD/Merck
and Oncothyreon may agree upon in writing;
	 
	 	1.1.13	 	“Closing Time” means 11:00 a.m. (Edmonton time) on the Closing Date, or such other
time as may be agreed to by EMD/Merck and Oncothyreon in writing;
	 
	 	1.1.14	 	“Confidential Information” is any and all information of a confidential nature
concerning Oncothyreon, EMD/Merck, the respective business and affairs of Oncothyreon
and EMD/Merck and the Purchased Business received in connection with this Agreement and
the prior relationships or collaborations between Oncothyreon and EMD/Merck;
	 
	 	1.1.15	 	“Disclosed Personal Information” has the meaning set forth in Section 5.3;
	 
	 	1.1.16	 	“Disclosure Schedule” means schedule set out as Schedule N to this Agreement;
	 
	 	1.1.17	 	“Environmental Law” means any Applicable Law relating to the environment including
those pertaining to

	 	1.1.17.1	 	reporting, licensing, permitting, investigating, remediating and cleaning
up in connection with any presence or Release, or the threat of the same, of
Hazardous Substances, and
	 
	 	1.1.17.2	 	the manufacture, processing, distribution, use, treatment, storage,
disposal, transport, handling and the like of Hazardous Substances, including
those pertaining to occupational health and safety;

	 	1.1.18	 	“Excluded Assets” means those items described in Schedule O to this Agreement;
	 
	 	1.1.19	 	“Excluded Liabilities” has the meaning set out in Section 2.8;

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

4

	 	1.1.20	 	“Governmental Authority” means any domestic or foreign legislative, executive,
judicial or administrative body or person having jurisdiction in the relevant
circumstances;
	 
	 	1.1.21	 	“Hazardous Substance” means any substance or material that is prohibited, controlled
or regulated by any Governmental Authority pursuant to Environmental Laws including
pollutants, contaminants, dangerous goods or substances, toxic or hazardous substances
or materials, wastes (including solid non-hazardous wastes and subject wastes),
petroleum and its derivatives and by-products and other hydrocarbons, all as defined in
or pursuant to any Environmental Law;
	 
	 	1.1.22	 	“Indemnified Party” means a Party to this Agreement who is seeking indemnification
pursuant to Article 4 of this Agreement;
	 
	 	1.1.23	 	“Indemnifying Party” means a Party to this Agreement from whom the Indemnified Party
is seeking indemnification pursuant to Article 4 of this Agreement;
	 
	 	1.1.24	 	“Inventory Assets” means all of Oncothyreon’s right, title and interest in those
inventory assets specified in Schedule A to this Agreement;
	 
	 	1.1.25	 	“Key Employees” means those employees listed and identified as such in Schedule H;
	 
	 	1.1.26	 	“Lease” means that certain lease agreement made as of the 18th day of December, 2008
between Edmonton Economic Development Corporation and Oncothyreon Canada;
	 
	 	1.1.27	 	“Leased Premises Assets” means all of Oncothyreon’s right, title and interest in
those leased premises assets specified in Schedule B to this Agreement;
	 
	 	1.1.28	 	“License Agreement” means that certain amended and restated license agreement dated
December 18, 2008 and made between Merck and Biomira Management, together with any
amendments to or replacements of or substitutes for such amended and restated license
agreement;
	 
	 	1.1.29	 	“Losses” means any and all claims, liabilities, obligations, losses, costs, expenses
(including reasonable legal, accounting and similar expenses), fines, taxes, levies,
deficiencies, assessments, charges, penalties, damages, settlements and judgments (the
amount of which to be determined on an after tax basis, after taking full account of
any tax benefit but after taking full account of the tax consequences of an indemnity
payment in respect of a Loss), provided, however, that the term “Losses” shall exclude
(i) any losses covered under any third party insurance policy, if any, to the extent
that the proceeds from insurance are actually received by the Indemnified Party, (ii)
the amount of any recovery, settlement or payment by or against another person, other
than the Indemnified Party, who may be liable in whole or in part for any such loss, to
the extent that such amounts are actually

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

5

			

	 		 	received by the Indemnified Party, and (iii) any indirect, special or consequential
damages or loss of profits;
	 
	 	1.1.30	 	“Manufacturing Contracts” means all of Oncothyreon’s right, title and interest in
those contracts related to the development, manufacture, testing and release of BLP25
set forth in Schedule C to this Agreement;
	 
	 	1.1.31	 	“Material Adverse Effect” means, when used in connection with the Purchased Business,
any change, event, violation, inaccuracy, circumstance or effect that is or could
reasonably be expected to be materially adverse to the business, assets, liabilities,
financial condition, results of operations of the Purchased Business;
	 
	 	1.1.32	 	“Notice of Claim” means a written notice from an Indemnified Party to an Indemnifying
Party of any event, omission or occurrence which the Indemnified Party has determined
will or could give rise to Losses which are indemnifiable under this Agreement;
	 
	 	1.1.33	 	“Other Assets” means, when used in connection with the Purchased Business, all of
Oncothyreon’s right, title and interest in the assets listed in Schedule D to this
Agreement;
	 
	 	1.1.34	 	“Party” means a party to this Agreement and “Parties” means all of them;
	 
	 	1.1.35	 	“Personal Information” has the meaning set forth in Section 5.3;
	 
	 	1.1.36	 	“Premises” means the premises that are the subject of the Lease;
	 
	 	1.1.37	 	“Privacy Laws” has the meaning set forth in Section 5.3;
	 
	 	1.1.38	 	“Purchase Price” has the meaning set forth in Section 2.1;
	 
	 	1.1.39	 	“Purchased Business” means, solely in relation to BLP25, all activities at present
and generally during the six (6) month period preceding the Closing Date carried on by
Oncothyreon on a global basis specifically related to the business of developing or
optimizing manufacturing processes, developing or optimizing drug substances, drug
products and drug product presentations, developing or optimizing analytical test
methods, manufacturing, testing, releasing and supplying BLP25;
	 
	 	1.1.40	 	“Release” means any release or discharge of any Hazardous Substance including any
discharge, spray, injection, inoculation, abandonment, deposit, spillage, leakage,
seepage, pouring, emission, emptying, throwing, dumping, placing, exhausting, escape,
leach, migration, dispersal, dispensing or disposal;
	 
	 	1.1.41	 	“Specifications” means, with respect to the Inventory Assets, the specifications in
relation thereto set forth in Schedule P hereto; and

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

6

	 	1.1.42	 	“Transferred Employees” means those employees of Oncothyreon employed in connection
with the Purchased Business whose names are set forth in Schedule E to this Agreement.

Section 1.2 Interpretation

	 	In this Agreement:
	 
	 	1.2.1	 	the inclusion of headings and a table of contents are for convenience of
reference only and are not to be considered or taken into account in construing the
provisions of this Agreement or to in any way qualify, modify or explain the effect of
any such provisions;
	 
	 	1.2.2	 	unless the context otherwise requires, references to an Article, Section,
Subsection, paragraph or Schedule, by number, letter or otherwise refer to the article,
section, subsection, paragraph or schedule, as the case may be, bearing that
designation in this Agreement;
	 
	 	1.2.3	 	words importing the singular shall include the plural and vice versa and words
importing a particular gender shall include all genders;
	 
	 	1.2.4	 	wherever the words “include”, “includes” or “including” are used, they shall
be deemed to be followed by the words “without limitation” and the words following
“include”, “includes” or “including” shall not be considered to set forth an exhaustive
list;
	 
	 	1.2.5	 	the words “hereof”, “herein”, “hereto”, “hereinafter”, “hereunder”, “herby”
and similar expressions shall be construed as referring to this Agreement in its
entirety and not to any particular section or portion of it;
	 
	 	1.2.6	 	all monetary amounts are expressed in United States currency;
	 
	 	1.2.7	 	where a term is defined in this Agreement, a derivative of that term shall
have a corresponding meaning unless the context otherwise requires; and
	 
	 	1.2.8	 	the term “actual knowledge of Oncothyreon” shall refer to the actual knowledge
of Robert Kirkman, Ed Taylor and Gary Christianson.

Section 1.3 Business Days

     If, pursuant to this Agreement, a notice must be given or an action taken within a specified
period or on or before a specified date and such period ends on, or such date falls on a day that
is not a Business Day, such notice may be given or such action may be taken on the next succeeding
day which is a Business Day.

Section 1.4 Schedules

     The following Schedules are attached hereto and form a part of this Agreement:

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

7

Schedule A — Inventory Assets

Schedule B — Leased Premises Assets

Schedule C — Manufacturing Contracts

Schedule D — Other Assets

Schedule E — Transferred Employees

Schedule F — Assumed Liabilities

Schedule G — Allocation of Purchase Price

Schedule H — Key Employees

Schedule I  — Form of Non-Competition Agreement

Schedule J — Form of Employment Agreement — Key Employees

Schedule K — Form of Employment Agreement — Non-Key Employees

Schedule L — Legal Opinions — Oncothyreon’s Counsel

Schedule M — Form of Press Release

Schedule N — Disclosure Schedule

Schedule O — Excluded Assets

Schedule P — Specifications

Wherever any term or condition, express or implied, of such Schedules conflicts or is at variance
with any term or condition in the body of this Agreement, such term or condition in the body of
this Agreement shall prevail.

ARTICLE 2

AGREEMENT OF PURCHASE AND SALE

Section 2.1 Agreement of Purchase and Sale of Assets

	 	Subject to the terms and conditions hereinafter set forth, Oncothyreon hereby agrees to:
	 
	 	2.1.1	 	sell, assign, transfer and convey its entire right, title and interest in the
Assets (other than the Inventory Assets) to EMD and EMD agrees to purchase
Oncothyreon’s right, title and interest in the Assets (other than the Inventory Assets)
from Oncothyreon; and
	 
	 	2.1.2	 	sell, assign, transfer and convey its entire right, title and interest in the
Inventory Assets to Merck and Merck agrees to purchase Oncothyreon’s right, title and
interest in the Inventory Assets from Oncothyreon;
	 
	 	
for the aggregate purchase price of U.S. $2,526,752.03 (the “Purchase Price”), subject to
adjustment as provided in Section 2.5, which Purchase Price shall be payable by EMD and Merck to
Oncothyreon in accordance with Section 2.3.

Section 2.2 Closing Time

     The purchase and sale of the Assets shall be effective as of the Closing Time.

Section 2.3 Payment of Purchase Price

     The Purchase Price shall be paid as follows:

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

8

	 	2.3.1	 	U.S.$547,597.42 to Oncothyreon Canada from EMD for the Leased Premises Assets,
the Lease, the Manufacturing Contracts and the Other Assets; and
	 
	 	2.3.2	 	U.S.$1,979,154.61 to Biomira Management from Merck for the Inventory Assets

     The Purchase Price shall be paid in full by EMD and Merck to Oncothyreon Canada and Biomira
Management as set forth above at Closing by way of wire transfer of immediately available funds to
a bank designated by them or by such other means as Oncothyreon Canada and Biomira Management may
designate in writing.

Section 2.4 Allocation of Purchase Price

     The Purchase Price shall be allocated among the Assets in the manner described in Schedule G
to this Agreement.

Section 2.5 Adjustment

     The Purchase Price has been determined in part on the basis that the Inventory Assets have a
value of U.S.$1,979,154.61 as of the date hereof. The Inventory Assets located at the facilities of
Oncothyreon Canada in Edmonton, Alberta will be confirmed as at the close of business on the
Business Day before the Closing Date by a physical count supervised jointly by representatives of
Oncothyreon and EMD/Merck. The Inventory Assets located at Baxter Pharmaceutical Solutions LLC
(“Baxter”) in Bloomington, Indiana, will be confirmed as at the close of business on the Business
Day before the Closing Date by Biomira Management. If the value of the Inventory Assets is less
than the portion of the Purchase Price allocated to such Assets in Schedule G hereto, the portion
of the Purchase Price payable to Biomira Management shall be decreased by the difference. If the
value of the Inventory Assets exceeds the portion of the Purchase Price allocated to such Assets in
Schedule G hereto, the portion of the Purchase Price payable to Biomira Management shall be
increased by the difference.

Section 2.6 Goods and Services Tax and Sales Tax

     Where tax is otherwise required to be collected by Oncothyreon pursuant to Part IX of the
Excise Tax Act (Canada), Oncothyreon and EMD agree that they will make a joint election pursuant to
subsection 167(1) of the Excise Tax Act (Canada) in prescribed form, if applicable. If the
election is not available to Oncothyreon and EMD for any reason, Oncothyreon shall invoice EMD for
the Goods and Services Tax associated with the transfer of the Assets and EMD shall pay the Goods
and Services Tax to Oncothyreon, as well as any interest or penalties for which Oncothyreon is
liable as a result of having made the election hereunder. Without duplication, EMD agrees to pay
any other applicable transfer, value added and/or sales taxes payable upon Closing or upon
registration of title to the Assets, as applicable.

Section 2.7 Assumed Liabilities

     Subject to Closing, EMD and Merck agree to assume, pay, discharge, perform and fulfill on and
after the Closing Time the following obligations and liabilities of Oncothyreon with respect to the
Assets and the Transferred Employees (collectively, the “Assumed Liabilities”):

	 	2.7.1	 	those obligations and liabilities set forth in Schedule F; and

 

	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

9

	 	2.7.2	 	all obligations required to be performed after the Closing Time pursuant to
the Manufacturing Contracts and the Lease, provided that EMD and Merck shall not assume
any obligations that arise after the Closing Time but relate to liabilities occurring
prior to the Closing Time.

Section 2.8 Excluded Liabilities

     Except as set forth in Section 2.7 or otherwise specifically set forth in this Agreement, EMD
does not and will not assume or otherwise become liable in any way for any obligations and
liabilities of Oncothyreon whatsoever that may be or become payable by Oncothyreon in relation to
the Assets and/or the Transferred Employees arising before the Closing Time, including but not
limited to any taxes resulting from or arising as a consequence of the sale of the Assets by
Oncothyreon to EMD (“Excluded Liabilities”).

Section 2.9 Transferred Employees

     EMD covenants and agrees to offer employment to each of the Transferred Employees, immediately
following the Closing Time, on the terms and pursuant to the offer letters provided by EMD to
Oncothyreon Canada under cover of EMD’s letter of December 18, 2008. EMD agrees to recognize the
length of service accrued by each Transferred Employee with Oncothyreon for statutory purposes
only. Oncothyreon shall be responsible for paying to each of the Transferred Employees all unpaid
wages, salaries, bonuses, holiday pay, vacation pay, termination pay, severance pay, change of
control payments and any retention payments arising from the Transferred Employees’ employment with
Oncothyreon and the cessation of employment with Oncothyreon.

Section 2.10 As Is

	 	Except as specifically set forth in Section 3.1 and 3.4 of this Agreement:
	 
	 	2.10.1	 	EMD and Merck acknowledge and agree that all of the Assets are being sold by
Oncothyreon to EMD and Merck, as the case may be, under this Agreement on an “as is
where is” basis; and
	 
	 	2.10.2	 	Oncothyreon makes no representation or warranty, whether express or implied, with
respect to the Assets and/or the Transferred Employees including, without limitation,
any representation as to fitness for a particular purpose or merchantable quality.

ARTICLE 3

REPRESENTATIONS AND WARRANTIES

Section 3.1 Representations and Warranties — Oncothyreon

     Oncothyreon (jointly and severally) represents and warrants to EMD/Merck that, except as set
out in the Disclosure Schedule:

	 	3.1.1	 	Oncothyreon Canada has been duly incorporated and organized and is a validly
subsisting corporation under the laws of Canada;

 

	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

10

	 	3.1.2	 	Biomira Management has been duly incorporated and organized and is a validly
subsisting corporation under the laws of Delaware;
	 
	 	3.1.3	 	Oncothyreon Parent has been duly incorporated and organized and is a validly
subsisting corporation under the laws of Delaware;
	 
	 	3.1.4	 	Oncothyreon has all requisite power and authority to enter into and perform
all of its obligations under this Agreement;
	 
	 	3.1.5	 	the execution, delivery and performance by Oncothyreon of this Agreement has
been duly and validly authorized by all necessary action of Oncothyreon;
	 
	 	3.1.6	 	this Agreement is a valid and binding obligation of Oncothyreon enforceable in
accordance with its terms, subject to applicable bankruptcy, insolvency, reorganization
and other laws affecting creditor’s rights generally and the discretionary nature of
certain remedies (including specific performance and injunctive relief);
	 
	 	3.1.7	 	the execution and delivery of this Agreement by Oncothyreon and the
consummation by Oncothyreon of the transactions contemplated by this Agreement have
been duly and validly authorized and will not violate, nor be in conflict with, in
either case in a material adverse manner:

	 	3.1.7.1	 	any of the articles, by-laws or charter documents of Oncothyreon;
	 
	 	3.1.7.2	 	any provisions of any agreement or instrument to which Oncothyreon is a
party or by which it is bound; or
	 
	 	3.1.7.3	 	any law applicable to Oncothyreon or the Assets;

	 	3.1.8	 	there are no liens for taxes upon the Assets, except for statutory liens for
current taxes not yet due;
	 
	 	3.1.9	 	Oncothyreon Canada is a GST registrant and has a subsisting GST registration
number of 106795784RT0001;
	 
	 	3.1.10	 	Oncothyreon Canada is not a non-resident of Canada within the meaning of the Income
Tax Act (Canada);
	 
	 	3.1.11	 	Oncothyreon has not incurred any obligation or liability, contingent or otherwise,
for brokers’ or finders’ fees in respect of the transactions contemplated by this
Agreement for which EMD shall have any obligation or liability;
	 
	 	3.1.12	 	the Assets are all of the material assets used in carrying on of the Purchased
Business;
	 
	 	3.1.13	 	no portion of the Purchased Business is being conducted by anyone other than
Oncothyreon;

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

11

	 	3.1.14	 	subject to the provisions thereof, Oncothyreon is the legal and beneficial owner of
the Assets, with good and marketable title thereto free and clear of all mortgages,
charges, liens, pledges, claims, security interests and other encumbrances of
whatsoever nature, and Oncothyreon has good right, power and authority to sell and
assign the Assets to EMD in the manner provided in this Agreement;
	 
	 	3.1.15	 	Oncothyreon is not in material default, nor has it received any written notice of
material default, under any agreements relating to the Assets or any of them and
Oncothyreon has no actual knowledge of any substantial physical damage to or alteration
in or to the Assets, or any of them, which would materially adversely affect the
Assets;
	 
	 	3.1.16	 	the Inventory Assets will meet the Specifications upon the release thereof as
contemplated in Section 3.4.2;
	 
	 	3.1.17	 	Oncothyreon is not a party to any material contract or commitment relating to the
Purchased Business outside the usual and ordinary course of the Purchased Business;
	 
	 	3.1.18	 	the Lease and the Manufacturing Contracts are in full force and effect and
Oncothyreon is not in breach or default in any material respect under the Lease and/or
any of the Manufacturing Contracts;
	 
	 	3.1.19	 	Oncothyreon is not a party to or bound by any guarantee, indemnification, surety or
similar obligation pertaining to the Purchased Business;
	 
	 	3.1.20	 	except for the Lease, Oncothyreon is not a party to any lease or agreement in the
nature of a lease for real property, whether as lessor or lessee pertaining to the
Purchased Business;
	 
	 	3.1.21	 	none of Oncothyreon or any of its subsidiaries has any agreement, option or
commitments to acquire any securities of any corporation or to acquire or lease any
real property or material assets to be used in or in connection with the Purchased
Business other than, in the latter case, those assets that are to be used in the usual
and ordinary course of business of the Purchased Business;
	 
	 	3.1.22	 	there are no material claims, proceedings, actions, lawsuits, administrative
proceedings or governmental investigations to the actual knowledge of Oncothyreon in
existence or contemplated or threatened against or with respect to Oncothyreon or the
Assets which could result in impairment or loss of the Assets or which might otherwise
materially adversely affect the Assets;
	 
	 	3.1.23	 	Oncothyreon has not received any written notice of violation or alleged violation of:

	 	3.1.23.1	 	the provisions of any of its contracts; or
	 
	 	3.1.23.2	 	any Applicable Laws;

 

	+ 	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

12

	 	 	 	which, in either case, could materially adversely effect the Assets;

	 	3.1.24	 	the operation of the Assets is in compliance with all Applicable Laws;
	 
	 	3.1.25	 	all material consents, licenses, permits and approvals required for the operation of
the Assets have been obtained and are in good standing in all material respects;
	 
	 	3.1.26	 	other than this Agreement, there is no agreement, option or other right or privilege
outstanding in favour of any person for the purchase from Oncothyreon of any or all of
the Assets;
	 
	 	3.1.27	 	the Books and Records have been maintained in the usual and ordinary course,
consistent with past practice and all material transactions relating to the Purchased
Business have been accurately recorded in such Books and Records and, other than in the
ordinary course of business, such Books and Records have not been altered nor has any
information been destroyed;
	 
	 	3.1.28	 	other than where the contrary would not materially and adversely impact title to, or
the value of, the Assets or would not create any liability or obligation of EMD
following the Closing Time:

	 	3.1.28.1	 	Oncothyreon has not received any written notice of any non-compliance with
any Environmental Law;
	 
	 	3.1.28.2	 	Oncothyreon has not received any order or directive which relates to
environmental matters and which requires any work, repairs, construction or
capital expenditure;
	 
	 	3.1.28.3	 	Oncothyreon has not received any demand or notice with respect to the
breach of any Environmental Law applicable to Oncothyreon or the Purchased
Business;
	 
	 	3.1.28.4	 	to the actual knowledge of Oncothyreon, there are no claims, investigations
or inquiries pending or threatened against Oncothyreon based on non-compliance
with any Environmental Law;
	 
	 	3.1.28.5	 	Oncothyreon has not received any claim, complaint, notice, letter of
violation, inquiry or request for information involving any matter which
remains unresolved as of the date hereof with respect to any alleged violation
of any Environmental Law or regarding potential liability under any
Environmental Law; and
	 
	 	3.1.28.6	 	there are no sites, locations or operations at which Oncothyreon is
currently undertaking, or has completed, any removal, remedial or response
action relating to any disposal or Release of environmental contaminants, as
required by Environmental Laws;

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

13

	 	3.1.29	 	there are no environmental permits used in or required to carry on the Purchased
Business in its usual or ordinary course;
	 
	 	3.1.30	 	Oncothyreon has not used the Leased Premises Assets or any facilities pertaining to
the Purchased Business, or permitted them to be used, to generate, manufacture, refine,
treat, transport, store, handle, dispose, transfer, produce or process Hazardous
Substances except in compliance in all material respects with all Environmental Laws;
	 
	 	3.1.31	 	Oncothyreon has provided EMD with copies of all analyses and monitoring data for
soil, groundwater and surface water and all reports pertaining to any environmental
assessments or audits relating to the Purchased Business that were obtained by, or are
in the possession or control of, Oncothyreon;
	 
	 	3.1.32	 	Oncothyreon does not have any outstanding bonds, debentures, mortgages, notes or
other indebtedness and is not subject to any agreement to create any bonds, debentures,
mortgages, notes or other indebtedness, including guarantees, indemnifications or like
obligations and liabilities, relating to the Assets except for operating and other
costs relating to the Assets which are or will be incurred in the ordinary course of
Oncothyreon’s business;
	 
	 	3.1.33	 	Oncothyreon is not a party to or bound by any contract or commitment to pay any
management fee pertaining to the Purchased Business;
	 
	 	3.1.34	 	Oncothyreon does not have any written employment contract relating to the Purchased
Business with any person whomsoever;
	 
	 	3.1.35	 	there are no consultants engaged by Oncothyreon or any of its Affiliates in
connection with the Purchased Business;
	 
	 	3.1.36	 	since June 30, 2008, there have been no changes in the terms and conditions of
employment of any employees of the Purchased Business, including their salaries,
remuneration or any other payments to them, and there have been no changes in any
remuneration payable or benefits provided to any officer, director, consultant or
independent contractor of the Purchased Business and Oncothyreon has not agreed or
otherwise become committed to change any of the foregoing since that date;
	 
	 	3.1.37	 	there are no benefit plans, programs, agreements or arrangements (whether written or
unwritten) maintained, contributed to, or provided by Oncothyreon or any Affiliate
thereof for the benefit of any of its employees, former employees or independent
contractors of Oncothyreon employed or retained in connection with the Purchased
Business or their respective dependants or beneficiaries (the “Benefit Plans”)
including all bonus, deferred compensation, incentive compensation, share purchase,
share option, stock appreciation, phantom stock, savings, profit sharing, severance or
termination pay, health or other medical, life, disability or other insurance (whether
insured or self-insured), supplementary unemployment benefit, pension, retirement and
supplementary retirement plans,

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

14

			
	 	 	programs, agreements and arrangements except for any statutory plans to which
Oncothyreon is obliged to contribute or comply, or plans administered pursuant to
applicable federal, provincial or state health, worker’s compensation and employment
insurance legislation;
	 
	3.1.38	 	 Oncothyreon has and is employing all Transferred Employees in compliance with all
applicable material taxation, health, labour and employment laws, rules, regulations,
notices and orders;
	 
	3.1.39	 	 there is no lien against the Assets as a result of Workers’ Compensation legislation
and, to the actual knowledge of Oncothyreon, Oncothyreon has complied in all material
respects with the requirements of the Workers’ Compensation Act (Alberta) and the
Employment Standards Act (Alberta);
	 
	3.1.40	 	 Oncothyreon is not a party to any collective bargaining agreement or other agreement
with a trade union or other employees’ association;
	 
	3.1.41	 	 to the actual knowledge of Oncothyreon, none of the Transferred Employees have
executed or are otherwise bound by a non-competition agreement which would restrict
their ability to be employed by EMD in connection with the Purchased Business; and
	 
	3.1.42	 	 none of the Assets disposed of by Oncothyreon pursuant to this Agreement are taxable
Canadian property for purposes of the Income Tax Act (Canada).

Section 3.2 Representations and Warranties — EMD and Merck

     EMD and Merck (jointly and severally) represent and warrant to Oncothyreon that:

	 	3.2.1	 	EMD has been duly incorporated and organized and is a validly subsisting
corporation under the laws of Ontario;
	 
	 	3.2.2	 	Merck has been duly incorporated and organized and is a validly subsisting
corporation under the laws of Germany;
	 
	 	3.2.3	 	EMD has all requisite power and authority to enter into and perform all of its
obligations under this Agreement;
	 
	 	3.2.4	 	Merck has all requisite power and authority to enter into and perform all of
its obligations under this Agreement;
	 
	 	3.2.5	 	the execution, delivery and performance by EMD and Merck of this Agreement has
been duly and validly authorized by all necessary action of EMD and Merck and this
Agreement is a valid and binding obligation of EMD and Merck enforceable in accordance
with its terms, subject to applicable bankruptcy, insolvency, reorganization and other
laws affecting creditor’s rights generally and the discretionary nature of certain
remedies (including specific performance and injunctive relief);

 

	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

15

	 	3.2.6	 	the execution and delivery of this Agreement by EMD and Merck and the
consummation by EMD and Merck of the transactions contemplated by this Agreement have
been duly and validly authorized and will not violate, nor be in conflict with, in
either case in a material adverse manner:

	 	3.2.6.1	 	any of the articles, by-laws or charter documents of EMD or Merck, as the
case may be;
	 
	 	3.2.6.2	 	any provisions of any agreement or instrument to which EMD and/or Merck is a
party or by which it is bound; or
	 
	 	3.2.6.3	 	any law applicable to EMD and/or Merck or the Assets;

	 	3.2.7	 	EMD is a GST registrant and has a subsisting GST registration number of 12397
5260 RT; and
	 
	 	3.2.8	 	neither EMD nor Merck has incurred any obligation or liability, contingent or
otherwise, for brokers’ or finders’ fees in respect of the transactions contemplated by
this Agreement for which Oncothyreon shall have any obligation or liability.

Section 3.3 Survival

     The representations and warranties set forth in Sections 3.1 and 3.2 hereof shall be deemed to
have been made again on the Closing Date and

	 	3.3.1	 	the representations and warranties set forth in Sections 3.1.5 and 3.1.16
shall continue in full force and effect following the Closing Date; and
	 
	 	3.3.2	 	all other representations and warranties shall continue in full force and
effect until the expiration of a period of one (1) year from the Closing Date.

Section 3.4 Inventory Asset Specifications

	 	3.4.1	 	Notwithstanding any other provision to the contrary in this Agreement, the
sole liability of Oncothyreon in relation to the Inventory Assets (including, without
limitation, the representation and warranty in Section 3.1.16 of this Agreement) shall
be to refund to Merck the amount paid by Merck pursuant to this Agreement and / or the
Amended and Restated Supply Agreement (2006) (less any amount paid by Oncothyreon to
Baxter Pharmaceutical Solutions LLC) in respect of any Inventory Assets which, after
complying with Section 3.4.2, are found not to conform with the Specifications.
	 
	 	3.4.2	 	The Parties agree, notwithstanding any provision to the contrary in this
Agreement or any other agreement, that Merck shall be responsible for properly
releasing the Inventory Assets and shall diligently pursue all such actions (including
without limitation under the Manufacturing Contracts) that are necessary and/or
desirable to permit the Inventory Assets to be released in a timely manner in
accordance with the applicable Specifications. The Parties shall cooperate in such
regard. If, after complying with its obligations above, Merck

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

16

			
	 	 	alleges that any of such Inventory Assets are not capable of being released in
accordance with the applicable Specifications, Merck shall send to Oncothyreon a
written notice to such effect and the reasons therefor. If Oncothyreon disagrees
with Merck’s assertion that such Inventory Assets are not capable of being released
in accordance with the applicable Specifications, quality representatives of
Oncothyreon and Merck shall negotiate in good faith to assess the matter. In the
event that the quality representatives of Oncothyreon and Merck are unable to agree
on whether the Inventory Assets in question are capable of being released in
accordance with the applicable Specifications, then an independent laboratory or
quality assurance consultant, mutually agreed upon in writing by the Parties, shall
assess the matter and analyse samples of the alleged non-conforming Inventory Assets
to determine whether such Inventory Assets are capable of being released in
accordance with the applicable Specifications. The Parties shall be bound by the
analysis of such laboratory or consultant. The costs incurred in connection with
retaining any laboratory or quality assurance consultant shall be borne by Merck if
the Inventory Assets in question are found to be capable of being released in
accordance with the applicable Specifications and by Oncothyreon if the Inventory
Assets in question are found not to be capable of being released in accordance with
the applicable Specifications.

ARTICLE 4

INDEMNIFICATION

Section 4.1 Oncothyreon Indemnification

     Subject to the limitations set forth in Sections 3.4 and 4.3, Oncothyreon (jointly and
severally) agrees to indemnify EMD and Merck against and hold EMD and Merck harmless from any and
all Losses which EMD and Merck may suffer or incur as a result of, in respect of or arising out of:

	 	4.1.1	 	a breach of the representations and warranties of Oncothyreon under this
Agreement;
	 
	 	4.1.2	 	a breach of any covenant or agreement of Oncothyreon contained in this
Agreement;
	 
	 	4.1.3	 	subject to EMD and Merck complying with their obligations under this Agreement
in relation to the Transferred Employees, any liability relating to the employment in
connection with the Purchased Business by Oncothyreon of any employees of Oncothyreon
other than Transferred Employees who accept job offers with EMD and/or Merck; and
	 
	 	4.1.4	 	any Excluded Liabilities.

Notwithstanding any other provision herein, the liability of Oncothyreon and the indemnity granted
by Oncothyreon to EMD and Merck pursuant to Section 4.1.1 shall only apply if written notice of
such claim hereunder together with reasonable particulars is provided to Oncothyreon within one (1)
year following the Closing Date, provided that such time limitation shall not apply

 

	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

17

	in respect of a breach of the representation or warranty contained in Sections 3.1.5 and 3.1.16 or
a breach of the representations, warranties, covenants or agreements of Oncothyreon that is based
upon fraud. The liability of Oncothyreon and the indemnity granted by Oncothyreon to EMD and Merck
pursuant to Sections 4.1.2, 4.1.3 and 4.1.4 shall survive the Closing Date and continue in full
force indefinitely.

Section 4.2 EMD and Merck Indemnification

EMD and Merck, jointly and severally, agree to indemnify Oncothyreon against and hold Oncothyreon
harmless from any and all Losses which Oncothyreon may suffer or incur as a result of, in respect
of or arising out of:

	 	4.2.1	 	a breach of the representations and warranties of EMD and/or Merck under this
Agreement;
	 
	 	4.2.2	 	a breach of any covenant or agreement of EMD and/or Merck contained in this
Agreement; and
	 
	 	4.2.3	 	any Assumed Liabilities.

Notwithstanding any other provision in this Agreement, the liabilities of EMD and Merck and the
indemnities granted by EMD and Merck to Oncothyreon pursuant to Section 4.2.1 shall only apply if
written notice of such claim hereunder together with reasonable particulars is provided to EMD and
Merck within one (1) year following the Closing Date, provided that such time limitation shall not
apply in respect of a breach of the representations, warranties, covenants or agreements of EMD
that is based upon fraud. The liabilities of EMD and Merck and the indemnities granted by EMD and
Merck to Oncothyreon pursuant to Sections 4.2.2 and 4.2.3 shall survive the Closing Date and
continue in full force indefinitely.

Section 4.3 Limitations on Liabilities and Indemnities

     Notwithstanding anything to the contrary set out in this Agreement:

	 	4.3.1	 	other than claims under Section 3.4 hereof or claims in respect of Section
3.1.5 hereof, neither EMD nor Merck shall be entitled to recover any losses, damages or
costs (including without limitation Losses) from Oncothyreon as a result of the
indemnities set out in Section 4.1 hereof or otherwise under this Agreement until the
aggregate amount of such losses, damages or costs equals or exceeds the sum of $50,000
;
	 
	 	4.3.2	 	the sum of $1,500,000 (plus any amounts properly owing by Oncothyreon to Merck
pursuant to Section 3.4 hereof) represents the maximum aggregate liability of
Oncothyreon under this Agreement and as such the maximum aggregate amount of the
losses, damages and costs (including without limitation Losses) that EMD and Merck are
entitled to recover from Oncothyreon as a result of the indemnities set out in Section
4.1 hereof or otherwise under this Agreement other than claims made in relation to a
breach of Section 3.1.5 in which case the maximum aggregate liability of Oncothyreon
under this Agreement shall be

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

18

			
	 	 	$11,000,000 (less any portion of the $1,500,000 paid by Oncothyreon to EMD or Merck
in respect of other claims hereunder);
	 
	4.3.3	 	 the Indemnifying Party and the Indemnified Party shall cooperate fully with
each other with respect to third party claims, and shall keep each other fully advised
with respect thereto (including supplying copies of all relevant documentation promptly
as it becomes available);
	 
	4.3.4	 	 if the amount of any Loss incurred by any Indemnified Party at any time
subsequent to the receipt of payment from the Indemnifying Party in respect of such
Loss is reduced by:

	 	4.3.4.1	 	any net tax benefit to the Indemnified Party; or
	 
	 	4.3.4.2	 	any recovery, settlement or otherwise under or pursuant to any insurance
coverage, or pursuant to any claim, recovery, settlement or payment by or
against another person;

then, to the extent such reduction was not considered in determining the payment
from the Indemnifying Party, the amount of such reduction shall promptly be repaid
by the Indemnified Party to the Indemnifying Party. Upon making payment in full in
respect of the Loss, the Indemnifying Party shall, to the extent of such payment,
unless expressly prohibited pursuant to the written terms of any relevant insurance
policy, be subrogated to all rights of the Indemnified Party against any third party
in respect of such Loss and the Indemnified Party shall, at the request of the
Indemnifying Party, assign all such rights to the Indemnifying Party on an “as is
where is” basis;

	 	4.3.5	 	no Party shall have the right to bring any proceedings against any other Party
for a breach of any representation, warranty, covenant or agreement contained in this
Agreement, except for a proceeding brought in accordance with the provisions of this
Article 4; and
	 
	 	4.3.6	 	no Party shall have any liability to any other Party or any other person
pursuant to this Agreement for any special, indirect or consequential damages,
including but not limited to loss of profits, loss of business opportunities or loss of
business investment.

Section 4.4 Claim for Indemnity

	 	4.4.1	 	The Indemnified Party shall notify the Indemnifying Party by a Notice of Claim
which shall be given promptly after the Indemnified Party becomes aware of its own
claim or that of a third party. A Notice of Claim shall specify in reasonable detail
the nature and any particulars of the event, omission or occurrence giving rise to a
right of indemnification hereunder. With respect to any Notice of Claim, other than a
third party claim, following receipt of Notice of Claim from the Indemnified Party, the
Indemnifying Party shall have thirty (30) days to make such investigation of the Claim
as is considered necessary or desirable. For the

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

19

	 	 	 	purpose of such investigation, the Indemnified Party shall make available to the
Indemnifying Party the information relied upon by the Indemnified Party to
substantiate the Claim, together with all such other information as the Indemnifying
Party may reasonably request. If both Parties agree at or prior to the expiration
of such thirty (30) day period (or any mutually agreed upon extension thereof) to
the validity and amount of such Claim, the Indemnifying Party shall immediately pay
to the Indemnified Party the full agreed upon amount of the Claim, failing which the
matter shall be determined by a court of competent jurisdiction.
	 
	 	4.4.2	 	The Indemnified Party shall diligently and vigorously defend and contest each
third party claim, demand, suit, action or proceeding which may become or does become
the subject of a Notice of Claim, and, in any event, shall do so in the same manner as
it would defend and contest a matter for which it was not indemnified. With respect to
any third party claim, demand, suit, action or proceeding which is the subject of a
Notice of Claim, the Indemnifying Party shall, in good faith and at its own expense, be
entitled to defend, contest or otherwise protect against any such claim, demand, suit,
action or proceeding with legal counsel of its own selection, unless otherwise agreed
in writing at the Indemnifying Party’s option with the Indemnified Party. The
Indemnified Party shall have the right to participate, at its own expense, in the
defence thereof through counsel of its own choice and shall assert any and all cross
claims or counterclaims it may have. So long as the Indemnifying Party is defending in
good faith any such third party claim, demand, suit, action or proceeding, the
Indemnified Party shall at all times cooperate, at its own expense, in all reasonable
ways with, make its relevant files and records reasonably available for inspection and
copying by, and make its employees available or otherwise render reasonable assistance
to, the Indemnifying Party. In the event that the Indemnifying Party fails to timely
defend, contest or otherwise protect against any such third party claim, demand, suit,
action or proceeding, the Indemnified Party (i) shall have the right to defend, contest
and assert cross claims or counterclaims, or otherwise protect against, the same; and
(ii) may make any compromise or settlement thereof, provided that the Indemnified Party
shall not settle or dispose of any such matter without the prior written consent of the
Indemnifying Party, such consent not to be unreasonably withheld.

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

20

ARTICLE 5

COVENANTS

Section 5.1 Covenants of Oncothyreon

	 	5.1.1	 	Except as otherwise contemplated by the Agreement or consented to in writing
by EMD, from the date of this Agreement until Closing, Oncothyreon covenants and agrees
with EMD as follows:

	 	5.1.1.1	 	to carry on the Purchased Business in the usual and ordinary course,
consistent with past practice, provided that all acts and proceedings involving
a commitment in excess of $25,000 or for more than three months duration will
be subject to the prior approval of EMD, which approval will not be
unreasonably withheld;
	 
	 	5.1.1.2	 	to use all reasonable commercial efforts to preserve intact the Assets and
the Purchased Business, organization and goodwill, to keep available the
employees of the Purchased Business as a group and to maintain satisfactory
relationships with suppliers and others with whom the Purchased Business has
business relationships;
	 
	 	5.1.1.3	 	to use all reasonable commercial efforts to cause its current insurance
policies with respect to the Purchased Business not to be cancelled or
terminated or any other coverage thereunder to lapse, unless simultaneously
with such terminations, cancellation or lapse, replacement policies
underwritten by insurance companies of nationally recognized standing providing
coverage equal to or greater than the coverage under the cancelled, terminated
or lapsed policies, and where possible, for substantially similar premiums, are
in full force and effect;
	 
	 	5.1.1.4	 	with their December 31, 2008 pay packages, Oncothyreon Canada shall pay to
the Transferred Employees all unpaid wages, bonuses, salaries, holiday pay,
vacation pay, termination pay, severance pay, change of control payments and
retention payments due up to such date (with EMD to reimburse Oncothyreon
Canada for such payments relating to the period from the Closing Time to
December 31, 2008 as per the transition services agreement with respect thereto
entered into between EMD and Oncothyreon Canada);
	 
	 	5.1.1.5	 	to promptly advise EMD in writing of the occurrence of any Material Adverse
Effect in respect of the Purchased Business or of any facts that come to their
attention which would cause any of Oncothyreon’s representations and warranties
herein contained to be untrue in any respect;
	 
	 	5.1.1.6	 	to maintain the Books and Records in the usual and ordinary course,

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED
SEPARATELY WITH THE COMMISSION

 

21

	 	 	 	consistent with past practice, to record all transactions on a basis consistent
with that practice and to transfer to EMD on the Closing Date such Books and
Records that are onsite at the Premises in their full and complete form to EMD;
	 
	 	5.1.1.7	 	on or before the Closing Date, Oncothyreon shall take or cause to be taken
all necessary action (including all necessary corporate action) to authorize
performance of all covenants to be performed by Oncothyreon pursuant to this
Agreement including, but not restricted to, the transfer of the Assets to EMD;
	 
	 	5.1.1.8	 	on the Closing Date, Oncothyreon shall deliver or cause to be delivered to
EMD:

	 	5.1.1.8.1	 	a certificate or other instrument of Oncothyreon or of
officers of Oncothyreon as EMD or EMD’s counsel may reasonably
think necessary in order to establish that the obligations and
covenants contained in this Agreement to have been performed or
complied with by Oncothyreon at or prior to the Closing Time have
been performed or complied with and that the representations and
warranties of Oncothyreon herein given are true and correct at the
Closing Time;
	 
	 	5.1.1.8.2	 	a favourable opinion of Oncothyreon’s counsel substantially in
the form set out in Schedule L;
	 
	 	5.1.1.8.3	 	evidence of continuing insurance for any obligations or
liabilities arising before the Closing Date but for which a claim
has only been submitted following the Closing Date; and
	 
	 	5.1.1.8.4	 	the following documents:

	 	a)	 	a certified copy
of the resolutions of the directors of each of
Oncothyreon Canada, Biomira Management and Oncothyreon
Parent approving the execution of this Agreement and
matters related thereto;
	 
	 	b)	 	a certified copy
of the resolutions of the shareholders of Oncothyreon
Canada and Biomira Management approving the sale of all
or substantially all assets;
	 
	 	c)	 	the transition
services agreement between Oncothyreon Canada and EMD;
	 
	 	d)	 	the License
Agreement;

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED
SEPARATELY WITH THE COMMISSION

 

22

	 	e)	 	written consent
for the assignment of the following agreements:

	 	i)	 	the Manufacturing Contracts; and
	 
	 	ii)	 	the Lease;

	 	f)	 	assignment
agreements in respect of:

	 	i)	 	the Manufacturing Contracts;
	 
	 	ii)	 	the Lease;
	 
	 	iii)	 	the equipment lease, dated January 26, 2006,
between Dell Financial Services Canada and
Biomira Inc.; and
	 
	 	iv)	 	the technology lease, dated September 20, 2007,
between Compugen Finance Inc. and Biomira Inc.;
and

	 	g)	 	the general
conveyance between Oncothyreon, EMD and Merck.

	 	5.1.1.9	 	on the Closing Date, Oncothyreon shall deliver to EMD sole and exclusive
physical possession of all keys, lock combinations, safe combinations, computer
passwords, properties, assets, books, records, documents and other items
applicable to the Assets and the Purchased Business; and
	 
	 	5.1.1.10	 	Biomira Management will have delivered to Corixa Corporation (d/b/a
GlaxoSmithKline Biologicals N.A.) a Firm Forecast, pursuant to the supply
agreement dated October 20, 2004, as amended, of its requirements for Licensed
Adjuvant in each of the eight calendar quarters for the period beginning on
April 1, 2009 and ending on March 31, 2011.

Section 5.2 Covenants of EMD and Merck

	 	5.2.1	 	Except as otherwise contemplated by this Agreement or consented to in writing
by Oncothyreon, from the date of this Agreement until Closing, EMD and Merck covenant
and agree with Oncothyreon as follows:

	 	5.2.1.1	 	on or before the Closing Date, EMD and Merck shall take all corporate action
necessary to ratify the execution of this Agreement and to authorize the
performance of all covenants to be performed by EMD and Merck pursuant to this
Agreement;
	 
	 	5.2.1.2	 	on the Closing Date, EMD and Merck shall pay the Purchase Price to

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED
SEPARATELY WITH THE COMMISSION

 

23

	 	 	 	Oncothyreon in accordance with Section 2.3 hereof; and
	 
	 	5.2.1.3	 	on the Closing Date, EMD shall deliver or cause to be delivered to
Oncothyreon

	 	5.2.1.3.1	 	the following documents:

	 	a)	 	an employment
agreement, in the form set out in Schedule J, entered
into by each of the Key Employees;
	 
	 	b)	 	the transition
services agreement between Oncothyreon Canada and EMD;
	 
	 	c)	 	assignment
agreements in respect of:

	 	i)	 	the Manufacturing Contracts;
	 
	 	ii)	 	the Lease;
	 
	 	iii)	 	the equipment lease, dated January 26, 2006,
between Dell Financial Services Canada and
Biomira Inc.; and
	 
	 	iv)	 	the technology lease, dated September 20, 2007,
between Compugen Finance Inc. and Biomira Inc.;
and

	 	d)	 	the general
conveyance between Oncothyreon, EMD and Merck..

	 	5.2.1.4	 	on the Closing Date, Merck shall deliver or cause to be delivered to
Oncothyreon

	 	5.2.1.4.1	 	the following documents:

	 	a)	 	the License
Agreement; and
	 
	 	b)	 	the general
conveyance between Oncothyreon, EMD and Merck.

Section 5.3 Compliance with Privacy Laws

	 	5.3.1	 	EMD and Merck acknowledge and agree that EMD and Merck must comply at all
times with Privacy Laws which govern the collection, use and disclosure of Personal
Information disclosed to EMD and/or Merck pursuant to or in connection with this
Agreement (the “Disclosed Personal Information”).
	 
	 	5.3.2	 	Neither EMD nor Merck shall use the Disclosed Personal Information for any

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED
SEPARATELY WITH THE COMMISSION

 

24

	 	 	 	purposes other than those related to the performance of this Agreement and the
completion of the transactions contemplated by this Agreement.
	 
	 	5.3.3	 	Each of the Parties acknowledges and confirms that the disclosure of Personal
Information is necessary for the purposes of determining if the Parties shall proceed
with the purchase and sale transaction contemplated in this Agreement and that the
disclosure of Personal Information relates solely to the carrying on of the business
which is the subject of this Agreement, or the completion of the purchase and sale
transaction contemplated in this Agreement.
	 
	 	5.3.4	 	EMD and Merck shall at all times keep strictly confidential all Disclosed
Personal Information provided to it, and shall instruct those employees responsible for
processing such Disclosed Personal Information to protect the confidentiality of that
information in a manner consistent with EMD’s and Merck’s obligations hereunder. EMD
and Merck shall ensure that access to the Disclosed Personal Information shall be
restricted to those employees or service providers of EMD and Merck who have a bona
fide need to access that information in order to fulfill their obligations in the
course of their employment or in providing services to EMD and/or Merck.
	 
	 	5.3.5	 	The Parties shall fully cooperate with one another, with the individuals to
whom the Personal Information relates, and any government authority charged with
enforcement of Privacy Laws, in responding to inquiries, complaints, requests for
access, and claims in respect of Disclosed Personal Information.
	 
	 	5.3.6	 	EMD and Merck undertake, after the Closing Date, to utilize the Disclosed
Personal Information only for those purposes for which the Disclosed Personal
Information was initially collected from or in respect of the applicable employees or
other persons.
	 
	 	5.3.7	 	If Closing does not occur, on the request of Oncothyreon, EMD and Merck shall
forthwith, other than as required by law, cease all use of the Disclosed Personal
Information acquired by EMD and/or Merck in connection with this Agreement and will
return to Oncothyreon or, at Oncothyreon’s request, destroy in a secure manner, the
Disclosed Personal Information (and any copies thereof) and provide Oncothyreon with a
certificate of a senior officer of EMD confirming such destruction.

For the purposes of this Section 5.3, “Privacy Laws” shall mean any and all Applicable Laws
relating to privacy and the collection, use and disclosure of Personal Information in all
applicable jurisdictions, including the Personal Information Protection and Electronic Documents
Act (Canada) and/or any comparable provincial law, including without limitation, the Personal
Information Protection Act (Alberta) and “Personal Information” shall mean any personal information
about an identifiable individual but does not include an individual’s business contact information.

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED
SEPARATELY WITH THE COMMISSION

 

25

Section 5.4 Apportionment

     The Parties agree that rent expenses, property taxes, utility charges, and the like, will be
apportioned at the Closing in an equitable manner as of the close of business of the day
immediately preceding the Closing Date (the “Adjustment Date”) so that the income and expense items
with respect to the period up to and including the Adjustment Date will be for Oncothyreon’s
account and the income and expense items with respect to the period after the Adjustment Date will
be for EMD’s account. For purposes of this Section 5.4, the term “equitable manner” will mean that
Oncothyreon will be allocated such items based on a fraction, the numerator of which is the number
of days in the applicable period ending on the Adjustment Date and the denominator of which is the
total number of days in such period, and EMD will be allocated the remainder.

ARTICLE 6

NON-SOLICITATION AND NON-COMPETITION

Section 6.1 Non-Solicitation

     Subject to Section 6.3, Oncothyreon will not, in any manner whatsoever, without the prior
consent of EMD, at any time during a period of two years from the Closing Date, directly or
indirectly:

	 	6.1.1	 	induce or endeavour to induce any person to leave his or her employment with
EMD; or
	 
	 	6.1.2	 	employ or attempt to employ or assist any person to employ any person employed
by EMD.

Section 6.2 Non-Solicitation — EMD

     Subject to Section 6.3, EMD will not, in any manner whatsoever, without the prior consent of
Oncothyreon, at any time during a period of two years from the Closing Date, directly or
indirectly:

	 	6.2.1	 	induce or endeavour to induce any person employed by Oncothyreon, other than
Transferred Employees, to leave his or her employment with Oncothyreon; or
	 
	 	6.2.2	 	employ or attempt to employ or assist any person to employ any person employed
by Oncothyreon, other than Transferred Employees.

Section 6.3 Proviso

     For purposes of Section 6.1 and Section 6.2, solicitation and/or inducement shall not include
solicitation or inducement of any persons who are solicited or induced by advertising in
periodicals or newspapers of general circulation, or by an employee search firm acting on
Oncothyreon’s or EMD’s behalf, so long as Oncothyreon or EMD, as the case may be, did not direct or
encourage such firm to solicit such person. Further, Sections 6.1 and 6.2 shall not apply to the
hiring of any person who responds to such solicitations or inducements.

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED
SEPARATELY WITH THE COMMISSION

 

26

ARTICLE 7

CLOSING, CONDITIONS AND TERMINATION

Section 7.1 Closing

     The sale and purchase of the Assets will be completed at the Closing Time at the offices of
Fraser Milner Casgrain LLP, 2900 Manulife Place, 10180 — 101 Street, Edmonton, Alberta.

Section 7.2 Conditions for the Benefit of EMD

     The sale by Oncothyreon and the purchase by EMD of the Assets is subject to the following
conditions, which are for the exclusive benefit of EMD and which are to be performed or complied
with at or prior to the Closing Time:

	 	7.2.1	 	the representations and warranties of Oncothyreon set forth in Section 3.1
will be true and correct in all material respects at the Closing Time with the same
force and effect as if made at and as of such time;
	 
	 	7.2.2	 	Oncothyreon will have performed or complied with all of the obligations and
covenants in this Agreement to be performed or complied with by Oncothyreon at or prior
to the Closing Time;
	 
	 	7.2.3	 	no action or proceeding will be pending or threatened by any person to enjoin,
restrict or prohibit:

	 	(i)	 	the sale and purchase of the Assets contemplated hereby; or
	 
	 	(ii)	 	the right of EMD to conduct the Purchased Business;

	 	7.2.4	 	non-competition agreements shall have been entered into between the Key
Employees and EMD, substantially in the form set out in Schedule I;
	 
	 	7.2.5	 	employment agreements shall have been entered into between each of the Key
Employees and EMD, substantially in the form set out in Schedule J;
	 
	 	7.2.6	 	Biomira Management will have entered into the License Agreement;
	 
	 	7.2.7	 	no Material Adverse Effect will have occurred in relation to the Purchased
Business from the date hereof to the Closing Time; and
	 
	 	7.2.8	 	all necessary steps and proceedings will have been taken to permit the Assets
to be duly and regularly transferred to and registered in the name of EMD (or as
directed by EMD) including obtaining the consents to the assignments of any contracts
or other commitments as set forth in the Disclosure Schedule.

Section 7.3 Conditions for the Benefit of Oncothyreon

     The sale by Oncothyreon and the purchase by EMD/Merck of the Assets is subject to the
following conditions, which are for the exclusive benefit of Oncothyreon and which are to be
performed or complied with at or prior to the Closing Time:

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED
SEPARATELY WITH THE COMMISSION

 

27

	 	7.3.1	 	the representations and warranties of EMD and Merck set forth in Section 3.2
will be true and correct in all material respects at the Closing Time with the same
force and effect as if made at and as of such time;
	 
	 	7.3.2	 	EMD and Merck will have performed or complied with all of the obligations and
covenants in this Agreement to be performed or complied with by EMD and Merck prior to
the Closing Time; and
	 
	 	7.3.3	 	Merck will have entered into the License Agreement.

 Section 7.4   Waiver of Condition

     Merck, in the case of a condition set out in Section 7.2, and Oncothyreon, in the case of a
condition set out in Section 7.3, will have the exclusive right to waive the performance or
compliance of such condition in whole or in part and on such terms as may be agreed upon without
prejudice to any of its rights in the event of non-performance of or non-compliance with any other
condition in whole or in part. Any such waiver will not constitute a waiver of any other
conditions in favour of the waiving party.

 Section 7.5 Termination

     This Agreement may be terminated, by written notice:

	 	7.5.1	 	by Oncothyreon or EMD if a material breach of any representation, warranty,
covenant, obligation or other provision of this Agreement has been committed by the
other party and such breach has not been waived or cured within 30 days following the
date on which the non-breaching party notifies the other party of such breach;
	 
	 	7.5.2	 	by EMD if any condition in Section 7.2 has not been satisfied as of the
Closing Time and EMD has not waived such condition on or before the Closing Date;
	 
	 	7.5.3	 	by Oncothyreon if any condition in Section 7.3 has not been satisfied as of
the Closing Time and Oncothyreon has not waived such condition on or before the Closing
Date;
	 
	 	7.5.4	 	by written agreement of Oncothyreon and EMD; or
	 
	 	7.5.5	 	by Oncothyreon or EMD if the Closing has not occurred by January 30, 2009.

ARTICLE 8

MISCELLANEOUS

Section 8.1 Treatment of Excluded Assets

     The Parties agree that the Excluded Assets may be removed from the Premises by Oncothyreon
following the date of this Agreement until February 28, 2009. Following the Closing Time,
Oncothyreon may not enter into the Premises to remove the Excluded Assets, or for any other reason,
without the prior consent of EMD, such consent not to be unreasonably withheld, and upon
forty-eight (48) hours prior notice. The Parties agree that the Excluded

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED
SEPARATELY WITH THE COMMISSION

 

28

Assets are the property of Oncothyreon, shall be removed from the Premises no later than February
28, 2009 by Oncothyreon and that EMD and Merck shall have no responsibility for, or liability for,
any damage that may occur to the Excluded Assets provided that EMD and Merck exercise the same care
with respect to storage of the Excluded Assets as they would in relation to storage of their own
assets of similar type. For greater certainty, Oncothyreon agrees to maintain insurance coverage
over the Excluded Assets for so long as they are situated on the Premises and shall, subject to EMD
and Merck exercising the standard of care referred to above in relation to the Excluded Assets, be
responsible for any damage to any of the Assets of EMD or Merck as a result of the storage at the
Premises or movement by Oncothyreon of the Excluded Assets from the Premises.

Section 8.2 Further Acts

     Each of the Parties hereto shall execute and deliver any further documents and do all acts and
things as the requesting Party may reasonably require to carry out the true intent and meaning of
this Agreement, including, without limiting the generality of the foregoing, assisting another
Party with the discharging of no longer applicable security registrations. Notwithstanding the
generality of the foregoing, Oncothyreon agrees to preserve intact and maintain any and all Books
and Records not physically transferred at the Closing Time to EMD/Merck for a period of no less
than two (2) years following the Closing Time and to provide originals and/or true copies of any
such Books and Records to Merck as soon as reasonably practicable following a written request of
the same.

Section 8.3 Parties of Interest

     This Agreement shall enure to the benefit of and be binding upon the Parties hereto, their
permitted assigns and successors.

Section 8.4 Entire Agreement

     This Agreement and the License Agreement constitute the entire agreement between the Parties
hereto with respect to the subject matter hereof and supersedes all prior negotiations, proposals
and agreements, whether oral or written, with respect to the subject matter hereof.

Section 8.5 Notices

     Any notice required to be given under the terms hereof may be given by a Party hereto by
delivering or telecopying such notice to the Party to which it is to be given at the address or
telecopy number below or at such other existing municipal address or telecopy number as that Party
may provide in writing to the other Party in lieu thereof in accordance with this Section 6.4:

	 	8.5.1	 	In the case of Oncothyreon:

	 	 	 	Biomira Management, Inc.

2601 Fourth Avenue, Suite 500

Seattle WA 98121

United States of America

Attention: President

Facsimile: (206) 801-2101

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED
SEPARATELY WITH THE COMMISSION

 

29

	 	8.5.2	 	In the case of EMD:

	 	 	 	2695 North Sheridan Way

Suite 200

Mississauga, Ontario

L5K 2N6

Attention: President

Facsimile: (905) 919-0299

	 	8.5.3	 	In the case of Merck:

	 	 	 	Merck KGaA

Frankfurter Strasse 250

D-64293 Darmstadt

Germany

Attention: Merck Serono Legal Department

Facsimile: +49-6151-72-2373

Any such notice shall be deemed to have been received by a Party hereto immediately upon delivery
or telecopy transmission of such notice to such Party at its address or telecopy number in such
notice.

Section 8.6 Waiver

     Failure by any Party hereto to insist in any one or more instances upon the strict performance
of any one of the covenants contained herein shall not be construed as a waiver or relinquishment
of such covenant. No waiver by any Party hereto of any such covenant shall be deemed to have been
made unless expressed in writing and signed by the waiving Party.

Section 8.7 Severability

     Any provision hereof which is prohibited or unenforceable in any jurisdiction shall be
ineffective to the extent of such prohibition or unenforceability without invalidating the
remaining provisions hereof and any such prohibition or unenforceability in any jurisdiction shall
not invalidate or render unenforceable such provision in any other jurisdiction.

Section 8.8 Amendments

     No term or provision hereof may be amended, discharged or terminated, except by an instrument
in writing signed by the Parties hereto.

Section 8.9 Public Announcements and Regulatory Filings

Oncothyreon, EMD and Merck agree that a press release, substantially in the form of press
release attached as Schedule M, shall be issued by each of Oncothyreon and EMD/Merck to
announce the execution of this Agreement. With respect to any other press releases or public
statements related to the subject matter of this Agreement, except with respect to subject
matter already in the public domain or as required by law,

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED
SEPARATELY WITH THE COMMISSION

 

30

Oncothyreon and EMD/Merck shall each provide the other party with a copy of the proposed
press release or public statement for review and approval, such approval not be unreasonably
withheld. With respect to the filing of this Agreement with the U.S. Securities and Exchange
Commission and any similar regulatory authorities, as may be required by Applicable Law,
Oncothyreon shall provide EMD/Merck with a copy of the proposed filing version of this
Agreement for review and comment.

Section 8.10 Confidentiality

Oncothyreon, EMD and Merck agree not to (directly or indirectly) disclose, allow access to,
transmit or transfer any of the other Party’s Confidential Information to a third party
without the prior written consent of the other Party hereto or unless such disclosure is
required by Applicable Law or an applicable regulatory authority. This obligation of
confidentiality shall remain in force for a period of ten (10) years from the Closing Date.
The Parties further recognize that, as contemplated in Section 8.1, there will be certain
assets and proprietary information of Oncothyreon and its Affiliates at the Premises for a
period of time following the Closing and EMD and Merck covenant and agree not to use, in any
manner, any such assets or information and to strictly maintain the confidentiality thereof.

Section 8.11 Assignment

     Oncothyreon shall not be entitled to assign this Agreement or any of its interests or
entitlements under the Agreement without the prior written consent of EMD. EMD shall be entitled to
assign this Agreement and any of its interests or entitlements under this Agreement to any one or
more of its Affiliates.

Section 8.12 Time of Essence

     Time shall be of the essence of this Agreement.

Section 8.13 Governing Law

     This Agreement shall be governed by and construed in accordance with the laws of the province
of Alberta and the federal laws of Canada applicable therein and the Parties attorn to the
exclusive jurisdiction of the courts of the Province of Alberta.

Section 8.14 Survival

     The covenants and agreements set out in Articles 3,4 and 6 and Sections 8.1, 8.2, 8.4, 8.5,
8.9 and 8.10 hereof shall survive the Closing Date.

Section 8.15 Counterparts

     This Agreement may be executed in several counterparts, each of which when so executed shall
be deemed to be an original and shall have the same force and effect as an original but such
counterparts together shall constitute but one and the same instrument.

Section 8.16 Faxed Copies

     A faxed copy or telecopy of this Agreement shall have the same force and effect as an
originally executed copy of this Agreement.

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED
SEPARATELY WITH THE COMMISSION

 

31

ARTICLE 9

EXECUTION

This Agreement is agreed to and accepted by:

	 	 	 	 	 	 	 
	BIOMIRA MANAGEMENT, INC.	 	EMD SERONO CANADA INC.
	 
	 	 	 	 	 	 
	By:

	 	/s/ Robert L. Kirkman, M.D.
	 	By:
	 	/s/ Deborah Brown
	 

	 	 
	 	 	 	 
	Title:
	 	 President & CEO
	 	Title:
	 	 Managing Director
	 
	 	 
	 	 	 	 
	 
	 	 	 	 	 	 
	By:

	 	 	 	By:
	 	/s/ William Hilson
	 

	 	 
	 	 	 	 
	Title:
	 	 	 	Title: 	 	Finance Director
	 
	 	 	 	 	 	 
	 
	MERCK KGAA	 	ONCOTHYREON CANADA INC.
	 
	 	 	 	 	 	 
	By:

	 	/s/ Andreas Stickler
	 	By:
	 	/s/ Robert L. Kirkman, M.D.
	 
	 	 	 	 	 	 
	Title:

	 	 Head of M&A
	 	Title:
	 	 President
	 

	 	 
	 	 	 	 
	 
	 	 	 	 	 	 
	By:

	 	 	 	By:	 	 
	 

	 	 
	 	 	 	 
	Title:

	 	 	 	Title:	 	 
	 

	 	 
	 	 	 	 
	 
	 	 	 	 	 	 
	ONCOTHYREON INC.	 	 	 	 
	 
	 	 	 	 	 	 
	By:

	 	/s/ Robert L. Kirkman, M.D.	 	 	 	 
	 

	 	 	 	 	 	 
	Title:

	 	President & CEO	 	 	 	 
	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	By:
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	Title:
	 	  	 	 	 	 
	 

	 	 	 	 	 	 

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED
SEPARATELY WITH THE COMMISSION

 

 

Schedule A

Inventory Assets

[+]

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED
SEPARATELY WITH THE COMMISSION

 

 

Schedule B

Leased Premises Assets

See Schedule D

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED
SEPARATELY WITH THE COMMISSION

 

 

Schedule C

Manufacturing Contracts

1. Adjuvant Supply Agreement, dated October 20, 2004, as amended, between Corixa Corporation
(d/b/a GlaxoSmithKline Biologicals N.A.) and Biomira International Inc. (assigned to Biomira
Management Inc. on December 7, 2007)

2. Product Development and Clinical Supply Agreement, dated September 10, 1999, as amended,
between Baxter Pharmaceutical Solutions LLC and Biomira USA, Inc.

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED
SEPARATELY WITH THE COMMISSION

 

Schedule D

Other Assets

Oncothyreon Canada Inc

Asset Listing by Department

As of September 30, 2008

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Dept	 	 	 	 	 	 	 	 	 	 	 	 	 	Net Book	 	 	 	Serial	 	Model	 	 	 	 
	Code	 	Number	 	Description	 	Purch Date	 	Purch Price	 	Value	 	Manufacturer	 	Number	 	Number	 	AFE #	 	Location
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	2050	 	 	 	1127	 	 	3com linkswitch 1000 100b-fx d

	 	29-May-97
	 	 	5,200.00	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	2050	 	 	 	1128	 	 	3com superstack II switch 300

	 	29-May-97
	 	 	7,799.00	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	2050	 	 	 	1129	 	 	3com superstack II switch 1000

	 	29-May-97
	 	 	14,739.00	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	2050	 	 	 	1193	 	 	IBM PC server

	 	7-Jul-98
	 	 	16,000.00	 	 	 	0.00	 	 	 	 	 	23P5206	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	2050	 	 	 	1269	 	 	Proxima projector

	 	28-Feb-00
	 	 	6,008.00	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	00-2-010	 	 	 	 	 
	 	2050	 	 	 	1283	 	 	Xerox N3225, HP laserjet 4050T

	 	15-May-00
	 	 	11,422.00	 	 	 	0.00	 	 	 	 	HPUSBB 012481
	 	 	 	 	 	 	00-2-017	 	 	 	 	 
	 	2050	 	 	 	1319	 	 	Computer (former lease)

	 	8-Jul-01
	 	 	34,571.76	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	01-2-004	 	 	SRVRM

	 	2050	 	 	 	1324	 	 	Buyout of Lease

	 	31-Aug-01
	 	 	41,175.65	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	01-2-012	 	 	 	 	 
	 	2050	 	 	 	1332	 	 	Computer Lease — reclass to

	 	30-Nov-01
	 	 	154,962.20	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	2050	 	 	 	1403	 	 	Scanner, Fujitsu

	 	30-Sep-03
	 	 	12,000.00	 	 	 	0.00	 	 	Fujitsu
	 	 	504441	 	 	FI-4750C
	 	 	03-4-019	 	 	IS

	 	2050	 	 	 	1409	 	 	Hewlett-Packard Comp (BUSA)

	 	20-Dec-04
	 	 	69,166.22	 	 	 	0.00	 	 	Hewlett Packard
	 	 	 	 	 	 	 	 	 	 	100123	 	 	 	 	 
	 	2050	 	 	 	1417	 	 	Dell Financial Computer Lease

	 	13-Jul-05
	 	 	139,732.38	 	 	 	0.00	 	 	Dell/HP
	 	 	 	 	 	 	 	 	 	 	2/5/1932	 	 	 	 	 
	 	2050	 	 	 	1434	 	 	Citrix WANScalers 8500

	 	19-Jun-07
	 	 	8,550.91	 	 	 	5,225.49	 	 	Compugen
	 	ORB-7500-1
	 	NETCIR7500
	 	 	2/7/1951	 	 	 	 	 
	 	2050	 	 	 	1435	 	 	Leased HP Computer servers

	 	28-Sep-07
	 	 	163,524.70	 	 	 	104,474.15	 	 	Compugen
	 	 	 	 	 	HP Servers (SAN)
	 	 	2/7/1952	 	 	 	 	 
	 	2050	 	 	 	1441	 	 	HP 4050 TN Printer

	 	1-Aug-00
	 	 	2,247.42	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	2050	 	 	 	1452	 	 	Dell Computers BuyOutEndofTerm

	 	8-Jul-08
	 	 	25,105.00	 	 	 	23,012.92	 	 	Dell/HP
	 	 	 	 	 	 	 	 	 	 	2/8/2005	 	 	Edmonton

	 	2050	 	 	 	1459	 	 	MPSM6110 IMPRNTR/STMPS/SDDL F6

	 	30-Sep-08
	 	 	5,625.12	 	 	 	5,468.87	 	 	 	 	 	100E5487	 	 	MPSM6110
	 	 	 	 	 	 	 	 
	 	2060	 	 	 	1440	 	 	Xerox Workcentre 7665

	 	7-Nov-07
	 	 	31,500.00	 	 	 	25,725.00	 	 	Xerox
	 	VDR548760
	 	WC 7665
	 	 	8/7/1958	 	 	 	 	 
	 	2060	 	 	 	1449	 	 	Xerox Workcentre 4150XF

	 	26-May-08
	 	 	4,299.00	 	 	 	3,109.12	 	 	Xerox
	 	 	L99041198	 	 	4150XF
	 	 	 	 	 	 	 	 
	 	2060	 	 	 	1450	 	 	Walk-in Cooler

	 	3-Jun-08
	 	 	17,848.00	 	 	 	17,489.75	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Edmonton, AB

	 	2060	 	 	 	1458	 	 	Xerox Workcentre 4150S

	 	30-Sep-08
	 	 	4,299.00	 	 	 	4,227.35	 	 	Xerox
	 	 	L99358267	 	 	WC4150S
	 	 	 	 	 	 	 	 
	 	2070	 	 	 	1	 	 	van

	 	1-Jan-92
	 	 	3,500.00	 	 	 	0.00	 	 	Dodge
	 	VIN 2B7GB13TSHK278889
	 	RAM150
	 	 	 	 	 	 	 	 
	 	2070	 	 	 	160	 	 	Biomira Sign & Plaque

	 	15-Jun-92
	 	 	8,121.50	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	2070	 	 	 	177	 	 	Biomira North Renovations

	 	29-Jun-92
	 	 	18,227.00	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	2070	 	 	 	270	 	 	Electrical & Add-on Furniture

	 	20-Aug-92
	 	 	8,370.50	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	2070	 	 	 	298	 	 	Forma Model 6097 Glassware Ste

	 	8-Sep-92
	 	 	8,933.80	 	 	 	0.00	 	 	Forma
	 	 	51354-375	 	 	6097	 	 	 	 	 	 	B204	 
	 	2070	 	 	 	299	 	 	Fury Glassware Dryer Model 609

	 	8-Sep-92
	 	 	9,000.00	 	 	 	0.00	 	 	Forma
	 	 	51354-376	 	 	6097	 	 	 	 	 	 	F113	 
	 	2070	 	 	 	403	 	 	Low Temperature Calibration Un

	 	16-Nov-92
	 	 	6,610.00	 	 	 	0.00	 	 	TECHNE
	 	 	31728/1	 	 	DB45M
	 	 	 	 	 	Metrology

	 	2070	 	 	 	404	 	 	High Temperature Calibration U

	 	16-Nov-92
	 	 	7,400.00	 	 	 	0.00	 	 	TECHNE
	 	 	30913/1	 	 	DB1200M
	 	 	 	 	 	Metrology

	 	2070	 	 	 	453	 	 	Vivarium Cage & Bottle Washer

	 	28-Jan-93
	 	 	36,000.00	 	 	 	0.00	 	 	Better Built
	 	 	6855	 	 	550	 	 	 	 	 	VIVARIUM

	 	2070	 	 	 	479	 	 	Waste Storage Building

	 	22-Feb-93
	 	 	10,263.00	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	2070	 	 	 	495	 	 	Renovations to the Vivarium

	 	27-Feb-93
	 	 	131,375.39	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	2070	 	 	 	574	 	 	Precision RTD Thermometer

	 	21-Jun-93
	 	 	5,437.95	 	 	 	0.00	 	 	Azonics
	 	 	T1742-3139	 	 	A1011	 	 	 	 	 	Metrology

	 	2070	 	 	 	721	 	 	Digital Pressure Calibration S

	 	8-Feb-94
	 	 	13,540.00	 	 	 	0.00	 	 	 	 	 	6051513	 	 	 	 	 	 	 	 	 	 	Metrology

	 	2070	 	 	 	904	 	 	Eagle 3000 Scientific Series S

	 	22-Sep-94
	 	 	47,804.00	 	 	 	0.00	 	 	AMSCO
	 	 	12539403	 	 	3000	 	 	 	 	 	 	L106	 
	 	2070	 	 	 	1233	 	 	Office Furniture for B

	 	1-Apr-99
	 	 	17,046.25	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	99-8-009	 	 	 	 	 
	 	2070	 	 	 	1300	 	 	Millwork- counters/fume hood

	 	23-Nov-00
	 	 	4,437.50	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	00-8-029	 	 	 	F219	 

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

37

Oncothyreon Canada Inc

Asset Listing by Department

As of September 30, 2008

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Dept	 	 	 	 	 	 	 	 	 	 	 	 	 	Net Book	 	 	 	Serial	 	Model	 	 	 	 
	Code	 	Number	 	Description	 	Purch Date	 	Purch Price	 	Value	 	Manufacturer	 	Number	 	Number	 	AFE #	 	Location
	 
	 	2070	 	 	 	1305	 	 	Front reception renovation

	 	24-Jan-01
	 	 	10,025.80	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	00-8-034	 	 	 	 	 
	 	2070	 	 	 	1312	 	 	Free standing pedestal desk (r

	 	 30-May-01
	 	 	499	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	00-8-034	 	 	 	 	 
	 	2070	 	 	 	1313	 	 	25 Chairs, various styles

	 	11-Jun-01
	 	 	8,934.00	 	 	 	0.00	 	 	All-West
	 	 	 	 	 	 	 	 	 	 	01-8-008	 	 	Immunology

	 	2070	 	 	 	1325	 	 	Finance/Clinical/Tech Op’s des

	 	29-Sep-01
	 	 	5,965.00	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	01-8-014	 	 	 	 	 
	 	2070	 	 	 	1327	 	 	Chair Replacements

	 	11-Oct-01
	 	 	9,990.62	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	01-8-016	 	 	 	 	 
	 	2070	 	 	 	1334	 	 	Scotsman Ice Flaker Machine

	 	8-Mar-02
	 	 	5,679.00	 	 	 	0.00	 	 	Scotsman
	 	542503-07D / AFE325AS-1A
	 	AFE325AS-1A
	 	 	02-8-003	 	 	 	B211	 
	 	2070	 	 	 	1338	 	 	Upgrade HVAC / Clean Suite Fac

	 	21-Jun-02
	 	 	43,561.95	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	02-8-008	 	 	 	 	 
	 	2070	 	 	 	1342	 	 	Stainless Steel Storage Cabine

	 	30-Jun-02
	 	 	11,050.00	 	 	 	0.00	 	 	Halbar Stainless
	 	 	 	 	 	 	 	 	 	 	02-8-007	 	 	Viv cabinets

	 	2070	 	 	 	1385	 	 	Hart Scientific Low Temp Calib

	 	1-Nov-01
	 	 	3,086.39	 	 	 	0.00	 	 	Hart Scientific
	 	 	A1A023	 	 	9402 HDRC
	 	02-12-USA
	 	 	F212	 
	 	2070	 	 	 	1401	 	 	Vivarium Expansion

	 	28-Feb-00
	 	 	71,797.77	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	00-8-011	 	 	 	 	 
	 	2070	 	 	 	1402	 	 	Basement/main floor exp. (QC)

	 	30-Mar-98
	 	 	342,938.90	 	 	 	0.10	 	 	 	 	 	 	 	 	 	 	 	 	 	99-8-007	 	 	 	 	 
	 	2070	 	 	 	1405	 	 	Stair Repairs

	 	30-Jul-04
	 	 	22,350.00	 	 	 	3,725.00	 	 	Dawson Wallace Const
	 	 	 	 	 	 	 	 	 	 	04-8-021	 	 	Edmonton

	 	2070	 	 	 	1425	 	 	Reliance 500 Glassware Washer

	 	21-Nov-05
	 	 	49,571.00	 	 	 	21,500.11	 	 	Steris
	 	 	3634305001	 	 	Reliance 500
	 	 	8/5/1938	 	 	 	F113	 
	 	2070	 	 	 	1432	 	 	Kaye CTR-80 Bath (-80C to 30C)

	 	31-Oct-06
	 	 	13,010.00	 	 	 	6,776.08	 	 	GE Sensing
	 	 	X0390	 	 	CTR-80
	 	 	8/6/1946	 	 	Metrology

	 	2070	 	 	 	1436	 	 	Walk in Cooler

	 	28-Sep-07
	 	 	15,570.00	 	 	 	12,196.50	 	 	Coral Engineering
	 	 	 	 	 	8x8x7.5 walk-in cooler
	 	 	8/7/1950	 	 	second floor F212

	 	2070	 	 	 	1437	 	 	Data and Telephone Cabling

	 	21-Sep-07
	 	 	36,808.38	 	 	 	30,253.67	 	 	R&T Networks
	 	 	 	 	 	 	 	 	 	 	2/7/1956	 	 	second floor

	 	2070	 	 	 	1444	 	 	Building Renovations 2008

	 	12-Mar-08
	 	 	102,587.00	 	 	 	90,618.54	 	 	Edmonton Economics	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	2070	 	 	 	1445	 	 	Avaya Phone System

	 	31-Mar-08
	 	 	24,391.00	 	 	 	21,951.88	 	 	Telus Communications	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	8020	 	 	 	993	 	 	TOC Analyzer & Validation Supp

	 	18-Jul-95
	 	 	29,477.16	 	 	 	0.00	 	 	 	 	 	9507-276	 	 	 	 	 	 	 	 	 	 	 	F219	 
	 	8020	 	 	 	1112	 	 	REVCO 45 cu.ft fridge

	 	16-Apr-97
	 	 	4,460.83	 	 	 	0.00	 	 	Revco
	 	NB-110726
	 	REBL304AVA
	 	 	 	 	 	 	F219	 
	 	8020	 	 	 	1147	 	 	HP 6890 series gas chromatogra

	 	27-Aug-97
	 	 	51,946.77	 	 	 	0.00	 	 	 	 	US00009603
	 	 	 	 	 	 	 	 	 	 	F219	 
	 	8020	 	 	 	1179	 	 	Autosampler for existing Dione

	 	16-Apr-98
	 	 	18,090.00	 	 	 	0.00	 	 	Beckman
	 	 	00-151	 	 	508	 	 	 	 	 	 	F219	 
	 	8020	 	 	 	1261	 	 	Waters Bus/SAT kit

	 	13-Jan-00
	 	 	2,630.00	 	 	 	0.00	 	 	Waters
	 	 	 	 	 	 	 	 	 	 	00-8-001	 	 	 	F219	 
	 	8020	 	 	 	1262	 	 	Laser scattering Device s/n 10

	 	30-Jan-00
	 	 	72,235.62	 	 	 	0.00	 	 	Precision Detection
	 	 	 	 	 	PL-ELS-1000
	 	 	00-8-002	 	 	 	F219	 
	 	8020	 	 	 	1303	 	 	HPLC pump (model 2690)

	 	27-Dec-00
	 	 	44,736.91	 	 	 	0.00	 	 	Waters
	 	M99SM7648M
	 	2695	 	 	 	 00-8-001	 	 	 	F219	 
	 	8020	 	 	 	1316	 	 	HPLC system and software

	 	24-Jun-01
	 	 	68,072.50	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	01-8-010	 	 	 	F219	 
	 	8020	 	 	 	1341	 	 	Evaporativ Light Scattering De

	 	15-May-01
	 	 	22,689.45	 	 	 	0.00	 	 	Polymer Laboratories
	 	 	003-653	 	 	PL-ELS 1000
	 	 	02-8-017	 	 	 	B213	 
	 	8020	 	 	 	1366	 	 	HPLC Detector

	 	1-Jun-96
	 	 	17,757.98	 	 	 	0.00	 	 	Waters
	 	 	L97996450M	 	 	996photodioarray
	 	02-12-USA
	 	 	F219	 
	 	8020	 	 	 	1369	 	 	HPLC High Pressure Chromatogra

	 	1-Dec-97
	 	 	71,538.26	 	 	 	0.00	 	 	Waters
	 	 	M975M4937M	 	 	2690	 	 	02-12-USA
	 	 	F219	 
	 	8020	 	 	 	1370	 	 	HPLC — SAT/IN Module

	 	1-Dec-97
	 	 	2,738.87	 	 	 	0.00	 	 	Waters
	 	M97SAT735M
	 	SAT
	 	02-12-USA
	 	 	F219	 
	 	8020	 	 	 	1381	 	 	Shimadzu UV Mini 1240 Spectoph

	 	1-Oct-00
	 	 	7,009.49	 	 	 	0.00	 	 	Shimadzu Corp
	 	 	A10913780220	 	 	UVMini-1240
	 	02-12-USA
	 	 	F219	 
	 	8020	 	 	 	1384	 	 	Harris -85o Freezer

	 	1-Jun-01
	 	 	12,628.24	 	 	 	0.00	 	 	Harris
	 	 	4743	 	 	 	 	 	 	02-12-USA
	 	 	F219	 
	 	8030	 	 	 	477	 	 	Microzone 6 ft Biological Con

	 	21-Feb-93
	 	 	7,872.00	 	 	 	0.00	 	 	Microzone Corp
	 	 	902-7268	 	 	BM6-2A-49
	 	 	 	 	 	 	F214	 
	 	8030	 	 	 	678	 	 	Wedgewood Ph Monitor (2)

	 	16-Nov-93
	 	 	12,898.24	 	 	 	0.00	 	 	Sepracor
	 	 	33201	 	 	600	 	 	 	 	 	 	 	F-221	 
	 	8030	 	 	 	703	 	 	BPG 200/500 Column (2)

	 	7-Jan-94
	 	 	11,880.00	 	 	 	0.00	 	 	Pharmacia
	 	 	20000950	 	 	BPG200/500
	 	 	 	 	 	 	F221	 
	 	8030	 	 	 	787	 	 	5x4-way Valve Manual Pharmacia

	 	10-Apr-94
	 	 	5,707.10	 	 	 	0.00	 	 	Pharmacia
	 	 	N/A	 	 	 	 	 	 	 	 	 	 	 	F221	 
	 	8030	 	 	 	914	 	 	Isotemp General Purpose 26 cu.

	 	6-Nov-94
	 	 	5,050.00	 	 	 	0.00	 	 	Fisher Scientific
	 	 	93766321	 	 	13-987-326R	 	 	 	 	 	 	F214	 

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

38

Oncothyreon Canada Inc

Asset Listing by Department

As of September 30, 2008

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Dept	 	 	 	 	 	 	 	 	 	 	 	 	 	Net Book	 	 	 	Serial	 	Model	 	 	 	 
	Code	 	Number	 	Description	 	Purch Date	 	Purch Price	 	Value	 	Manufacturer	 	Number	 	Number	 	AFE #	 	Location
	 
	 	8030	 	 	 	958	 	 	Watson Marlow Pump

	 	26-Mar-95
	 	 	5,000.00	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	8030	 	 	 	1068	 	 	Shimadzu Fluorometer and Softw

	 	9-Jul-96
	 	 	15,286.00	 	 	 	0.00	 	 	Shimadzu
	 	 	30099K	 	 	RF-551PC
	 	 	 	 	 	 	F221	 
	 	8030	 	 	 	1105	 	 	Ultrospec 3000

	 	6-Mar-97
	 	 	8,900.00	 	 	 	0.00	 	 	Pharmacia
	 	 	67679	 	 	Ultrospec 3000
	 	 	 	 	 	 	F214	 
	 	8030	 	 	 	1109	 	 	Sorvall RC-5C Plus

	 	1-Apr-97
	 	 	15,140.06	 	 	 	0.00	 	 	Mandel Scientific
	 	 	9503408	 	 	RC5C Plus
	 	 	 	 	 	 	F221	 
	 	8030	 	 	 	1253	 	 	3L Bioreactor

	 	10-Sep-99
	 	 	12,635.62	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	99-88-021 	 	 	F214	 
	 	8030	 	 	 	1254	 	 	Bioreactor

	 	30-Sep-99
	 	 	17,603.86	 	 	 	0.00	 	 	Applikon
	 	 	 	 	 	Z61103CT04
	 	99-88-018 	 	 	 	 
	 	8030	 	 	 	1260	 	 	508 Injector

	 	22-Dec-99 
	 	 	16,124.00	 	 	 	0.00	 	 	Beckman
	 	 	90010	 	 	508 Autosampler
	 	 	99-8-025	 	 	 	F221	 
	 	8030	 	 	 	1264	 	 	Ozone Monitor

	 	14-Feb-00
	 	 	6,802.95	 	 	 	0.00	 	 	PCI-Wedeco
	 	 	1414	 	 	HC400
	 	 	99-8-024	 	 	 	F221	 
	 	8030	 	 	 	1265	 	 	AKTA explorer HPLC system

	 	28-Dec-00
	 	 	76,890.79	 	 	 	0.00	 	 	Pharmacia (amersham)
	 	 	1937	 	 	 	 	 	 	 	00-8-003	 	 	 	F221	 
	 	8030	 	 	 	1309	 	 	BPG 200/500 Column DI/NI

	 	18-Mar-01
	 	 	7,287.00	 	 	 	0.00	 	 	PHARMACIA
	 	 	N/A	 	 	BPG200/500
	 	 	01-8-003	 	 	 	F221	 
	 	8030	 	 	 	1345	 	 	Rotor for Centrifuge CEN-2015

	 	31-Jul-02
	 	 	10,287.07	 	 	 	0.00	 	 	Sorvall
	 	 	10253675	 	 	SLA-3000
	 	 	02-8-015	 	 	 	F222	 
	 	8030	 	 	 	1355	 	 	Floor Scale 500 KG Cap w/term

	 	21-Aug-02
	 	 	9,505.00	 	 	 	0.00	 	 	Mettler
	 	1114584-1GD
	 	2888032001	 	 	 	02-8-009	 	 	 	F221	 
	 	8030	 	 	 	1358	 	 	Thermal Label Printer

	 	24-Sep-02
	 	 	1,655.00	 	 	 	0.00	 	 	Mettler
	 	0305503-4MA
	 	8865-0011	 	 	 	02-8-009	 	 	 	F221	 
	 	8030	 	 	 	1371	 	 	Dura-Stop MP Tray Dryer / Comp

	 	1-Jan-98
	 	 	77,855.25	 	 	 	0.00	 	 	FTS Systems Inc
	 	 	10493	 	 	TDS3C2C8100/7470
	 	02-12-USA
	 	 	F214	 
	 	8030	 	 	 	1372	 	 	Optima LE-80k ultracentrifuge

	 	1-Feb-98
	 	 	69,147.68	 	 	 	0.00	 	 	Beckman
	 	COL98A02
	 	Optima LE-80k
	 	02-12-USA
	 	 	F214	 
	 	8030	 	 	 	1374	 	 	Heat Exchanger

	 	5-Feb-98
	 	 	1,375.16	 	 	 	0.00	 	 	Exergy Inc
	 	 	12962	 	 	00169-3	 	 	02-12-USA
	 	 	F221	 
	 	8030	 	 	 	1376	 	 	Dura-Dry MP Freeze Dryer

	 	1-Jul-98
	 	 	12,093.06	 	 	 	0.00	 	 	FTS Systems
	 	 	10490	 	 	FD2085C0101
	 	02-12-USA
	 	 	F214	 
	 	8030	 	 	 	1377	 	 	Karl Fisher Titrator

	 	1-Oct-98
	 	 	11,954.00	 	 	 	0.00	 	 	Mettler Toledo
	 	MEB08872
	 	DL37/996Photodiode
	 	02-12-USA
	 	 	F221	 
	 	8030	 	 	 	1379	 	 	Calorimeter DSC w/ Monitor

	 	1-Dec-98
	 	 	84,368.75	 	 	 	0.00	 	 	Calorimetry Sciences
	 	 	165	 	 	4100 DSC
	 	02-12-USA
	 	 	F214	 
	 	8030	 	 	 	1380	 	 	Calorimeter DSC w/monitor & ci

	 	1-Dec-98
	 	 	620.39	 	 	 	0.00	 	 	Neslab
	 	 	198321173	 	 	RTE-140
	 	02-12-USA
	 	 	B217	 
	 	8030	 	 	 	1382	 	 	HPLC Allicance System

	 	30-Apr-01
	 	 	87,110.37	 	 	 	0.00	 	 	Waters
	 	 	D015M4107M	 	 	SHC (2690)
	 	02-12-USA
	 	 	F219	 
	 	8030	 	 	 	1383	 	 	PolymerLab Mass Evap Det HPLC2

	 	1-May-02
	 	 	22,689.45	 	 	 	0.00	 	 	Polymer Labs
	 	 	022-12T	 	 	PL-ELS-1000
	 	02-12-USA
	 	 	F219	 
	 	8030	 	 	 	1386	 	 	Sonicator

	 	1-Jan-02
	 	 	8,885.42	 	 	 	0.00	 	 	Misonix Inc.
	 	 	R0146	 	 	S3000	 	 	02-12-USA
	 	 	F214	 
	 	8030	 	 	 	1387	 	 	Applikon Bioreactors w/accesso

	 	1-Nov-99
	 	 	23,226.46	 	 	 	0.00	 	 	Applikon
	 	P	08359/5; P10578/4	 	 	P100	 	 	02-12-USA
	 	 	F214	 
	 	8030	 	 	 	1388	 	 	Stirrer Motor Assembly P1000C

	 	1-Sep-00
	 	 	10,039.87	 	 	 	0.00	 	 	Applikon
	 	P	01417/3; P05257/17	 	 	P1000	 	 	02-12-USA
	 	 	F214	 
	 	8030	 	 	 	1390	 	 	Bioreactor 7l, stirrer, access

	 	1-Jul-00
	 	 	14,163.83	 	 	 	0.00	 	 	Applikon Inc.
	 	 	 	 	 	 	 	 	 	02-12-USA
	 	 	F214	 
	 	8030	 	 	 	1391	 	 	Applikon Bioreactors w/ access

	 	1-Jul-01
	 	 	22,424.94	 	 	 	0.00	 	 	Applikon
	 	P	11105/12 ; P19968/48	 	 	P310	 	 	02-12-USA
	 	 	F214	 
	 	8030	 	 	 	1392	 	 	Dedicated Bioreactor

	 	8-Feb-98
	 	 	16,275.66	 	 	 	0.00	 	 	Applikon
	 	ADI10122261
	 	ADI1012
	 	02-12-USA
	 	 	F214	 
	 	8030	 	 	 	1393	 	 	Bioreactor (1L)

	 	4-Apr-98
	 	 	7,322.27	 	 	 	0.00	 	 	Applikon Inc
	 	 	 	 	 	 	 	 	 	02-12-USA
	 	 	F214	 
	 	8030	 	 	 	1394	 	 	Applikon Bioreactor w/ accesor

	 	1-Mar-98
	 	 	25,754.43	 	 	 	0.00	 	 	Applikon
	 	P	05735/11 ; P10578/63	 	 	P140	 	 	02-12-USA
	 	 	F214	 
	 	8030	 	 	 	1395	 	 	Bioreactor (3L)

	 	1-Aug-98
	 	 	2,426.96	 	 	 	0.00	 	 	Applikon Inc
	 	 	 	 	 	 	 	 	 	02-12-USA
	 	 	F214	 
	 	8030	 	 	 	1399	 	 	Double Incubator

	 	1-May-97
	 	 	4,069.60	 	 	 	0.00	 	 	VWR / Sheldon Mftg
	 	 	300594	 	 	1565	 	 	02-12-USA
	 	 	F221	 
	 	8030	 	 	 	1412	 	 	Two Fireking 4 Drawer Cabinets

	 	16-Feb-05
	 	 	4,474.00	 	 	 	1,192.92	 	 	Fireking
	 	 	 	 	 	4 drawer lateral
	 	 	8/5/2028	 	 	 	F215	 
	 	8030	 	 	 	1429	 	 	15L Applikon BioReactor

	 	28-Aug-06
	 	 	20,935.40	 	 	 	10,067.65	 	 	Applikon Inc.
	 	 	1101/01, P10496/7, P09759/7,	 	 	 	 	 	 	 	8/6/1945	 	 	Manufacturing B101010

	 	8040	 	 	 	1122	 	 	18 L Lyophilizer

	 	25-May-97
	 	 	14,480.00	 	 	 	0.00	 	 	VIRTIS
	 	 	202377 202325	 	 	UNITOP400SL 26031
	 	 	 	 	 	Pilot Plant

	 	8040	 	 	 	1411	 	 	60L S/Steel Pressure Vessel

	 	1-May-05
	 	 	27,939.15	 	 	 	5,871.15	 	 	T & C
	 	TO6253
	 	60L	 	 	 	8/5/2029	 	 	Baxter

	 	8040	 	 	 	1415	 	 	5L Applikon Bioreactor

	 	8-Jul-05
	 	 	15,786.70	 	 	 	2,959.99	 	 	Applikon Inc.
	 	P	06175/32;P04600/14	 	 	 	 	 	 	 	8/5/1931	 	 	Baxter

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

39

Oncothyreon Canada Inc

Asset Listing by Department

As of September 30, 2008

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Dept	 	 	 	 	 	 	 	 	 	 	 	 	 	Net Book	 	 	 	Serial	 	Model	 	 	 	 
	Code	 	Number	 	Description	 	Purch Date	 	Purch Price	 	Value	 	Manufacturer	 	Number	 	Number	 	AFE #	 	Location
	 
	 	8040	 	 	 	1419	 	 	Magnetic Stirrer/Motor Assembl

	 	8-Jul-05
	 	 	9,008.16	 	 	 	1,689.03	 	 	Applikon
	 	PO6175/25 P03384/1
	 	P140	 	 	 	8/5/1931	 	 	Baxter

	 	8040	 	 	 	1421	 	 	50L INOVA Intermediate Tank

	 	24-Aug-05
	 	 	42,562.62	 	 	 	9,753.98	 	 	INOVA
	 	 	N/A	 	 	50L	 	 	 	8/5/1937	 	 	Baxter

	 	8040	 	 	 	1422	 	 	INOVA Filling Parts

	 	1-May-05
	 	 	40,317.45	 	 	 	8,497.70	 	 	INOVA
	 	 	 	 	 	 	 	 	 	 	8/5/2029	 	 	Baxter

	 	8040	 	 	 	1427	 	 	15L Applikon Jacketed Vessel

	 	26-May-06 
	 	 	4,227.56	 	 	 	1,937.74	 	 	Applikon
	 	V3ME010051
	 	15L Jacketed Vessel
	 	 	8/6/1941	 	 	Baxter

	 	8040	 	 	 	1431	 	 	Lightnin Mixer Model G2S05R

	 	9-Nov-06
	 	 	5,730.33	 	 	 	2,984.59	 	 	 	 	 	R0653576101-02	 	 	G2SO5R
	 	 	8/6/1947	 	 	Baxter

	 	8040	 	 	 	1433	 	 	5L BioReactor

	 	31-Jan-07
	 	 	9,294.34	 	 	 	5,421.74	 	 	Applikon
	 	Z6110CT05/Z81315MG03/81313R645
	 	 	 	 	 	 	8/6/1949	 	 	Manufacturing

	 	8040	 	 	 	1443	 	 	60L Pressure Vessel

	 	11-Mar-08
	 	 	52,250.00	 	 	 	44,630.22	 	 	Baxter Pharm.
	 	 	 	 	 	 	 	 	 	 	8/6/1948	 	 	 	 	 
	 	8040	 	 	 	1446	 	 	Scale- up Stimuvax equipment

	 	22-Apr-08
	 	 	5,000.00	 	 	 	4,374.98	 	 	see notes
	 	see notes
	 	see notes
	 	 	8/8/2001	 	 	Process development

	 	8040	 	 	 	1453	 	 	Stirrer Controller P1000

	 	6-Aug-08
	 	 	4,758.00	 	 	 	4,559.74	 	 	Applikon
	 	P161627	 	 	P1000	 	 	 	8/5/1931	 	 	Edmonton

	 	8040	 	 	 	1454	 	 	Stirrer Motor Assembly P1000

	 	6-Aug-08
	 	 	4,304.00	 	 	 	4,124.66	 	 	Applikon
	 	P169894	 	 	P1000	 	 	 	8/5/1931	 	 	Edmonton

	 	8050	 	 	 	316	 	 	HP 1050 Series Autosampler

	 	14-Sep-92
	 	 	9,649.50	 	 	 	0.00	 	 	Hewlett Packard
	 	 	3141A01614	 	 	HP1050Series
	 	 	N/A	 	 	 	E205	 
	 	8050	 	 	 	317	 	 	High Speed Spectrophotometric

	 	14-Sep-92
	 	 	13,977.36	 	 	 	0.00	 	 	Hewlett Packard
	 	 	3149G01298	 	 	HP1050 Series
	 	 	N/A	 	 	 	E205	 
	 	8050	 	 	 	318	 	 	Automated Gradient LC System

	 	14-Sep-92
	 	 	15,741.00	 	 	 	0.00	 	 	Hewlett Packard
	 	 	3225A01584	 	 	HP1050 Series
	 	 	N/A	 	 	 	E205	 
	 	8050	 	 	 	905	 	 	Empty YMC Column 2000PSI

	 	28-Sep-94
	 	 	10,455.00	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Chemistry

	 	8050	 	 	 	1115	 	 	16 Port drying chamber

	 	6-May-97
	 	 	1,973.67	 	 	 	0.00	 	 	LABCONCO
	 	 	 	 	 	7522900	 	 	 	 	 	 	 	F218	 
	 	8050	 	 	 	1218	 	 	HPLC for PD/Chem Development

	 	30-Dec-98
	 	 	10,622.03	 	 	 	0.00	 	 	Waters
	 	 	B97996	 	 	996	 	 	 	 	 	 	F218	 
	 	8050	 	 	 	1219	 	 	HPLC for PD/Chem Development

	 	30-Dec-98
	 	 	39,377.97	 	 	 	0.00	 	 	Waters
	 	 	K965M4 608M	 	 	2690	 	 	 	 	 	 	 	F218	 
	 	8050	 	 	 	1248	 	 	Electrochemical detector with

	 	23-Jun-99
	 	 	13,535.00	 	 	 	0.00	 	 	Applikon Inc.
	 	 	 	 	 	Z61103CT04
	 	 	99-9-019	 	 	 	 	 
	 	8050	 	 	 	1400	 	 	Waters HPLC P2000

	 	12-Nov-98
	 	 	58,059.09	 	 	 	0.00	 	 	Waters
	 	MX7AM8182M
	 	DSC
	 	 	 	 	 	 	F213	 
	 	8070	 	 	 	220	 	 	Metrohm Titroprocessor w/Acces

	 	20-Jul-92
	 	 	17,305.35	 	 	 	0.00	 	 	Metrohm
	 	 	2N4/223	 	 	682 Titroprocessor
	 	 	N/A	 	 	 	E212	 
	 	8070	 	 	 	253	 	 	Optical Activity Model AA-5 An

	 	5-Aug-92
	 	 	13,929.76	 	 	 	0.00	 	 	Optical Activity
	 	 	15-19-10A	 	 	AA-5
	 	 	N/A	 	 	 	E213	 
	 	8070	 	 	 	338	 	 	Model 3MO Micro-Osmometer

	 	27-Sep-92
	 	 	4,933.00	 	 	 	0.00	 	 	Advanced Instruments
	 	 	42365F	 	 	3MO
	 	 	N/A	 	 	 	E213	 
	 	8070	 	 	 	754	 	 	Diode-Array Spectrophotometer

	 	14-Mar-94
	 	 	15,945.00	 	 	 	0.00	 	 	Hewlett Packard
	 	 	3338A04616	 	 	8452A	 	 	 	N/A	 	 	 	E205	 
	 	8070	 	 	 	1137	 	 	HP 1100 Automated binary LC3D

	 	10-Jul-97
	 	 	59,624.17	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	97-8-021	 	 	 	B213	 
	 	8070	 	 	 	1146	 	 	HP1100 automated binary LC3D s

	 	13-Aug-97
	 	 	59,148.95	 	 	 	0.00	 	 	Hewlett Packard
	 	See Notes
	 	See Notes
	 	 	97-8-021	 	 	 	E205	 
	 	8070	 	 	 	1164	 	 	plate reader Spectra MAX340

	 	29-Dec-97
	 	 	25,000.00	 	 	 	0.00	 	 	Molecular Devices
	 	 	M01232	 	 	340	 	 	 	N/A	 	 	 	E205	 
	 	8070	 	 	 	1239	 	 	HPLC system, installed with ac

	 	27-Apr-99
	 	 	73,678.20	 	 	 	0.00	 	 	Hewlett Packard
	 	 	 	 	 	Series 1100 see notes
	 	 	99-8-004/ 99-8-005	 	 	 	E205	 
	 	8070	 	 	 	1240	 	 	HPLC system, Hardware for 1239

	 	27-Apr-99
	 	 	11,693.55	 	 	 	0.00	 	 	Hewlett Packard
	 	 	 	 	 	Series 1100
	 	 	99-8-005	 	 	 	E205	 
	 	8070	 	 	 	1241	 	 	HPLC system, software for 1239

	 	27-Apr-99
	 	 	1,637.80	 	 	 	0.00	 	 	Hewlett Packard
	 	 	 	 	 	Series 1100
	 	 	99-8-005	 	 	 	E205	 
	 	8070	 	 	 	1243	 	 	HPLC system, installed with ac

	 	27-Apr-99
	 	 	4,686.35	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	99-8-003	 	 	 	 	 
	 	8070	 	 	 	1270	 	 	Flourescence detector HP 1100

	 	5-Mar-00
	 	 	14,441.00	 	 	 	0.00	 	 	Hewlett Packard
	 	DE92001584
	 	Series 1100
	 	 	00-8-012	 	 	 	E205	 
	 	8070	 	 	 	1297	 	 	Microplate Washer 96 well

	 	5-Oct-00
	 	 	9,895.00	 	 	 	0.00	 	 	Dynex Technologies
	 	1UWA1658
	 	Ultrawash Plus
	 	 	00-8-025	 	 	 	E207	 
	 	8070	 	 	 	1301	 	 	RCS High Flow Air Sampler

	 	3-Dec-00
	 	 	5,344.06	 	 	 	0.00	 	 	Biotest
	 	 	31222	 	 	Biotest
	 	 	00-8-033	 	 	 	F116	 
	 	8070	 	 	 	1317	 	 	Environmental chambers (2x20 c

	 	25-Jun-01
	 	 	46,297.06	 	 	 	0.00	 	 	Lab Line
	 	 	0601-0005	 	 	EC22560
	 	 	01-8-005	 	 	 	208	 
	 	8070	 	 	 	1322	 	 	Environmental chambers (2x20 c

	 	26-Aug-01
	 	 	2,555.77	 	 	 	0.00	 	 	Lab-Line
	 	 	0601-0001	 	 	EC22560
	 	 	01-8-005	 	 	 	208	 
	 	8070	 	 	 	1323	 	 	Environmental chambers (19 cub

	 	26-Aug-01
	 	 	18,533.38	 	 	 	0.00	 	 	Lab-Line
	 	 	0901-0001	 	 	EC24075
	 	 	  01-8-005	 	 	 	208	 
	 	8070	 	 	 	1360	 	 	Runtime21 Security Chem Server

	 	30-Sep-02
	 	 	66,607.35	 	 	 	0.00	 	 	Agilent
	 	US20741069
	 	H2118A	 	 	 	02-8-005	 	 	SERVER ROOM

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

40

Oncothyreon Canada Inc

Asset Listing by Department

As of September 30, 2008

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Dept	 	 	 	 	 	 	 	 	 	 	 	 	 	Net Book	 	 	 	Serial	 	Model	 	 	 	 
	Code	 	Number	 	Description	 	Purch Date	 	Purch Price	 	Value	 	Manufacturer	 	Number	 	Number	 	AFE #	 	Location
	 
	 	8070	 	 	 	1364	 	 	Accusizer 788/Aps (2 pcs)

	 	1-May-02
	 	 	68,920.80	 	 	 	0.00	 	 	Particle Sizing
	 	 	203702	 	 	780 APS
	 	02-11-USA
	 	 	B217	 
	 	8070	 	 	 	1368	 	 	Evaporative light scatter. det

	 	1-Dec-98
	 	 	20,692.36	 	 	 	0.00	 	 	Polymer Labs
	 	 	3652	 	 	PL-ELS-1000
	 	02-12-USA
	 	 	F219	 
	 	8070	 	 	 	1404	 	 	Microbalance, Prof. Level

	 	30-Jun-04
	 	 	16,991.18	 	 	 	0.00	 	 	VWR / Mettler
	 	 	1125171200	 	 	MX5
	 	 	04-8-022	 	 	 	8601/F116	 
	 	8070	 	 	 	1406	 	 	A/D Interface Box

	 	1-Aug-04
	 	 	4,184.00	 	 	 	0.00	 	 	Agilent
	 	CN00004762
	 	35900E	 	 	 	04-8-023	 	 	 	E205	 
	 	8070	 	 	 	1407	 	 	Chemstore License

	 	1-Aug-04
	 	 	14,965.00	 	 	 	0.00	 	 	 	 	Box #2310-03080
	 	 	 	 	 	 	04-8-023	 	 	Edmonton

	 	8070	 	 	 	1410	 	 	Coulter Particle Counter

	 	28-Jan-05
	 	 	23,898.60	 	 	 	1,991.44	 	 	Beckman Coulter
	 	AH48364
	 	Z1 Dual
	 	 	9/5/2027	 	 	 	B109	 
	 	8070	 	 	 	1413	 	 	Coulometer Titrator ModelDL39X

	 	17-Mar-05
	 	 	14,119.00	 	 	 	2,058.85	 	 	Mettler Toledo
	 	 	5127103667	 	 	DL39X
	 	 	8/5/1930	 	 	 	E212	 
	 	8070	 	 	 	1423	 	 	PL-ELS Evap. Light Scattering

	 	19-Oct-05
	 	 	19,000.56	 	 	 	5,148.48	 	 	Polymer Laboratories
	 	 	003-1259	 	 	PL-ELS 1000
	 	 	5/5/1940	 	 	 	E205	 
	 	8070	 	 	 	1426	 	 	Evapor. Light Detector

	 	2-Jun-06
	 	 	18,019.42	 	 	 	9,610.46	 	 	Agilent & Polymer
	 	 	003-1276	 	 	PL-ELS 1000
	 	 	8/6/1942	 	 	 	 	 
	 	8070	 	 	 	1428	 	 	Coulometric Titrator

	 	9-Jun-06
	 	 	15,460.00	 	 	 	8,385.19	 	 	Mettler Toledo
	 	 	5127215753	 	 	DL39X
	 	 	8/6/1943	 	 	 	 	 
	 	8070	 	 	 	1430	 	 	A/D interface box

	 	2-Jun-06
	 	 	4,186.00	 	 	 	2,235.41	 	 	Agilent Tecnologies
	 	CN00006137
	 	35900E	 	 	 	8/6/1942	 	 	 	 	 
	 	8070	 	 	 	1442	 	 	GC6890 Network GC System

	 	20-Feb-08
	 	 	40,094.75	 	 	 	33,412.27	 	 	Agilent Technologies
	 	CN10802005/US8559766H
	 	GC 6890N
	 	 	8/7/1963	 	 	 	 	 
	 	8070	 	 	 	1448	 	 	ImmunoSpot Analyzer&Software

	 	15-Apr-08
	 	 	8,995.00	 	 	 	7,870.60	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Edmonton, AB Canada

	 	8070	 	 	 	1447	 	 	8453UV- VisibleSpectrophotomtr

	 	30-Apr-08
	 	 	11,834.10	 	 	 	10,601.40	 	 	Agilent Technology
	 	CN22806871
	 	8453	 	 	 	8/8/2002	 	 	 	 	 
	 	8070	 	 	 	1451	 	 	H1141A/H1142A/H1143A/H1146A

	 	18-Jun-08
	 	 	2,565.90	 	 	 	2,352.06	 	 	Agilent Technologies
	 	 	 	 	 	 	 	 	 	 	8/8/2002	 	 	 	 	 
	 	8070	 	 	 	1456	 	 	NuAire Labgard Containment Cab

	 	3-Sep-08
	 	 	5,593.67	 	 	 	5,477.14	 	 	NuAire Inc
	 	 	 	 	 	NU-S813-400
	 	 	8/8/2006	 	 	 	 	 
	 	8080	 	 	 	1365	 	 	Fireproof File Cabinet

	 	1-Jun-02
	 	 	7,670.04	 	 	 	0.00	 	 	Fire King
	 	FL2002150011
	 	 	 	 	 	02-12-USA
	 	 	F102	 
	 	8080	 	 	 	1397	 	 	Fireproof File Cabinet

	 	1-Nov-00
	 	 	3,819.72	 	 	 	0.00	 	 	Fire King
	 	FL1999043022
	 	 	 	 	 	02-12-USA
	 	 	F102	 
	 	9020	 	 	 	165	 	 	Molecular Devices Thermomax Mi

	 	21-Jun-92
	 	 	18,000.00	 	 	 	0.00	 	 	Molecular Devices
	 	UVT-06515
	 	Thermomax
	 	 	 	 	 	 	B217	 
	 	9020	 	 	 	197	 	 	Refrigerated Tabletop Centrifu

	 	5-Jul-92
	 	 	5,920.00	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	B207	 
	 	9020	 	 	 	344	 	 	Refrigerated Tabletop Centrifu

	 	12-Oct-92
	 	 	9,690.63	 	 	 	0.00	 	 	Beckman
	 	ALR01J88
	 	Allegra G56R
	 	 	 	 	 	 	B207	 
	 	9020	 	 	 	484	 	 	Radioactive Fume Hood

	 	23-Feb-93
	 	 	14,115.00	 	 	 	0.00	 	 	HH Hawkins
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	B115	 
	 	9020	 	 	 	499	 	 	Nuaire Class II Type A/B3 4 ft

	 	8-Mar-93
	 	 	6,000.00	 	 	 	0.00	 	 	NU-AIRE
	 	26740AAN
	 	NU425-400
	 	 	 	 	 	 	B213	 
	 	9020	 	 	 	500	 	 	Nuaire Class II Type A/B3 4 ft

	 	8-Mar-93
	 	 	6,000.00	 	 	 	0.00	 	 	NU_AIRE
	 	26742AAN
	 	NU-425-400
	 	 	 	 	 	 	B213	 
	 	9020	 	 	 	506	 	 	Nuaire Class II Type A/B3 4 ft

	 	11-Mar-93
	 	 	6,000.00	 	 	 	0.00	 	 	NU-AIRE
	 	26737AAN
	 	NU-425-400
	 	 	 	 	 	 	B213	 
	 	9020	 	 	 	659	 	 	Deluxe Inverted Photozoom Micr

	 	21-Oct-93
	 	 	6,135.00	 	 	 	0.00	 	 	Bausch & Lomb
	 	AR4458
	 	Photozoom
	 	 	 	 	 	 	B207	 
	 	9020	 	 	 	720	 	 	FACSort Simultaneous Five Para

	 	7-Feb-94
	 	 	115,000.00	 	 	 	0.00	 	 	Becton Dickinson
	 	 	9-65680-00A	 	 	FACSort
	 	 	 	 	 	 	B207	 
	 	9020	 	 	 	755	 	 	Thermomax Microplate Reader, S

	 	14-Mar-94
	 	 	20,600.00	 	 	 	0.00	 	 	Molecular Devices
	 	UVT06587
	 	Thermomax
	 	 	 	 	 	 	 	 
	 	9020	 	 	 	767	 	 	Automated Kinetic ELISA Reader

	 	27-Mar-94
	 	 	19,200.00	 	 	 	0.00	 	 	Molecular Devices
	 	UVT06273
	 	Thermomax
	 	 	 	 	 	 	B217	 
	 	9020	 	 	 	885	 	 	Thermomax Microplate Reader

	 	12-Jul-94
	 	 	17,500.00	 	 	 	0.00	 	 	Molecular Devices
	 	UVT07181
	 	Thermomax
	 	 	 	 	 	 	B217	 
	 	9020	 	 	 	897	 	 	CONSORT OptiPac Optical Drive

	 	8-Aug-94
	 	 	8,190.00	 	 	 	0.00	 	 	Bering
	 	 	5600-113A074	 	 	01-09934-BD-REVN
	 	 	 	 	 	 	 	 
	 	9020	 	 	 	901	 	 	6” 7 Day Circular Recorder

	 	 24-Aug-94
	 	 	5,328.32	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	B213	 
	 	9020	 	 	 	1095	 	 	96 Well Harvester

	 	14-Jan-97
	 	 	12,065.54	 	 	 	0.00	 	 	Skatron
	 	 	88	 	 	11050	 	 	 	 	 	 	 	B114	 
	 	9020	 	 	 	1209	 	 	Microbeta Trilux 6 Detector

	 	27-Sep-98
	 	 	79,255.00	 	 	 	0.00	 	 	Wallac
	 	 	4501260	 	 	1450Microbeta
	 	 	 	 	 	 	B201	 
	 	9020	 	 	 	1212	 	 	FACstation

	 	28-Sep-98
	 	 	18,995.00	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	B207	 
	 	9020	 	 	 	1255	 	 	reallocation of Gammacell (gam

	 	22-Oct-99
	 	 	28,755.46	 	 	 	0.00	 	 	Atomic Energy of Can
	 	 	50	 	 	Gamma Cell 220
	 	 	99-92-016	 	 	 	C102A	 
	 	9020	 	 	 	1263	 	 	Incubator Shaker 4000 120v50

	 	7-Feb-00
	 	 	8,820.00	 	 	 	0.00	 	 	NewBrunswickScientif
	 	 	 	 	 	Innova 4000
	 	 	00-9-008	 	 	Offsite — Suresh

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

41

Oncothyreon Canada Inc

Asset Listing by Department

As of September 30, 2008

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Dept	 	 	 	 	 	 	 	 	 	 	 	 	 	Net Book	 	 	 	Serial	 	Model	 	 	 	 
	Code	 	Number	 	Description	 	Purch Date	 	Purch Price	 	Value	 	Manufacturer	 	Number	 	Number	 	AFE #	 	Location
	 
	 	9020	 	 	 	1285	 	 	Ultrawash ca70880-029

	 	6-Jun-00
	 	 	9,952.32	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	00-9-014	 	 	 	B217	 
	 	9020	 	 	 	1298	 	 	Cell harvester Mach III manual

	 	5-Nov-00
	 	 	19,260.00	 	 	 	0.00	 	 	Tomtec Harvester
	 	 	96-3M-428	 	 	Mach IIIm
	 	 	00-8-031	 	 	 	B201	 
	 	9020	 	 	 	1307	 	 	CO2 Incubator with gas guard

	 	14-Feb-01
	 	 	5,380.00	 	 	 	0.00	 	 	Forma Scientific
	 	 	90890-14580	 	 	WaterJacketed 3110
	 	 	01-9-001	 	 	 	B207	 
	 	9020	 	 	 	1315	 	 	Allegra Benchtop Centrifuge

	 	18-Jun-01
	 	 	15,078.48	 	 	 	0.00	 	 	Beckman
	 	ALR01F22
	 	Allegra6R
	 	 	01-9-009	 	 	 	B213	 
	 	9020	 	 	 	1330	 	 	Plate Washer — Automated

	 	30-Oct-01
	 	 	9,126.63	 	 	 	0.00	 	 	Dynex
	 	1UWA1707
	 	Ultrawash Plus
	 	 	 	 	 	 	B217	 
	 	9020	 	 	 	1359	 	 	-20c Freezer

	 	24-Sep-02
	 	 	9,190.53	 	 	 	0.00	 	 	Kendro Lab. Products
	 	V07M-593954-VM
	 	ULT1740-3X-A35
	 	 	02-9-011	 	 	 	B207	 
	 	9020	 	 	 	1362	 	 	Coulter Particle Counter

	 	1-Aug-01
	 	 	21,271.12	 	 	 	0.00	 	 	Beckman-Coulter Inc.
	 	AE-29047
	 	Z1D	 	 	 	02-9-013	 	 	 	B213	 
	 	9020	 	 	 	1416	 	 	PLA Version 1.2 Software

	 	  12-May-05
	 	 	16,065.48	 	 	 	0.00	 	 	PLA
	 	 	 	 	 	PLA 1.2
	 	 	8/5/1933	 	 	 	B217	 
	 	9020	 	 	 	1420	 	 	ImmunoSpot Series 3A Analyzer

	 	15-Aug-05
	 	 	57,539.37	 	 	 	22,031.93	 	 	ImmunoSpot
	 	 	S3A800148	 	 	Series 3A
	 	 	9/5/1936	 	 	 	B213	 
	 	9030	 	 	 	375	 	 	Peptide Synthesizer Purificati

	 	28-Oct-92 
	 	 	67,756.00	 	 	 	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	B201	 
	 	9030	 	 	 	1142	 	 	Fraction collector

	 	29-Jul-97
	 	 	6,325.00	 	 	 	0.00	 	 	 	 	 	212501	 	 	 	 	 	 	 	 	 	 	 	B216	 
	 	9030	 	 	 	1143	 	 	Fraction collector jr

	 	29-Jul-97
	 	 	6,390.00	 	 	 	0.00	 	 	 	 	 	205496	 	 	 	 	 	 	 	 	 	 	 	B202	 
	 	9030	 	 	 	1235	 	 	Gradifac fraction collector &

	 	13-Apr-99
	 	 	12,210.75	 	 	 	0.00	 	 	 	 	 	199L20023	 	 	 	 	 	 	 	99-9-012	 	 	 	B215	 
	 	9030	 	 	 	1244	 	 	Fraction collector

	 	30-Apr-99
	 	 	14,830.00	 	 	 	0.00	 	 	 	 	 	212587	 	 	 	 	 	 	 	99-9-011	 	 	 	B216	 
	 	9030	 	 	 	1259	 	 	Fraction Collector

	 	16-Dec-99
	 	 	12,650.00	 	 	 	0.00	 	 	 	 	 	201G20403	 	 	 	 	 	 	 	99-9-022	 	 	 	B215	 
	 	9030	 	 	 	1288	 	 	Series 1 isocratic Digital Pum

	 	10-Jul-00
	 	 	1,970.00	 	 	 	0.00	 	 	 	 	 	N/A	 	 	 	 	 	 	 	00-9-021	 	 	 	B216	 
	 	9030	 	 	 	1290	 	 	Heidolph LR4000 with hand lift

	 	10-Jul-00
	 	 	7,305.12	 	 	 	0.00	 	 	 	 	 	50002818	 	 	Laborata 4000
	 	 	00-9-021	 	 	 	B202	 
	 	9030	 	 	 	1320	 	 	Fraction Collector with rack

	 	9-Jul-01
	 	 	14,712.00	 	 	 	0.00	 	 	 	 	 	199L20022	 	 	 	 	 	 	 	01-9-015	 	 	 	B202	 
	 	9030	 	 	 	1329	 	 	Isotemp Gen Purp. Refrigerator

	 	18-Oct-01
	 	 	7,228.00	 	 	 	0.00	 	 	Fisher
	 	 	 	 	 	 	 	 	 	 	01-9-019	 	 	 	B216	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 

	 	 	 	 	4,970,533.31	 	 	 	594,995.85	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

42

Oncothyreon Canada Inc

Asset Listing by Department — Assets at Baxter

As of September 30, 2008

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Dept	 	 	 	 	 	 	 	 	 	 	 	 	 	Net Book	 	 	 	 	 	 	 	 	 	 
	Code	 	Number	 	Description	 	Purch Date	 	Purch Price	 	Value	 	Manufacturer	 	Serial Number	 	Model Number	 	AFE #	 	Location
	 
	8040

	 	 	1411	 	 	60L S/Steel Pressure Vessel
	 	1-May-05
	 	 	27,939.15	 	 	 	5,871.15	 	 	T & C
	 	TO6253
	 	60L
	 	8/5/2029
	 	Baxter
	8040

	 	 	1415	 	 	5L Applikon Bioreactor
	 	8-Jul-05
	 	 	15,786.70	 	 	 	2,959.99	 	 	Applikon Inc.
	 	P06175/32;P04600/14
	 	 	 	8/5/1931
	 	Baxter
	8040

	 	 	1419	 	 	Magnetic Stirrer/Motor Assembl
	 	8-Jul-05
	 	 	9,008.16	 	 	 	1,689.03	 	 	Applikon
	 	PO6175/25 P03384/1
	 	P140
	 	8/5/1931
	 	Baxter
	8040

	 	 	1421	 	 	50L INOVA Intermediate Tank
	 	24-Aug-05
	 	 	42,562.62	 	 	 	9,753.98	 	 	INOVA
	 	N/A
	 	50L
	 	8/5/1937
	 	Baxter
	8040

	 	 	1422	 	 	INOVA Filling Parts
	 	1-May-05
	 	 	40,317.45	 	 	 	8,497.70	 	 	INOVA
	 	 	 	 	 	8/5/2029
	 	Baxter
	8040

	 	 	1427	 	 	15L Applikon Jacketed Vessel
	 	26-May-06
	 	 	4,227.56	 	 	 	1,937.74	 	 	Applikon
	 	V3ME010051
	 	15L Jacketed Vessel
	 	8/6/1941
	 	Baxter
	8040

	 	 	1431
	 	 	Lightnin Mixer Model G2S05R

	 	9-Nov-06

	 	 	5,730.33
	 	 	 	2,984.59	 	 	
	 	R0653576101-02

	 	
	 	8/6/1947

	 	Baxter

	
8040

	 	 	
1433	 	 	
5L BioReactor
	 	
31-Jan-07
	 	 	
9,294.34	 	 	 	
5,421.74	 	 	Applikon
	 	
Z6110CT05/Z81315MG03/81313R645
	 	
	 	
8/6/1949
	 	
Manufacturing
	8040

	 	 	1443	 	 	60L Pressure Vessel
	 	11-Mar-08
	 	 	52,250.00	 	 	 	44,630.22	 	 	Baxter Pharm.
	 	 	 	 	 	8/6/1948	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	 	 	 	207,116.31	 	 	 	83,746.14	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

Schedule E

Transferred Employees

[+]

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

 

Schedule F

Assumed Liabilities

1. Lease Agreement, dated December 18, 2008, between Edmonton Economic Development Corporation and
Oncothyreon Canada Inc.

2. Lease Agreement, dated January 26, 2006, between Dell Financial Services Canada and Biomira
Inc.

3. Portion of equipment pursuant to Lease Agreement, dated, between September 20, 2007, between
Compugen Finance Inc. and Biomira Inc.

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

 

Schedule G

Allocation of Purchase Price

[+] [Redaction continues for two pages]

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

 

Schedule H

Key Employees

Rob Dupuit

Leanne Gadowski

Patrick O’Reilly

James Flower

Diane Swanland

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

 

Schedule I

Form of Non-Competition Agreement

NON-COMPETITION AND NON-SOLICITATION AGREEMENT

     THIS NON-COMPETITION AND NON-SOLICITATION AGREEMENT (“Agreement”) is made as of  •
December, 2008,

     BETWEEN

      •, of the City of Edmonton in the Province of Alberta (the “Employee”)

- and -

     EMD Serono Canada Inc., a corporation incorporated under laws of the Province of Alberta (“EMD
Serono”).

WHEREAS:

     A. The Employee was employed by Oncothyreon Inc. (“Oncothyreon”) and EMD SERONO and
Oncothyreon entered into an Asset Purchase Agreement dated 18 December 2008 (“Asset Purchase
Agreement”); and

     B. EMD Serono offered employment to the Employee upon closing of the transaction (“Closing”),
conditional upon signing this Agreement.

     In consideration of the offer of employment from EMD Serono plus other valuable consideration,
the parties agree as follows:

Non-Competition and Non-Solicitation 

     1. The Employee agrees that during his/her employment and for a period of twelve (12) months
following the cessation of employment, he/she will not, without the prior written consent of EMD
Serono:

          (i) either individually or in conjunction with any person as principal, agent, consultant,
advisor, employee or shareholder (other than a holding of shares listed on a Canadian or United
States stock exchange that does not exceed ten percent (10%) of the outstanding shares so listed)
directly or indirectly engage in, work in, or lend money to any business, professional or
commercial activity competitive with the Business of EMD Serono within North America (“Territory”).
For clarity the “Business” of EMD Serono for the purposes of this Agreement shall include any
business in North America which provides any or all of the following products or services:

cancer vaccines.

          (ii) hire away or induce, coerce, counsel or entice any employee or consultant of EMD Serono
in the Territory to leave his/her employment or engagement with EMD Serono.

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

 

49

     2. Employee acknowledges and agrees that in accepting employment with EMD Serono, he/she is in
a fiduciary position and that all of the restrictions in this Agreement are reasonable, valid and
do not go beyond what is necessary to protect the business interests of EMD Serono and he agrees to
waive any defences to the strict enforcement of these restrictions. These restrictions are only
intended to safeguard against the Employee participating in competitive endeavours against EMD
Serono or hiring away staff of EMD Serono and not to restrict the Employee from being engaged in
other employment and businesses that are not in competition with EMD Serono in the Territory.

     3. Employee agrees that a breach of the terms of this Agreement would result in damages to EMO
Serono which could not adequately be compensated for by a monetary award and accordingly, in the
event of a breach, in addition to all other remedies available to EMD Serono at law or in equity,
EMD Serono will be entitled as a matter of right to apply to a Court for a restraining order,
injunction, decree or any other order as may be appropriate to ensure compliance with this
Agreement.

     4. If there are any provisions of this Agreement which are found not to be enforceable by a
Court, those provisions are to be severed and the remaining provisions shall remain in full force
and effect.

     5. This Agreement will be governed by the laws of the Province of Alberta and the parties
hereto irrevocably attorn to the jurisdiction of the Alberta Courts.

IN WITNESS WHEREOF the parties have executed this Agreement.

	 	 	 	 	 	 	 
	 

	 	 	 	EMD SERONO INC.	 	 
	 
	 	 	 	 	 	 
	 

	 	 	 	Per:	 	 
	 
	 	 	 	 	 	 
	 

	 	 	 	 	 	 
	 

	 	 	 	Deborah Brown	 	 
	 

	 	 	 	Managing Director, Canada	 	 
	 
	 	 	 	 	 	 
	SIGNED AND WITNESSED
	 	 	 	 	 	 
	in the presence of:
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 

Witness

	 	 
	 	 

 •
	 	 

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

 

Schedule J

Form of Employment Agreement — Key Employees

December  •, 2008

PERSONAL AND CONFIDENTIAL

[Name of Employee]

c/o Oncothyreon
2011 -94 Street, Suite 200
Edmonton, Alberta
T6N 1H1

			
	Re:	 	Employment Agreement

Dear  •:

We are very pleased to offer you the position of [insert position], effective January 1, 2009.
This letter will confirm our discussion and your offer of employment with EMD Serono Canada Inc.
(“EMD Serono”), which is conditional on the closing of a sale agreement between EMD Serono and your
current employer, Oncothyreon.

The terms and condition of your employment are as follows:

	 	 	 
	Scope of Work:

	 	As a [insert position], you will perform such duties
and exercise such powers related to this position as
EMD Serono may assign to you from time to time. You
may be employed by EMD Serono in a position other
than a [insert position], upon EMD Serono notifying
you in writing of such assignment in which event you
will, subject to the terms and conditions in this
Agreement continue to be employed by EMD Serono in
the position to which you have been promoted or
transferred to. In the event of any further change
in your position, the provisions of this Agreement
will apply, with the necessary changes being made.
A written job description will be provided to you.
	 
	 	 
	Place of Employment:

	 	You will perform your work and services for EMD
Serono, or for such other person, as may be
authorized by EMD Serono from time to time, in the
Edmonton Office. You will reside within a
reasonable daily commuting distance of such place of
employment provided that you will also perform your
work and services in such other places as EMD Serono
may require from time to time.
	 
	 	 
	Salary:

	 	Your annual salary will be $ • per annum based on a
37.5 hour work week. This payment will be deposited
directly into your account at the bank of your
choice, payable on a bi-weekly basis in arrears.
Your salary will be reviewed in April 2010.

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

 

52

	 	 	 
	Stimuvax Advancement 

Bonus:

	 	For the development of Stimuvax and as a financial
investment in you, EMD Serono will offer you a
special bonus based on the following three (3)
deliverables which are further specified in the
attached Schedule “A”:
	 
	 	 
	 

	 	1.  Delivery of all batches for continuous Clinical
Trial Supply throughout 2009 and comparability
submission for Semoy vs Baxter material. For the
achievement of this milestone you will receive a
lump sum payment equivalent to  • months of your then
current salary, less applicable taxes in January
2010.

	 
	 	 
	 

	 	2.  Comparability submission commercial scale vs
clinical scale. For the achievement of this 2010
milestone you will receive a lump sum payment
equivalent to  • months of your then current salary,
less applicable taxes in January 2011.

	 
	 	 
	 

	 	3.  Validation package commercial scale completed.
For the achievement of this 2011 milestone you will
receive a lump sum payment equivalent to  • months of
your then current salary less applicable taxes in
January 2012.

	 
	 	 
	 

	 	Should you resign or be terminated for any reason
during 2009 — 2011, you will not be eligible for any
bonus not already paid.
	 
	 	 
	Performance Bonus:

	 	Your target bonus is  •% of your base salary, however
the actual amount of bonus awarded will be based on
achievement of your own individual performance
objectives, as outlined in your Personal and
Professional Development Plan, and the group
objectives for EMD Serono Canada.
	 
	 	 
	 

	 	Should you resign or should your employment be
terminated for any reason during the plan year
(January to December) you will not be eligible for a
bonus payout.
	 
	 	 
	Vacation:

	 	Vacation time is accrued on a monthly basis
according to seniority. We will recognize your
prior service with Oncothyreon for vacation
purposes. You are eligible for  • weeks of vacation
time — accrued at  • days per month for each calendar
year of service. In addition to vacation you will
receive one (1) floater day.
	 
	 	 
	 

	 	Currently, the offices are closed during the last
week of December. Please refer to the Holiday
Schedule. This time is not considered part of your
vacation entitlement.
	 
	 	 
	 

	 	In the event your employment with EMD Serono is
terminated for any reason, EMD Serono will deduct
from your final pay cheque an amount equal to the
vacation pay you received for vacation time taken in
advance of its accrual.
	 
	 	 
	Benefits:

	 	You will be entitled to participate in EMD Serono’s
benefit program. A schedule of our benefits is
attached for your review.

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

 

53

	 	 	 
	Expenses:

	 	You will be reimbursed for all authorized travelling
and other out-of-pocket expenses actually and
properly incurred by you in connection with your
duties under this Agreement in accordance with EMD
Serono expense policy in effect from time to time.
For all such expenses, you will furnish to EMD
Serono statements and vouchers, as and when EMD
Serono requires.
	 
	 	 
	Duties and
Responsibilities:

	 	You will duly and diligently perform all the duties
assigned to you while in the employ of EMD Serono
and will truly and faithfully account for and
deliver to EMD Serono all money; securities and
things of value belonging to EMD Serono that you may
from time to time receive for, from or on account of
EMD Serono.
	 
	 	 
	Rules and
Regulations:

	 	You will be bound by and will faithfully observe and
abide by all the policies, rules and regulations of
EMD Serono from time to time in force which are
brought to your notice or of which you should
reasonably be aware.
	 
	 	 
	Patentable Invention

	 	In the event that you contribute to any patentable
invention arising while employed by EMD Serono, any
such patentable invention will be the exclusive
property of EMD Serono and EMD Serono will have the
exclusive right to file patent applications in the
name of EMD Serono in connection with such
patentable invention and you will co-operate with
EMD Serono and provide all necessary assistance in
the filing and prosecution of such patent
applications.
	 
	 	 
	Non-Disclosure:

	 	You will not (either during your employment or at
any time after the termination of your employment
for any reason) disclose any information relating to
the private or confidential affairs of EMD Serono or
relating to any secrets of EMD Serono to any person
other than for EMD Serono’s purposes and, without
limiting the generality of the foregoing, you will
not (either during your employment or at any time
after the termination of your employment for any
reason) disclose EMD Serono’s Proprietary
Information to any person other than for EMD
Serono’s purposes and will not (either during your
employment or at any time after the termination of
your employment for any reason) use for your own
purposes or for any purposes other than those of EMD
Serono any such information or secrets you may
acquire in relation to the business of EMD Serono’s
Proprietary Information.

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

 

54

	 	 	 
	Resignation:

	 	You may terminate your employment upon giving two
(2) weeks’ written notice to EMD Serono. You agree
that EMD Serono may waive the notice period by
paying to you an amount equivalent to a salary you
would have received during the notice period. You
also agree that such waiver by EMD Serono does not
constitute a termination of your employment by EMD
Serono.
	 
	 	 
	Termination of
Employment:

	 	EMD Serono may terminate your employment at any time
for cause without notice and without pay in lieu of
notice, severance, damages, bonus or other
compensation of any kind.
	 
	 	 
	 

	 	In the event EMD Serono terminates your employment
without cause, you will receive a lump sum payment
equivalent to:
	 
	 	 
	 

	 	a.  One year’s base salary, less statutory deductions,

	 
	 	 
	 

	 	b.  Performance Bonus pay at target for the period of
January 1 to your termination date, less statutory
deductions,

	 
	 	 
	 

	 	c.  Additional Performance Bonus pay at target for
one year following termination, less statutory
deductions.

	 
	 	 
	 

	 	This lump sum payment will include all payments due
to you upon termination of employment, including any
entitlements to pay in lieu of notice pursuant to
the Employment Standards Code (Alberta) and any
severance pay to which you may be entitled.
	 
	 	 
	 

	 	Please note that benefit coverage terminates
effective the date of termination of employment,
regardless of the manner of or reason for
termination, unless otherwise required by the
Employment Standards Code (Alberta), as amended.
	 
	 	 
	Release:

	 	In consideration of Oncothyreon Inc. and /or certain
of its affiliates negotiating the asset purchase
agreement with EMD Serono, and EMD Serono extending
the within offer of employment to you, you agree to
release Oncothyreon Inc. and its parents,
subsidiaries, affiliates, partners and related
companies (including their directors, officers,
employees and agents) (collectively “Oncothyreon”)
from all obligations and claims that you have or may
have (including but not limited to claims for notice
of termination, pay and benefits in lieu of notice,
termination pay, severance pay, bonus pay, retention
pay, overtime pay, vacation pay, wages and benefits)
relating to your employment with Oncothyreon, the
termination of that employment, and the
discontinuance of all benefit coverage. Without
limiting the generality of the foregoing, you
acknowledge that this release applies to all claims
you have or may have against Oncothyreon including
any claims under the Employment Standards Code
(Alberta) and the Human Rights, Citizenship and
Multiculturalism Act (Alberta).

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

 

55

	 	 	 
	Deduction from Final
Pay:

	 	EMD Serono reserves the right at the time of
separation to deduct any outstanding amounts owed by
you to EMD Serono from your final wages or bonus
amounts owing to you.
	 
	 	 
	Entire Agreement:

	 	This Agreement, the milestone concept attached as
Schedule “A”, the attached Non-Competition and
Non-Solicitation Agreement, marked as Schedule “B”,
and the policies of EMD Serono constitute the entire
agreement between you and EMD Serono with respect to
your employment and cancels and supersedes any prior
understandings and agreements between you and EMD
Serono with respect to your employment. There are
no representations, warranties, forms, conditions,
undertakings or collateral agreements, express,
implied or statutory between you and EMD Serono
other than as expressly set forth in this Agreement.
	 
	 	 
	Pre-Contractual 

Representation:

	 	You hereby waive any right to assert a claim based
on any pre-contractual representations, negligent or
otherwise, made by EMD Serono.
	 
	 	 
	Governing Law:

	 	This Agreement will be governed by and construed in
accordance with the laws of the Province of Alberta
and the laws of Canada applicable in Alberta.

Please carefully read and consider the terms and conditions described in this letter and confirm
your understanding by signing in the space provided below and return a signed copy to the attention
of Megan lannone — Human Resources or via confidential fax to 905-919-0291 no later than December
17, 2008. When you sign this letter, it will be a binding employment agreement between you and EMD
Serono.

[Insert name], we trust that this letter suitably represents our discussion and that you will
accept our offer. We look forward to you joining the EMD Serono team and wish you every success in
your new role.

Yours very truly,

EMD SERONO, CANADA INC

	 	 	 	 	 	 	 
	 
	 

	 	 	 	 	 	 
	Deborah Brown

	 	 	 	Debbie Lowe	 	 
	Managing Director, Canada

	 	 
	 	Director, Human Resources
	 	 

Enclosure

I have read, understand and voluntarily accept the terms of employment described above as
constituting a binding employment agreement between EMD Serono and myself.

	 	 	 	 	 
	 
	 

	 	 
	 	 
	[Employee Name]

	 	Date
	 	Social Insurance Number

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

 

56

Schedule “A” — Milestone Definition

[+] [Redaction continues for two pages]

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

 

57

Schedule “B” — Non-Competition and Non-Solicitation Agreement

NON-COMPETITION AND NON-SOLICITATION AGREEMENT

THIS NON-COMPETITION AND NON-SOLICITATION AGREEMENT (“Agreement”) is made as of 18 December, 2008,

BETWEEN

•, of the City of Edmonton in the Province of Alberta (the “Employee”)

- and -

EMD Serono Canada Inc., a corporation incorporated under laws of the Province of Alberta (“EMD
Serono”).

WHEREAS:

	A.	 	The Employee was employed by Oncothyreon Inc. (“Oncothyreon”) and EMD SERONO and Oncothyreon
entered into an Asset Purchase Agreement dated 18 December 2008 (“Asset Purchase Agreement”);
and
	 
	B.	 	EMD Serono offered employment to the Employee upon closing of the transaction (“Closing”),
conditional upon signing this Agreement.

In consideration of the offer of employment from EMD Serono plus other valuable consideration, the
parties agree as follows:

Non-Competition and Non-Solicitation

	1.	 	The Employee agrees that during his/her employment and for a period of twelve (12) months
following the cessation of employment, he/she will not, without the prior written consent of
EMD Serono:

	 	(i)	 	either individually or in conjunction with any person as principal, agent,
consultant, advisor, employee or shareholder (other than a holding of shares listed on
a Canadian or United States stock exchange that does not exceed ten percent (10%) of
the outstanding shares so listed) directly or indirectly engage in, work in, or lend
money to any business, professional or commercial activity competitive with the
Business of EMD Serono within North America (“Territory”). For clarity the “Business”
of EMD Serono for the purposes of this Agreement shall include any business in North
America which provides any or all of the following products or services:
	 
	 	 	 	cancer vaccines.

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

58

	 	(ii)	 	hire away or induce, coerce, counsel or entice any employee or consultant of
EMD Serono in the Territory to leave his/her employment or engagement with EMD Serono.

	2.	 	Employee acknowledges and agrees that in accepting employment with EMD Serono, he/she is in a
fiduciary position and that all of the restrictions in this Agreement are reasonable, valid
and do not go beyond what is necessary to protect the business interests of EMD Serono and he
agrees to waive any defences to the strict enforcement of these restrictions. These
restrictions are only intended to safeguard against the Employee participating in competitive
endeavours against EMD Serono or hiring away staff of EMD Serono and not to restrict the
Employee from being engaged in other employment and businesses that are not in competition
with EMD Serono in the Territory.
	 
	3.	 	Employee agrees that a breach of the terms of this Agreement would result in damages to EMD
Serono which could not adequately be compensated for by a monetary award and accordingly, in
the event of a breach, in addition to all other remedies available to EMD Serono at law or in
equity, EMD Serono will be entitled as a matter of right to apply to a Court for a restraining
order, injunction, decree or any other order as may be appropriate to ensure compliance with
this Agreement.
	 
	4.	 	If there are any provisions of this Agreement which are found not to be enforceable by a
Court, those provisions are to be severed and the remaining provisions shall remain in full
force and effect.
	 
	5.	 	This Agreement will be governed by the laws of the Province of Alberta and the parties hereto
irrevocably attorn to the jurisdiction of the Alberta Courts.

IN WITNESS WHEREOF the parties have executed this Agreement.

	 	 	 	 	 
	 	EMD SERONO INC.

Per:

 	 
	 	
 	 
	 	Deborah Brown 	 
	 	Managing Director, Canada 	 
	 

	 	 	 	 	 	 	 
	SIGNED AND WITNESSED

in the presence of:
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 
	 

Witness

	 	 
	 	 

•
	 	 

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

59

EMD Serono Canada & Your Offered Benefit

The Company recognizes that benefits are an integral part of the overall compensation package. On
an ongoing basis, the Human Resources Department reviews and monitors benefit programs to ensure
that the Company is offering a competitive and comprehensive benefits package to Employees.

Your Health & Welfare Benefits

Health Insurance

Vision Benefits

Dental Benefits

Short-Term Disability

Long-Term Disability (mandatory paid by employee)

Life Insurance, Accidental Death & Dismemberment Insurance

Your Retirement Benefits

Pension Plan

Employees are entitled to contribute a minimum of 1% to a maximum of 7% of their base salary to the
pension plan. The Company will match the Employee’s contribution up to a maximum of 7% of their
base salary. Both contributions are then invested through the pension plan carrier, where the
Employee chooses the type of funds. The pension plan carrier offers over thirty (30) funds from
100% equity to 100% fixed rate.

Additional Benefits

Wellness Reimbursement

All Employees working twenty (20) or more hours per week are eligible for Company-subsidized
memberships at health and/or wellness related programs and the purchase of home gym equipment.
Memberships can include immediate family members (spouse/domestic partner and children). The
Employee must be the principal member of a Family membership. The Company will reimburse on a
monthly basis 50% of the cost of health club memberships and/or any wellness related programs up to
$600 per year for Full-Time Employees.

Reimbursements are treated as taxable compensation and will be reflected on T4s at year-end. An
Employee taking part in this program will be required to reimburse the Company if they terminate
employment within one (1) year after receiving reimbursement.

Personal Computer Reimbursement

All Regular, Full-Time Employees who have completed one (1) full year of employment with

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

60

the Company are eligible to receive reimbursement for the purchase of a personal computer for home
use. The Company will reimburse the cost of a personal computer (hardware CPU, monitor, CD-ROM
drive, printer, modem, sound card, etc.) up to a maximum of $1,750. This reimbursement is
renewable every three years.

Reimbursements are treated as taxable compensation and will be reflected on T4s at year-end. An
Employee taking part in this program will be required to reimburse the Company if they terminate
employment within one (1) year after receiving reimbursement.

This program is not retroactive. Employees who have received reimbursement through the previous
policy ($1,500 per lifetime) will become eligible for the current program three years from the
initial reimbursement.

Employee Assistance Program — LifeBalance

EMD Serono offers private counseling through RBC Insurance (UnumProvident) which offers assistance
to Employees and family members who may be experiencing personal problems, that, in time, may
affect their personal and professional lives. The EAP services include assessment, short-term
counseling, referral and follow-up. In addition, LifeBalance offers a comprehensive resource and
referral program locating providers who offer childcare services, elder care services, financial
and legal services, as well as a host of other home and health providers. The EAP is strictly
confidential.

Flex Work Arrangements

The Company considers flexible work hours a viable alternative work arrangement in cases where
individual, job, and managerial characteristics are best suited to such an arrangement. Flexible
work hours provide flexibility from standard work hours and may be appropriate for some Employees
and some jobs, but not appropriate for others given the nature of the work that is performed. A
flexible work hours arrangement is not an entitlement, nor a Company-wide benefit, and in no way
changes an Employee’s terms and conditions with the Company.

Employee Referral Bonus Program

The Company recognizes that one of the most effective ways to find the right people for our Company
is through the people who know it best — our Employees.

The Company encourages Employee assistance in the recruitment of high quality, new Employees
through Employee referrals and rewards Employees for making such referrals, as we value our people
and we value your contribution to our business. That is why we have introduced the Employee
Referral Bonus Program, which is designed to reward you whenever you successfully refer a candidate
for a position at the Company.

All Regular Full-Time and Part-Time Employees of the Company who are paid via the Company’s
Canadian payroll may participate in this program with the exception of Employees within the Human
Resources Department, and the respective Hiring Manager of a position and any of their direct
reports.

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

61

December •, 2008

PERSONAL AND CONFIDENTIAL

[Name of Employee]

c/o Oncothyreon

2011 -94 Street, Suite 200

Edmonton, Alberta

T6N 1H1

Re: Employment Agreement

Dear •:

Following the acquisition of the Oncothyreon Inc. Edomonton site, we are pleased to offer you the
position of [insert position], effective January 1, 2009. This letter will confirm our discussion
and your offer of employment with EMD Serono Canada Inc. (“EMD Serono”), which is conditional on
the closing of a sale agreement between EMD Serono and your current employer, Oncothyreon.

The terms and condition of your employment are as follows:

	 	 	 
	Scope of Work:

	 	As a [insert position], you will
perform such duties and exercise
such powers related to this position
as EMD Serono may assign to you from
time to time. You may be employed
by EMD Serono in a position other
than a [insert position], upon EMD
Serono notifying you in writing of
such assignment in which event you
will, subject to the terms and
conditions in this Agreement
continue to be employed by EMD
Serono in the position to which you
have been promoted or transferred
to. In the event of any further
change in your position, the
provisions of this Agreement will
apply, with the necessary changes
being made. A written job
description will be provided to you.
	 
	 	 
	Place of Employment:

	 	You will perform your work and
services for EMD Serono, or for such
other person, as may be authorized
by EMD Serono from time to time, in
the Edmonton Office. You will
reside within a reasonable daily
commuting distance of such place of
employment provided that you will
also perform your work and services
in such other places as EMD Serono
may require from time to time.
	 
	 	 
	Salary:

	 	Your annual salary will be $• per
annum based on a 37.5 hour work
week. This payment will be
deposited directly into your account
at the bank of your choice, payable
on a bi-weekly basis in arrears.
Your salary will be reviewed in
April 2010.

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

62

	 	 	 
	Stimuvax Advancement Bonus:

	 	For the development of Stimuvax and
as a financial investment in you,
EMD Serono will offer you a special
bonus based on the following three
(3) deliverables which are further
specified in the attached Schedule
“A”:
	 
	 	 
	 

	 	1.  Delivery of all batches for
continuous Clinical Trial Supply
throughout 2009 and comparability
submission for Semoy vs Baxter
material. For the achievement of
this milestone you will receive a
lump sum payment equivalent to •
months of your then current salary,
less applicable taxes in January
2010.

	 
	 	 
	 

	 	2.  Comparability submission
commercial scale vs clinical scale.
For the achievement of this 2010
milestone you will receive a lump
sum payment equivalent to • months
of your then current salary, less
applicable taxes in January 2011.

	 
	 	 
	 

	 	3.  Validation package commercial
scale completed. For the
achievement of this 2011 milestone
you will receive a lump sum payment
equivalent to • months of your then
current salary less applicable taxes
in January 2012.

	 
	 	 
	 

	 	Should you resign or be terminated
for any reason during 2009 — 2011,
you will not be eligible for any
bonus not already paid.
	 
	 	 
	Performance Bonus:

	 	Your target bonus is •% of your base
salary, however the actual amount of
bonus awarded will be based on
achievement of your own individual
performance objectives, as outlined
in your Personal and Professional
Development Plan, and the group
objectives for EMD Serono Canada. 

Should you resign or should your
employment be terminated for any
reason during the plan year (January
to December) you will not be
eligible for a bonus payout.
	 
	 	 
	Vacation:

	 	Vacation time is accrued on a
monthly basis according to
seniority. We will recognize your
prior service with Oncothyreon for
vacation purposes. You are eligible
for • weeks of vacation time -
accrued at • days per month for each
calendar year of service. In
addition to vacation you will
receive one (1) floater day.
	 
	 	 
	 

	 	Currently, the offices are closed
during the last week of December.
Please refer to the Holiday
Schedule. This time is not
considered part of your vacation
entitlement.
	 
	 	 
	 

	 	In the event your employment with
EMD Serono is terminated for any
reason, EMD Serono will deduct from
your final pay cheque an amount
equal to the vacation pay you
received for vacation time taken in
advance of its accrual.

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

63

	 	 	 
	Benefits:

	 	You will be entitled to participate
in EMD Serono’s benefit program. A
schedule of our benefits is attached
for your review.
	 
	 	 
	Expenses:

	 	You will be reimbursed for all
authorized travelling and other
out-of-pocket expenses actually and
properly incurred by you in
connection with your duties under
this Agreement in accordance with
EMD Serono expense policy in effect
from time to time. For all such
expenses, you will furnish to EMD
Serono statements and vouchers, as
and when EMD Serono requires.
	 
	 	 
	Duties and Responsibilities:

	 	You will duly and diligently perform
all the duties assigned to you while
in the employ of EMD Serono and will
truly and faithfully account for and
deliver to EMD Serono all money;
securities and things of value
belonging to EMD Serono that you may
from time to time receive for, from
or on account of EMD Serono.
	 
	 	 
	Rules and Regulations:

	 	You will be bound by and will
faithfully observe and abide by all
the policies, rules and regulations
of EMD Serono from time to time in
force which are brought to your
notice or of which you should
reasonably be aware.
	 
	 	 
	Patentable Invention

	 	In the event that you contribute to
any patentable invention arising
while employed by EMD Serono, any
such patentable invention will be
the exclusive property of EMD Serono
and EMD Serono will have the
exclusive right to file patent
applications in the name of EMD
Serono in connection with such
patentable invention and you will
co-operate with EMD Serono and
provide all necessary assistance in
the filing and prosecution of such
patent applications.
	 
	 	 
	Non-Disclosure:

	 	You will not (either during your
employment or at any time after the
termination of your employment for
any reason) disclose any information
relating to the private or
confidential affairs of EMD Serono
or relating to any secrets of EMD
Serono to any person other than for
EMD Serono’s purposes and, without
limiting the generality of the
foregoing, you will not (either
during your employment or at any
time after the termination of your
employment for any reason) disclose
EMD Serono’s Proprietary Information
to any person other than for EMD
Serono’s purposes and will not
(either during your employment or at
any time after the termination of
your employment for any reason) use
for your own purposes or for any
purposes other than those of EMD
Serono any such information or
secrets you may acquire in relation
to the business of EMD Serono’s
Proprietary Information.

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

64

	 	 	 
	Resignation:

	 	You may terminate your employment
upon giving two (2) weeks’ written
notice to EMD Serono. You agree
that EMD Serono may waive the notice
period by paying to you an amount
equivalent to a salary you would
have received during the notice
period. You also agree that such
waiver by EMD Serono does not
constitute a termination of your
employment by EMD Serono.
	 
	 	 
	Termination of Employment:

	 	EMD Serono may terminate your
employment at any time for cause
without notice and without pay in
lieu of notice, severance, damages,
bonus or other compensation of any
kind.
	 
	 	 
	 

	 	In the event EMD Serono terminates
your employment, you will receive a
lump sum payment equivalent to two
(2) weeks base salary, per year of
service, including your past service
at Oncothyreon Inc. This lump sum
payment will include all payments
due to you upon termination of
employment, including any
entitlements to pay in lieu of
notice pursuant to the Employment
Standards Code (Alberta) and any
severance pay to which you may be
entitled.
	 
	 	 
	Deduction from Final Pay:

	 	EMD Serono reserves the right at the
time of separation to deduct any
outstanding amounts owed by you to
EMD Serono from your final wages or
bonus amounts owing to you.
	 
	 	 
	Entire Agreement:

	 	This Agreement, the milestone
concept attached as Schedule “A”,
the attached Non-Competition and
Non-Solicitation Agreement, marked
as Schedule “B”, and the policies of
EMD Serono constitute the entire
agreement between you and EMD Serono
with respect to your employment and
cancels and supersedes any prior
understandings and agreements
between you and EMD Serono with
respect to your employment. There
are no representations, warranties,
forms, conditions, undertakings or
collateral agreements, express,
implied or statutory between you and
EMD Serono other than as expressly
set forth in this Agreement.
	 
	 	 
	Pre-Contractual Representation:

	 	You hereby waive any right to assert
a claim based on any pre-contractual
representations, negligent or
otherwise, made by EMD Serono.
	 
	 	 
	Governing Law:

	 	This Agreement will be governed by
and construed in accordance with the
laws of the Province of Alberta and
the laws of Canada applicable in
Alberta.

Please carefully read and consider the terms and conditions described in this letter and confirm
your understanding by signing in the space provided below and return a signed copy to the attention
of Megan lannone — Human Resources or via confidential fax to 905-919-0291 no later than December
17, 2008. When you sign this letter, it will be a binding employment agreement between you and EMD
Serono.

[Insert name], we trust that this letter suitably represents our discussion and that you will
accept

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

65

our offer. We look forward to you joining the EMD Serono team and wish you every success in your
new role.

	 	 	 	 	 	 	 
	Yours very truly,
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	EMD SERONO, CANADA INC
	 	 	 	 	 	 
	 
	 
	 	 	 	 	 	 
	 

Deborah Brown

	 	 
	 	 

Debbie Lowe
	 	 
	Managing Director, Canada

	 	 	 	Director, Human Resources	 	 

Enclosure

I have read, understand and voluntarily accept the terms of employment described above as
constituting a binding employment agreement between EMD Serono and myself.

	 	 	 	 	 	 	 
	 

[Employee Name]

	 	 

Date
	 	 

Social Insurance Number
	 	 

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

66

Schedule “A” — Milestone Definition

[+] [Redaction continues for two pages]

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

 

67

Schedule “B” — Non-Competition and Non-Solicitation Agreement

NON-COMPETITION AND NON-SOLICITATION AGREEMENT

THIS NON-COMPETITION AND NON-SOLICITATION AGREEMENT (“Agreement”) is made as of 18 December, 2008,

BETWEEN

          •, of the City of Edmonton in the Province of Alberta (the “Employee”)

- and -

EMD Serono Canada Inc., a corporation incorporated under laws of the Province of Alberta (“EMD
Serono”).

WHEREAS:

	A.	 	The Employee was employed by Oncothyreon Inc. (“Oncothyreon”) and EMD SERONO and Oncothyreon
entered into an Asset Purchase Agreement dated 18 December 2008 (“Asset Purchase Agreement”);
and
	 
	B.	 	EMD Serono offered employment to the Employee upon closing of the transaction (“Closing”),
conditional upon signing this Agreement.

In consideration of the offer of employment from EMD Serono plus other valuable consideration, the
parties agree as follows:

Non-Competition and Non-Solicitation

	1.	 	The Employee agrees that during his/her employment and for a period of twelve (12) months
following the cessation of employment, he/she will not, without the prior written consent of
EMD Serono:

	 	(i)	 	either individually or in conjunction with any person as principal, agent,
consultant, advisor, employee or shareholder (other than a holding of shares listed on
a Canadian or United States stock exchange that does not exceed ten percent (10%) of
the outstanding shares so listed) directly or indirectly engage in, work in, or lend
money to any business, professional or commercial activity competitive with the
Business of EMD Serono within North America (“Territory”). For clarity the “Business”
of EMD Serono for the purposes of this Agreement shall include any business in North
America which provides any or all of the following products or services:
	 
	 	 	 	cancer vaccines.
	 
	 	(ii)	 	hire away or induce, coerce, counsel or entice any employee or consultant of

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

68

	 	 	 	EMD Serono in the Territory to leave his/her employment or engagement with EMD
Serono.

	2.	 	Employee acknowledges and agrees that in accepting employment with EMD Serono, he/she is in a
fiduciary position and that all of the restrictions in this Agreement are reasonable, valid
and do not go beyond what is necessary to protect the business interests of EMD Serono and he
agrees to waive any defences to the strict enforcement of these restrictions. These
restrictions are only intended to safeguard against the Employee participating in competitive
endeavours against EMD Serono or hiring away staff of EMD Serono and not to restrict the
Employee from being engaged in other employment and businesses that are not in competition
with EMD Serono in the Territory.
	 
	3.	 	Employee agrees that a breach of the terms of this Agreement would result in damages to EMD
Serono which could not adequately be compensated for by a monetary award and accordingly, in
the event of a breach, in addition to all other remedies available to EMD Serono at law or in
equity, EMD Serono will be entitled as a matter of right to apply to a Court for a restraining
order, injunction, decree or any other order as may be appropriate to ensure compliance with
this Agreement.
	 
	4.	 	If there are any provisions of this Agreement which are found not to be enforceable by a
Court, those provisions are to be severed and the remaining provisions shall remain in full
force and effect.
	 
	5.	 	This Agreement will be governed by the laws of the Province of Alberta and the parties hereto
irrevocably attorn to the jurisdiction of the Alberta Courts.

IN WITNESS WHEREOF the parties have executed this Agreement.

	 	 	 	 	 
	 	EMD SERONO INC.

Per:

 	 
	 	
 	 
	 	Deborah Brown 	 
	 	Managing Director, Canada 	 
	 

SIGNED AND WITNESSED

in the presence of:

	 	 	 	 	 	 	 
	 
	 

	 	 	 	 	 	 
	Witness

	 	 
	 	•
	 	 

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

69

EMD Serono Canada & Your Offered Benefit

The Company recognizes that benefits are an integral part of the overall compensation package. On
an ongoing basis, the Human Resources Department reviews and monitors benefit programs to ensure
that the Company is offering a competitive and comprehensive benefits package to Employees.

Your Health & Welfare Benefits

Health Insurance

Vision Benefits

Dental Benefits

Short-Term Disability

Long-Term Disability (mandatory paid by employee)

Life Insurance, Accidental Death & Dismemberment Insurance

Your Retirement Benefits

Pension Plan

Employees are entitled to contribute a minimum of 1% to a maximum of 7% of their base salary to the
pension plan. The Company will match the Employee’s contribution up to a maximum of 7% of their
base salary. Both contributions are then invested through the pension plan carrier, where the
Employee chooses the type of funds. The pension plan carrier offers over thirty (30) funds from
100% equity to 100% fixed rate.

Additional Benefits

Wellness Reimbursement

All Employees working twenty (20) or more hours per week are eligible for Company-subsidized
memberships at health and/or wellness related programs and the purchase of home gym equipment.
Memberships can include immediate family members (spouse/domestic partner and children). The
Employee must be the principal member of a Family membership. The Company will reimburse on a
monthly basis 50% of the cost of health club memberships and/or any wellness related programs up to
$600 per year for Full-Time Employees.

Reimbursements are treated as taxable compensation and will be reflected on T4s at year-end. An
Employee taking part in this program will be required to reimburse the Company if they terminate
employment within one (1) year after receiving reimbursement.

Personal Computer Reimbursement

All Regular, Full-Time Employees who have completed one (1) full year of employment with

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

70

the Company are eligible to receive reimbursement for the purchase of a personal computer for home
use. The Company will reimburse the cost of a personal computer (hardware CPU, monitor, CD-ROM
drive, printer, modem, sound card, etc.) up to a maximum of $1,750. This reimbursement is
renewable every three years.

Reimbursements are treated as taxable compensation and will be reflected on T4s at year-end. An
Employee taking part in this program will be required to reimburse the Company if they terminate
employment within one (1) year after receiving reimbursement.

This program is not retroactive. Employees who have received reimbursement through the previous
policy ($1,500 per lifetime) will become eligible for the current program three years from the
initial reimbursement.

Employee Assistance Program — LifeBalance

EMD Serono offers private counseling through RBC Insurance (UnumProvident) which offers assistance
to Employees and family members who may be experiencing personal problems, that, in time, may
affect their personal and professional lives. The EAP services include assessment, short-term
counseling, referral and follow-up. In addition, LifeBalance offers a comprehensive resource and
referral program locating providers who offer childcare services, elder care services, financial
and legal services, as well as a host of other home and health providers. The EAP is strictly
confidential.

Flex Work Arrangements

The Company considers flexible work hours a viable alternative work arrangement in cases where
individual, job, and managerial characteristics are best suited to such an arrangement. Flexible
work hours provide flexibility from standard work hours and may be appropriate for some Employees
and some jobs, but not appropriate for others given the nature of the work that is performed. A
flexible work hours arrangement is not an entitlement, nor a Company-wide benefit, and in no way
changes an Employee’s terms and conditions with the Company.

Employee Referral Bonus Program

The Company recognizes that one of the most effective ways to find the right people for our Company
is through the people who know it best — our Employees.

The Company encourages Employee assistance in the recruitment of high quality, new Employees
through Employee referrals and rewards Employees for making such referrals, as we value our people
and we value your contribution to our business. That is why we have introduced the Employee
Referral Bonus Program, which is designed to reward you whenever you successfully refer a candidate
for a position at the Company.

All Regular Full-Time and Part-Time Employees of the Company who are paid via the Company’s
Canadian payroll may participate in this program with the exception of Employees within the Human
Resources Department, and the respective Hiring Manager of a position and any of their direct
reports.

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

72

Schedule K

Form of Employment Agreement — Non-Key Employees

<DATE>

PERSONAL AND CONFIDENTIAL

<NAME>

c/o Oncothyreon
2011 — 94 Street, Suite 200
Edmonton, Alberta
T6N 1H1

Re: Employment Agreement

Dear <NAME>:

Following the acquisition of the Oncothyreon Inc. Edomonton site, we are pleased to offer you the
position of <TITLE>, reporting to <MANAGER’S NAME AND TITLE> effective January 1, 2009.
This letter will confirm our discussion and your offer of employment with EMD Serono Canada Inc.
(“EMD Serono”), which is conditional on the closing of a sale agreement between EMD Serono and your
current employer, Oncothyreon.

The terms and condition of your employment are as follows:

	 	 	 
	Scope of Work:

	 	As a <TITLE, you will perform
such duties and exercise such powers
related to this position as EMD
Serono may assign to you from time
to time. You may be employed by EMD
Serono in a position other than a
<TITLE>, upon EMD Serono
notifying you in writing of such
assignment in which event you will,
subject to the terms and conditions
in this Agreement continue to be
employed by EMD Serono in the
position to which you have been
promoted or transferred to. In the
event of any further change in your
position, the provisions of this
Agreement will apply, with the
necessary changes being made. A
written job description will be
provided to you.
	 
	 	 
	Place of 
Employment:

	 	You will perform your work and
services for EMD Serono, or for such
other person, as may be authorized
by EMD Serono from time to time, in
the Edmonton Office. You will
reside within a reasonable daily
commuting distance of such place of
employment provided that you will
also perform your work and services
in such other places as EMD Serono
may require from time to time.
	 
	 	 
	Salary:

	 	Your annual salary will be
<SALARY> per annum based on a
37.5 hour work week. This payment
will be deposited directly into your
account at the bank of your choice,
payable on a bi-weekly basis in
arrears. Your salary will be
reviewed in April 2010.
	 
	Stimuvax 
Advancement
 Bonus:

	 	For the development of Stimuvax and
as a financial investment in you,
EMD Serono will offer you a special
bonus based on the following three
(3) deliverables which are further
specified in the attached Schedule
“A”:

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

73

	 	 	 
	 

	 	1. Delivery of all batches for
continuous Clinical Trial Supply
throughout 2009 and comparability
submission for Semoy vs Baxter
material. For the achievement of
this milestone you will receive a
lump sum payment equivalent to
<x> months of your then
current salary, less applicable
taxes in January 2010.

	 
	 	 
	 

	 	2. Comparability submission
commercial scale vs clinical scale.
For the achievement of this 2010
milestone you will receive a lump
sum payment equivalent to <x>
months of your then current salary,
less applicable taxes in January
2011.

	 
	 	 
	 

	 	3. Validation package commercial
scale completed. For the achievement
of this 2011 milestone you will
receive a lump sum payment
equivalent to <x> months of
your then current salary less
applicable taxes in January 2012.

	 
	 	 
	 

	 	Should you resign or be terminated
for any reason during 2009 — 2011,
you will not be eligible for any
bonus not already paid.
	 
	 	 
	Performance 
Bonus:

	 	Your target bonus is <BONUS>
of your base salary however the
actual amount of bonus awarded will
be based on achievement of your own
individual performance objectives,
as outlined in your Personal and
Professional Development Plan, and
the group objectives for EMD Serono
Canada.
	 
	 	 
	 

	 	Should you resign or should your
employment be terminated for any
reason during the plan year (January
to December) you will not be
eligible for a bonus payout.
	 
	 	 
	Vacation:

	 	Vacation time is accrued on a
monthly basis according to
seniority. We will recognize your
prior service with Oncothyreon for
vacation purposes. You are eligible
for <VACATION AMOUNT> weeks of
vacation time — accrued at
<ACCRUAL> days per month for
each calendar year of service. Your
prorated vacation entitlement for
<YEAR> will be <PRORATED
AMOUNT> days. In addition to
vacation you will receive one (1)
floater day.
	 
	 	 
	 

	 	Currently, the offices are closed
during the last week of December.
Please refer to the Holiday
Schedule. This time is not
considered part of your vacation
entitlement.
	 
	 	 
	 

	 	In the event your employment with
EMD Serono is terminated for any
reason, EMD Serono will deduct from
your final pay cheque an amount
equal to the vacation pay you
received for vacation time taken in
advance of its accrual
	 
	 	 
	Benefits:

	 	You will be entitled to participate
in EMD Serono’s benefit program. A
schedule of our benefits is attached
for your review.
	 
	 	 
	Expenses:

	 	You will be reimbursed for all
authorized travelling and other
out-of-pocket expenses actually and
properly incurred by you in
connection with your

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

74

	 	 	 
	 

	 	duties under
this Agreement in accordance with
EMD Serono expense policy in effect
from time to time. For all such
expenses, you will furnish to EMD
Serono statements and vouchers, as
and when EMD Serono requires.
	 
	 	 
	Duties and Responsibilities

	 	You will duly and diligently perform
all the duties assigned to you while
in the employ of EMD Serono and will
truly and faithfully account for and
deliver to EMD Serono all money;
securities and things of value
belonging to EMD Serono that you may
from time to time receive for, from
or on account of EMD Serono.
	 
	 	 
	Rules and Regulations:

	 	You will be bound by and will
faithfully observe and abide by all
the policies, rules and regulations
of EMD Serono from time to time in
force which are brought to your
notice or of which you should
reasonably be aware.
	 
	 	 
	Patentable 
Invention

	 	In the event that you contribute to
any patentable invention arising
while employed by EMD Serono, any
such patentable invention will be
the exclusive property of EMD Serono
and EMD Serono will have the
exclusive right to file patent
applications in the name of EMD
Serono in connection with such
patentable invention and you will
co-operate with EMD Serono and
provide all necessary assistance in
the filing and prosecution of such
patent applications.
	 
	 	 
	Non-Disclosure:

	 	You will not (either during your
employment or at any time after the
termination of your employment for
any reason) disclose any information
relating to the private or
confidential affairs of EMD Serono
or relating to any secrets of EMD
Serono to any person other than for
EMD Serono’s purposes and, without
limiting the generality of the
foregoing, you will not (either
during your employment or at any
time after the termination of your
employment for any reason) disclose
EMD Serono’s Proprietary Information
to any person other than for EMD
Serono’s purposes and will not
(either during your employment or at
any time after the termination of
your employment for any reason) use
for your own purposes or for any
purposes other than those of EMD
Serono any such information or
secrets you may acquire in relation
to the business of EMD Serono’s
Proprietary Information.
	 
	 	 
	Resignation:

	 	You may terminate your employment
upon giving two (2) weeks’ written
notice to EMD Serono. You agree
that EMD Serono may waive the notice
period by paying to you an amount
equivalent to a salary you would
have received during the notice
period. You also agree that such
waiver by EMD Serono does not
constitute a termination of your
employment by EMD Serono.

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

75

	 	 	 
	Termination of Employment:

	 	EMD Serono may terminate your
employment at any time for cause
without notice and without pay in
lieu of notice, severance, damages,
bonus or other compensation of any
kind. 

In the event EMD Serono terminates
your employment, you will receive a
lump sum payment equivalent to two
(2) weeks base salary, per year of
service, including your past service
at Oncothyreon Inc. This lump sum
payment will include all payments
due to you upon termination of
employment, including any
entitlements to pay in lieu of
notice pursuant to the Employment
Standards Code (Alberta) and any
severance pay to which you may be
entitled.
	 
	 	 
	Deduction from Final Pay:

	 	EMD Serono reserves the right at the
time of separation to deduct any
outstanding amounts owed by you to
EMD Serono from your final wages or
bonus amounts owing to you.
	 
	 	 
	Entire Agreement:

	 	This Agreement, the milestone
concept attached as Schedule “A”,
and the policies of EMD Serono
constitute the entire agreement
between you and EMD Serono with
respect to your employment and
cancels and supersedes any prior
understandings and agreements
between you and EMD Serono with
respect to your employment. There
are no representations, warranties,
forms, conditions, undertakings or
collateral agreements, express,
implied or statutory between you and
EMD Serono other than as expressly
set forth in this Agreement.
	 
	 	 
	Pre-Contractual Representation:

	 	You hereby waive any right to assert
a claim based on any pre-contractual
representations, negligent or
otherwise, made by EMD Serono.
	 
	 	 
	Governing Law:

	 	This Agreement will be governed by
and construed in accordance with the
laws of the Province of Alberta and
the laws of Canada applicable in
Alberta.

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

76

Please carefully read and consider the terms and conditions described in this letter and confirm
your understanding by signing in the space provided below and return a signed copy to the attention
of Megan Iannone — Human Resources or via confidential fax to 905-919-0291 no later than December
23, 2008. When you sign this letter, it will be a binding employment agreement between you and EMD
Serono.

<NAME>, we trust that this letter suitably represents our discussion and that you will accept
our offer. We look forward to you joining the EMD Serono Technical Operations team and wish you
every success in your new role.

Yours very truly,

EMD SERONO, CANADA INC

	 	 	 	 	 	 	 
	 
	Deborah Brown
	 	 	 	Debbie Lowe
	 	 
	Managing Director, Canada

	 	 	 	Director, Human Resources	 	 

Enclosure

I have read, understand and voluntarily accept the terms of employment described above as
constituting a binding employment agreement between EMD Serono and myself.

	 	 	 	 	 
	 

	 	 
	 	 
	<NAME>

	 	Date
	 	Social Insurance Number

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

77

Schedule “A” — Milestone Definition

[+] [Redaction continues for two pages]

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

 78

EMD SERONO CANADA & YOUR OFFERED BENEFITS 

The Company recognizes that benefits are an integral part o the overall compensation package. On
an ongoing basis, the Human Resources Department reviews and monitors benefit programs to ensure
that the Company is offering a competitive and comprehensive benefits package to Employees.

Your Health & Welfare Benefits

Health Insurance

Vision Benefits

Dental Benefits

Short-Term Disability

Long-Term Disability (mandatory paid by employee)

Life Insurance, Accidental Death & Dismemberment Insurance

Your Retirement Benefits

Pension Plan

Employees are entitled to contribute a minimum of 1% to a maximum of 7% of their base salary to the
pension plan. The Company will match the Employee’s contribution up to a maximum of 7% of their
base salary. Both contributions are then invested through the pension plan carrier, where the
Employee chooses the type of funds. The pension plan carrier offers over thirty (30) funds from
100% equity to 100% fixed rate.

Additional Benefits

Wellness Reimbursement

All Employees working twenty (20) or more hours per week are eligible for Company-subsidized
memberships at health and/or wellness related programs and the purchase of home gym equipment.
Memberships can include immediate family members (spouse/domestic partner and children). The
Employee must be the principal member of a Family membership. The Company will reimburse on a
monthly basis 50% of the cost of health club memberships and/or any wellness related programs up to
$600 per year for Full-Time Employees.

Reimbursements are treated as taxable compensation and will be reflected on T4s at year-end. An
Employee taking part in this program will be required to reimburse the Company if they

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED
SEPARATELY WITH THE COMMISSION

 

79

terminate employment within one (1) year after receiving reimbursement.

Personal Computer Reimbursement

All Regular, Full-Time Employees who have completed one (1) full year of employment with the
Company are eligible to receive reimbursement for the purchase of a personal computer for home use.
The Company will reimburse the cost of a personal computer (hardware CPU, monitor, CD-ROM drive,
printer, modem, sound card, etc.) up to a maximum of $1,750. This reimbursement is renewable every
three years.

Reimbursements are treated as taxable compensation and will be reflected on T4s at year-end. An
Employee taking part in this program will be required to reimburse the Company if they terminate
employment within one (1) year after receiving reimbursement.

This program is not retroactive. Employees who have received reimbursement through the previous
policy ($1,500 per lifetime) will become eligible for the current program three years from the
initial reimbursement.

Employee Assistance Program — LifeBalance 

EMD Serono offers private counseling through RBC Insurance (UnumProvident) which offers assistance
to Employees and family members who may be experiencing personal problems, that, in time, may
affect their personal and professional lives. The EAP services include assessment, short-term
counseling, referral and follow-up. In addition, LifeBalance offers a comprehensive resource and
referral program locating providers who offer childcare services, elder care services, financial
and legal services, as well as a host of other home and health providers. The EAP is strictly
confidential.

Flex Work Arrangements

The Company considers flexible work hours a viable alternative work arrangement in cases where
individual, job, and managerial characteristics are best suited to such an arrangement. Flexible
work hours provide flexibility from standard work hours and may be appropriate for some Employees
and some jobs, but not appropriate for others given the nature of the work that is performed. A
flexible work hours arrangement is not an entitlement, nor a Company-wide benefit, and in no way
changes an Employee’s terms and conditions with the Company.

Employee Referral Bonus Program

The Company recognizes that one of the most effective ways to find the right people for our Company
is through the people who know it best — our Employees.

The Company encourages Employee assistance in the recruitment of high quality, new Employees
through Employee referrals and rewards Employees for making such referrals, as we value our people
and we value your contribution to our business. That is why we have introduced the Employee
Referral Bonus Program, which is designed to reward you whenever you successfully refer a candidate
for a position at the Company.

All Regular Full-Time and Part-Time Employees of the Company who are paid via the Company’s
Canadian payroll may participate in this program with the exception of Employees within the Human
Resources Department, and the respective Hiring Manager of a position and any of their direct
reports.

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED
SEPARATELY WITH THE COMMISSION

 

80

<DATE>

PERSONAL AND CONFIDENTIAL

<NAME>

c/o Oncothyreon

2011 — 94 Street, Suite 200

Edmonton, Alberta

T6N 1H1

Re: Employment Agreement

Dear <NAME>:

We are very pleased to offer you the position of <TITLE>, effective January 1, 2009 reporting
to <NAME — TITLE>. This letter will confirm our discussion and your offer of employment with
EMD Serono Canada Inc. (“EMD Serono”), which is conditional on the closing of a sale agreement
between EMD Serono and your current employer, Oncothyreon.

The terms and condition of your employment are as follows:

	 	 	 
	Scope of Work:

	 	As a <TITLE>, you will perform such duties and
exercise such powers related to this position as EMD
Serono may assign to you from time to time. You may be
employed by EMD Serono in a position other than a
<TITLE>, upon EMD Serono notifying you in writing
of such assignment in which event you will, subject to
the terms and conditions in this Agreement continue to
be employed by EMD Serono in the position to which you
have been promoted or transferred to. In the event of
any further change in your position, the provisions of
this Agreement will apply, with the necessary changes
being made. A written job description will be provided
to you.
	 
	 	 
	Place of Employment:

	 	You will perform your work and services for EMD Serono,
or for such other person, as may be authorized by EMD
Serono from time to time, in the Edmonton Office. You
will reside within a reasonable daily commuting distance
of such place of employment provided that you will also
perform your work and services in such other places as
EMD Serono may require from time to time.
	 
	 	 
	Salary:

	 	Your annual salary will be $<SALARY>per annum
based on a 37.5 hour work week. This payment will be
deposited directly into your account at the bank of your
choice, payable on a bi-weekly basis in arrears. Your
salary will be reviewed in April 2010.
	 
	 	 
	Stimuvax 

Advancement Bonus:

	 	For the development of Stimuvax and as a financial
investment in you, EMD Serono will offer you a special
bonus based on the following three (3) deliverables
which are further specified in the attached Schedule
“A”:

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED
SEPARATELY WITH THE COMMISSION

 

81

	 	 	 
	 

	 	4.    Delivery of all batches for continuous Clinical Trial
Supply throughout 2009 and comparability submission for
Semoy vs Baxter material. For the achievement of this
milestone you will receive a lump sum payment equivalent
to <#> months of your then current salary, less
applicable taxes in January 2010.

	 
	 	 
	 

	 	5.    Comparability submission commercial scale vs clinical
scale. For the achievement of this 2010 milestone you
will receive a lump sum payment equivalent to <#>
months of your then current salary, less applicable
taxes in January 2011.

	 
	 	 
	 

	 	6.    Validation package commercial scale completed. For
the achievement of this 2011 milestone you will receive
a lump sum payment equivalent to <#> months of
your then current salary less applicable taxes in
January 2012.

	 
	 	 
	 

	 	Should you resign or be terminated for any reason during
2009 - 2011, you will not be eligible for any bonus not
already paid.
	 
	 	 
	Performance Bonus:

	 	Your target bonus is <%> of your base salary,
however the actual amount of bonus awarded will be based
on achievement of your own individual performance
objectives, as outlined in your Personal and
Professional Development Plan, and the group objectives
for EMD Serono Canada. 

Should you resign or should your employment be
terminated for any reason during the plan year (January
to December) you will not be eligible for a bonus
payout.
	 
	 	 
	Vacation:

	 	Vacation time is accrued on a monthly basis according to
seniority. We will recognize your prior service with
Oncothyreon for vacation purposes. You are eligible for
<#> weeks of vacation time — accrued at <#>
days per month for each calendar year of service. In
addition to vacation you will receive one (1) floater
day.
	 
	 	 
	 

	 	Currently, the offices are closed during the last week
of December. Please refer to the Holiday Schedule. This
time is not considered part of your vacation
entitlement.
	 
	 	 
	 

	 	In the event your employment with EMD Serono is
terminated for any reason, EMD Serono will deduct from
your final pay cheque an amount equal to the vacation
pay you received for vacation time taken in advance of
its accrual
	 
	 	 
	Benefits:

	 	You will be entitled to participate in EMD Serono’s
benefit program. A schedule of our benefits is attached
for your review.
	 
	 	 
	Expenses:

	 	You will be reimbursed for all authorized travelling and
other out-of-pocket expenses actually and properly
incurred by you in connection with your duties under
this Agreement in accordance with EMD Serono expense

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED
SEPARATELY WITH THE COMMISSION

 

82

	 	 	 
	 

	 	policy in effect from time to time. For all such
expenses, you will furnish to EMD Serono statements and
vouchers, as and when EMD Serono requires.
	 
	 	 
	Duties and
Responsibilities

	 	You will duly and diligently perform all the duties
assigned to you while in the employ of EMD Serono and
will truly and faithfully account for and deliver to EMD
Serono all money; securities and things of value
belonging to EMD Serono that you may from time to time
receive for, from or on account of EMD Serono.
	 
	 	 
	Rules and
Regulations:

	 	You will be bound by and will faithfully observe and
abide by all the policies, rules and regulations of EMD
Serono from time to time in force which are brought to
your notice or of which you should reasonably be aware.
	 
	 	 
	Patentable Invention

	 	In the event that you contribute to any patentable
invention arising while employed by EMD Serono, any such
patentable invention will be the exclusive property of
EMD Serono and EMD Serono will have the exclusive right
to file patent applications in the name of EMD Serono in
connection with such patentable invention and you will
co-operate with EMD Serono and provide all necessary
assistance in the filing and prosecution of such patent
applications.
	 
	 	 
	Non-Disclosure:

	 	You will not (either during your employment or at any
time after the termination of your employment for any
reason) disclose any information relating to the private
or confidential affairs of EMD Serono or relating to any
secrets of EMD Serono to any person other than for EMD
Serono’s purposes and, without limiting the generality
of the foregoing, you will not (either during your
employment or at any time after the termination of your
employment for any reason) disclose EMD Serono’s
Proprietary Information to any person other than for EMD
Serono’s purposes and will not (either during your
employment or at any time after the termination of your
employment for any reason) use for your own purposes or
for any purposes other than those of EMD Serono any such
information or secrets you may acquire in relation to
the business of EMD Serono’s Proprietary Information.
	 
	 	 
	Resignation:

	 	You may terminate your employment upon giving two (2)
weeks’ written notice to EMD Serono. You agree that EMD
Serono may waive the notice period by paying to you an
amount equivalent to a salary you would have received
during the notice period. You also agree that such
waiver by EMD Serono does not constitute a termination
of your employment by EMD Serono.

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED
SEPARATELY WITH THE COMMISSION

 

83

	 	 	 
	Termination of
Employment:

	 	EMD Serono may terminate your employment at any time for
cause without notice and without pay in lieu of notice,
severance, damages, bonus or other compensation of any
kind.
	 
	 	 
	 

	 	In the event EMD Serono terminates your employment
without cause, you will receive a lump sum payment
equivalent to:
	 
	 	 
	 

	 	a. <#>base salary, less statutory deductions,

	 
	 	 
	 

	 	b. Performance Bonus pay at target for the period of
January 1 to your termination date, less statutory
deductions,

	 
	 	 
	 

	 	c. Additional Performance Bonus pay at target for
<#> following termination, less statutory
deductions,

	 
	 	 
	 

	 	This lump sum payment will include all payments due to
you upon termination of employment, including any
entitlements to pay in lieu of notice pursuant to the
Employment Standards Code (Alberta) and any severance
pay to which you may be entitled.
	 
	 	 
	 

	 	Please note that benefit coverage terminates effective
the date of termination of employment, regardless of the
manner of or reason for termination, unless otherwise
required by the Employment Standards Code (Alberta), as
amended.
	 
	 	 
	Release

	 	In consideration of Oncothyreon Inc. and /or certain of
its affiliates negotiating the asset purchase agreement
with EMD Serono, and EMD Serono extending the within
offer of employment to you, you agree to release
Oncothyreon Inc. and its parents, subsidiaries,
affiliates, partners and related companies (including
their directors, officers, employees and agents)
(collectively “Oncothyreon”) from all obligations and
claims that you have or may have (including but not
limited to claims for notice of termination, pay and
benefits in lieu of notice, termination pay, severance
pay, bonus pay, retention pay, overtime pay, vacation
pay, wages and benefits) relating to your employment
with Oncothyreon, the termination of that employment,
and the discontinuance of all benefit coverage . Without
limiting the generality of the foregoing, you
acknowledge that this release applies to all claims you
have or may have against Oncothyreon including any
claims under the Employment Standards Code (Alberta) and
the Human Rights, Citizenship and Multiculturalism Act
(Alberta).
	 
	 	 
	Deduction from 

Final Pay:

	 	EMD Serono reserves the right at the time of separation
to deduct any outstanding amounts owed by you to EMD
Serono from your final wages or bonus amounts owing to
you.

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED
SEPARATELY WITH THE COMMISSION

 

84

	 	 	 
	Entire Agreement:

	 	This Agreement, the milestone concept attached as
Schedule “A”, the attached Non-Competition and
Non-Solicitation Agreement, marked as Schedule “B”, and
the policies of EMD Serono constitute the entire
agreement between you and EMD Serono with respect to
your employment and cancels and supersedes any prior
understandings and agreements between you and EMD Serono
with respect to your employment. There are no
representations, warranties, forms, conditions,
undertakings or collateral agreements, express, implied
or statutory between you and EMD Serono other than as
expressly set forth in this Agreement.
	 
	 	 
	Pre-Contractual 

Representation:

	 	You hereby waive any right to assert a claim based on
any pre-contractual representations, negligent or
otherwise, made by EMD Serono.
	 
	 	 
	Governing Law:

	 	This Agreement will be governed by and construed in
accordance with the laws of the Province of Alberta and
the laws of Canada applicable in Alberta.

Please carefully read and consider the terms and conditions described in this letter and confirm
your understanding by signing in the space provided below and return a signed copy to the attention
of Megan Iannone — Human Resources or via confidential fax to 905-919-0291 no later than December
23, 2008. When you sign this letter, it will be a binding employment agreement between you and EMD
Serono.

<NAME>, we trust that this letter suitably represents our discussion and that you will accept
our offer. We look forward to you joining the EMD Serono team and wish you every success in your
new role.

Yours very truly,

EMD SERONO, CANADA INC

	 	 	 
	 
	 	 
	 

	 	 
	Deborah Brown

	 	Debbie Lowe
	Managing Director, Canada

	 	Director, Human Resources

Enclosure

I have read, understand and voluntarily accept the terms of employment described above as
constituting a binding employment agreement between EMD Serono and myself.

	 	 	 	 	 
	 
	 	 	 	 
	 

	 	 
	 	 
	<NAME>

	 	Date
	 	Social Insurance Number

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED
SEPARATELY WITH THE COMMISSION

 

 

Schedule “A” — Milestone Definition

[+] [Redaction continues for two pages]

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED
SEPARATELY WITH THE COMMISSION

 

 

Schedule “B” — Non-Competition and Non-Solicitation Agreement

NON-COMPETITION AND NON-SOLICITATION AGREEMENT

     THIS NON-COMPETITION AND NON-SOLICITATION AGREEMENT (“Agreement”) is made as of 18 December,
2008,

BETWEEN

<NAME>, of the City of Edmonton in the Province of Alberta
(the “Employee”)

— and —

EMD Serono Canada Inc., a corporation incorporated under laws of the Province of Alberta
(“EMD Serono”).

WHEREAS:

	A.	 	The Employee was employed by Oncothyreon Inc. (“Oncothyreon”) and EMD SERONO and Oncothyreon
entered into an Asset Purchase Agreement dated 18 December 2008 (“Asset Purchase Agreement”);
and
	 
	B.	 	EMD Serono offered employment to the Employee upon closing of the transaction (“Closing”),
conditional upon signing this Agreement.

In consideration of the offer of employment from EMD Serono plus other valuable consideration, the
parties agree as follows:

Non-Competition and Non-Solicitation

	1.	 	The Employee agrees that during his/her employment and for a period of twelve (12) months
following the cessation of employment, he/she will not, without the prior written consent of
EMD Serono:

	 	(i)	 	either individually or in conjunction with any person as
principal, agent, consultant, advisor, employee or shareholder (other than a
holding of shares listed on a Canadian or United States stock exchange that
does not exceed ten percent (10%) of the outstanding shares so listed)
directly or indirectly engage in, work in, or lend money to any business,
professional or commercial activity competitive with the Business of EMD Serono
within North America (“Territory”). For clarity the “Business” of EMD Serono
for the purposes of this Agreement shall include any business in North America
which provides any or all of the following products or services:
	 
	 	 	 	cancer vaccines.

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED
SEPARATELY WITH THE COMMISSION

 

87

	 	(ii)	 	hire away or induce, coerce, counsel or entice any employee or
consultant of EMD Serono in the Territory to leave his/her employment or
engagement with EMD Serono.

	2.	 	Employee acknowledges and agrees that in accepting employment with EMD Serono, he/she is in a
fiduciary position and that all of the restrictions in this Agreement are reasonable, valid
and do not go beyond what is necessary to protect the business interests of EMD Serono and he
agrees to waive any defences to the strict enforcement of these restrictions. These
restrictions are only intended to safeguard against the Employee participating in competitive
endeavours against EMD Serono or hiring away staff of EMD Serono and not to restrict the
Employee from being engaged in other employment and businesses that are not in competition
with EMD Serono in the Territory.
	 
	3.	 	Employee agrees that a breach of the terms of this Agreement would result in damages to EMD
Serono which could not adequately be compensated for by a monetary award and accordingly, in
the event of a breach, in addition to all other remedies available to EMD Serono at law or in
equity, EMD Serono will be entitled as a matter of right to apply to a Court for a restraining
order, injunction, decree or any other order as may be appropriate to ensure compliance with
this Agreement.
	 
	4.	 	If there are any provisions of this Agreement which are found not to be enforceable by a
Court, those provisions are to be severed and the remaining provisions shall remain in full
force and effect.
	 
	5.	 	This Agreement will be governed by the laws of the Province of Alberta and the parties hereto
irrevocably attorn to the jurisdiction of the Alberta Courts.

     IN WITNESS WHEREOF the parties have executed this Agreement.

	 	 	 	 	 
	 	 EMD SERONO INC.

Per:

 	 
	 	 	 
	 	Deborah Brown	 
	 	Managing Director, Canada	 

SIGNED AND WITNESSED

in the presence of:

	 	 	 	 
	 
	 	 	 
	 

	 	 	 
	Witness

	 	<NAME>	 

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED
SEPARATELY WITH THE COMMISSION

 

88

EMD SERONO CANADA & YOUR OFFERED BENEFITS 

The Company recognizes that benefits are an integral part o the overall compensation package. On
an ongoing basis, the Human Resources Department reviews and monitors benefit programs to ensure
that the Company is offering a competitive and comprehensive benefits package to Employees.

Your Health & Welfare Benefits

Health Insurance

Vision Benefits

Dental Benefits

Short-Term Disability

Long-Term Disability (mandatory paid by employee)

Life Insurance, Accidental Death & Dismemberment Insurance

Your Retirement Benefits

Pension Plan

Employees are entitled to contribute a minimum of 1% to a maximum of 7% of their base salary to the
pension plan. The Company will match the Employee’s contribution up to a maximum of 7% of their
base salary. Both contributions are then invested through the pension plan carrier, where the
Employee chooses the type of funds. The pension plan carrier offers over thirty (30) funds from
100% equity to 100% fixed rate.

Additional Benefits

Wellness Reimbursement

All Employees working twenty (20) or more hours per week are eligible for Company-subsidized
memberships at health and/or wellness related programs and the purchase of home gym equipment.
Memberships can include immediate family members (spouse/domestic partner and children). The
Employee must be the principal member of a Family membership. The Company will reimburse on a
monthly basis 50% of the cost of health club memberships and/or any wellness related programs up to
$600 per year for Full-Time Employees.

Reimbursements are treated as taxable compensation and will be reflected on T4s at year-end.

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED
SEPARATELY WITH THE COMMISSION

 

89

An Employee taking part in this program will be required to reimburse the Company if they terminate
employment within one (1) year after receiving reimbursement.

Personal Computer Reimbursement

All Regular, Full-Time Employees who have completed one (1) full year of employment with the
Company are eligible to receive reimbursement for the purchase of a personal computer for home use.
The Company will reimburse the cost of a personal computer (hardware CPU, monitor, CD-ROM drive,
printer, modem, sound card, etc.) up to a maximum of $1,750. This reimbursement is renewable every
three years.

Reimbursements are treated as taxable compensation and will be reflected on T4s at year-end. An
Employee taking part in this program will be required to reimburse the Company if they terminate
employment within one (1) year after receiving reimbursement.

This program is not retroactive. Employees who have received reimbursement through the previous
policy ($1,500 per lifetime) will become eligible for the current program three years from the
initial reimbursement.

Employee Assistance Program — LifeBalance 

EMD Serono offers private counseling through RBC Insurance (UnumProvident) which offers assistance
to Employees and family members who may be experiencing personal problems, that, in time, may
affect their personal and professional lives. The EAP services include assessment, short-term
counseling, referral and follow-up. In addition, LifeBalance offers a comprehensive resource and
referral program locating providers who offer childcare services, elder care services, financial
and legal services, as well as a host of other home and health providers. The EAP is strictly
confidential.

Flex Work Arrangements

The Company considers flexible work hours a viable alternative work arrangement in cases where
individual, job, and managerial characteristics are best suited to such an arrangement. Flexible
work hours provide flexibility from standard work hours and may be appropriate for some Employees
and some jobs, but not appropriate for others given the nature of the work that is performed. A
flexible work hours arrangement is not an entitlement, nor a Company-wide benefit, and in no way
changes an Employee’s terms and conditions with the Company.

Employee Referral Bonus Program

The Company recognizes that one of the most effective ways to find the right people for our Company
is through the people who know it best — our Employees.

The Company encourages Employee assistance in the recruitment of high quality, new Employees
through Employee referrals and rewards Employees for making such referrals, as we value our people
and we value your contribution to our business. That is why we have introduced the Employee
Referral Bonus Program, which is designed to reward you whenever you successfully refer a candidate
for a position at the Company.

All Regular Full-Time and Part-Time Employees of the Company who are paid via the Company’s
Canadian payroll may participate in this program with the exception of Employees within the Human
Resources Department, and the respective Hiring Manager of a position and any of their direct
reports.

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED
SEPARATELY WITH THE COMMISSION

 

 

Schedule L

Legal Opinion — Oncothyreon’s Counsel

[+] [Redaction continues for nine pages]

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED
SEPARATELY WITH THE COMMISSION

 

Schedule M

Form of Press Release

MERCK SERONO

	 	 	 	 	 
	 

	 	 	 	Your Contact
	 

	 	 
	 	Raphaela Farrenkopf
	 

	 	 	 	Phone +49 6151-72-2274

News Release

December 19th 2008

Merck Serono Acquires Manufacturing Rights and Facility for Stimuvax from Oncothyreon

			
	•	 	Acquisition gives Merck Serono full control of the manufacturing process and reduces the
royalties payable on future sales of the product

Darmstadt, December 19, 2008 — Merck Serono, a division of Merck KGaA, announced today that it has
modified the license from Oncothyreon to include the right to manufacture Stimuvax® (BLP25 liposome
vaccine) and also has purchased current inventory and certain assets used for the manufacture of
Stimuvax from Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) for a total amount of approximately US$13
million. Merck Serono already held the clinical development and commercialization rights for
Stimuvax under license from Oncothyreon.

Stimuvax is a therapeutic vaccine in Phase III clinical development for non-small cell lung cancer
(NSCLC) and is the first investigational vaccine in unresectable stage III NSCLC to enter Phase III
clinical testing (the START study).

In conjunction with this transaction, EMD Serono Canada Inc., an affiliate of Merck KGaA, has
assumed control of Oncothyreon’s facility in Edmonton, Canada, which is primarily utilized for the
manufacture and development of Stimuvax. Merck Serono now has responsibility for development of
the commercial-scale manufacturing process. EMD Serono Canada intends to offer employment to the
majority of Oncothyreon’s 52 employees in Edmonton.

“Merck Serono’s acquisition of manufacturing rights for Stimuvax reflects our confidence in its
future role in the treatment of cancer and also our commitment to expanding our oncology portfolio
so that we can continue to provide oncologists and patients with innovative treatment options,”
said Hanns-Eberhard Erle, Executive Vice President Technical Operations, Merck Serono, a division
of Merck KGaA.

“In addition, with the Edmonton facility we are proud to be adding a group of experienced and
dedicated individuals to our workforce who will form a vital arm of the team that supports the
ongoing development of Stimuvax,” Erle continued.

The transfer of Stimuvax manufacturing rights has required the license agreement between Merck
Serono and Oncothyreon to be amended and restated. While potential payments upon achievement of
certain milestones under the previous agreements between Merck Serono and Oncothyreon

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

 

MERCK SERONO 

remain
unchanged, the royalty rates payable to Oncothyreon on future net sales are reduced. While the
previous agreements already included some limited manufacturing rights, the new agreement provides
Merck Serono with the full rights.

“We believe that the license of manufacturing rights for Stimuvax to Merck Serono is in the best
interest of the development of this product,” said Robert L. Kirkman, M.D., President and Chief
Executive Officer of Oncothyreon. “Merck Serono will be able to bring its resources and
manufacturing expertise to the development of a commercial manufacturing process for Stimuvax,
which has become a key component of its oncology pipeline. At Oncothyreon we will be able to focus
our resources on our proprietary pipeline of targeted small molecules in oncology.”

About Stimuvax

Merck KGaA is investigating the use of Stimuvax® (BLP25 Liposome Vaccine) in the treatment of
NSCLC. The vaccine was granted fast-track status in September 2004 by the FDA. Merck obtained the
exclusive worldwide licensing rights from Oncothyreon Inc., Bellevue, Washington, USA. Stimuvax is
being developed in Europe by Merck KGaA and in the United States by its affiliate, EMD Serono Inc.

START is a multi-center, randomized, double-blind, placebo-controlled study that will evaluate
patients with documented unresectable stage IIIA or IIIB NSCLC who have had a response or stable
disease after at least two cycles of platinum-based chemo-radiotherapy The study will involve more
than 1,300 patients in approximately 30 countries. For more information on the START study, or to
find a participating center and eligibility criteria, go to www.nsclcstudy.com. The study
is also listed on www.clinicaltrials.gov.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic
products for the treatment of cancer. Oncothyreon’s goal is to develop and commercialize novel
synthetic vaccines and targeted small molecules that have the potential to improve the lives and
outcomes of cancer patients. For more information, visit www.oncothyreon.com.

About Merck Serono

Merck Serono is the division for innovative prescription pharmaceuticals of Merck, a global
pharmaceutical and chemical group. Headquartered in Geneva, Switzerland, Merck Serono
discovers, develops, manufactures and markets innovative small molecules and biopharmaceuticals to
help patients with unmet medical needs. Its North Amencan business operates in the United States
and Canada as EMD Serono.

Merck Serono has leading brands serving patients with cancer (Erbitux®), multiple sclerosis

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-2-

 

MERCK SERONO

(Rebif®), infertility (Gonal-f®), endocrine and cardiometabolic disorders (Glucophage®, Concor®,
Saizen®, Serostim®), as well as psoriasis (Raptiva®).

With an annual R&D investment of around € 1bn, Merck Serono is committed to growing its business in
specialist-focused therapeutic areas including neurodegenerative diseases, oncology, fertility and
endocrinology, as well as new areas potentially arising out of research and development in
autoimmune and inflammatory diseases.

For more information, please visit www.merckserono.net or www.merck.de.

About Merck

All Merck Press Releases are distributed by e-mail at the same time they become available on the
Merck Website. Please go to www.subscribe.merck.de to register online, change your
selection or discontinue this service.

Merck is a global pharmaceutical and chemical company with total revenues of € 7.1 billion in 2007,
a history that began in 1668, and a future shaped by 32,458 employees in 59 countries. Its success
is characterized by innovations from entrepreneurial employees. Merck’s operating activities come
under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and
free shareholders own the remaining approximately 30%. In 1917 the US subsidiary Merck & Co. was
expropriated and has been an independent company ever since.

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-3-

 

ONCOTHYREON

MERCK KGAA ACQUIRES MANUFACTURING RIGHTS FOR STIMUVAX

FROM ONCOTHYREON

Seattle, Washington  — December 18, 2008 — Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) announced today
that Merck KGaA of Darmstadt, Germany has licensed the right to manufacture Stimuvax® and, through
its affiliate EMD Serono Canada Inc., purchased current inventory and certain assets utilized for
the manufacture of Stimuvax from Oncothyreon for consideration which includes net payments to
Oncothyreon totaling approximately US $13 million. Merck KGaA currently holds the clinical
development and commercialization rights for Stimuvax under license from Oncothyreon. Stimuvax is
a therapeutic vaccine in Phase 3 clinical development for non-small cell lung cancer.

In conjunction with this transaction Merck KGaA, through its affiliate EMD Serono Canada Inc., has
assumed control of Oncothyreon’s Edmonton, Canada, facility, which is primarily utilized for the
manufacture and development of Stimuvax. EMD Serono Canada intends to offer employment to the
majority of Oncothyreon’s 52 employees in Edmonton. In addition, Merck KGaA will be responsible
for all further development costs related to Stimuvax, including commercial-scale manufacturing
process development, and for the cost of goods at commercialization. The royalty rates payable to
Oncothyreon on future net sales of Stimuvax, if any, have been adjusted to reflect that Oncothyreon
is no longer responsible for these costs. Potential payments upon achievement of certain
milestones under the previous agreements between Merck KGaA and Oncothyreon remain unchanged. The
previously existing collaboration and supply agreements have been replaced by an amended and
restated license agreement.

“We believe that the license of manufacturing rights for Stimuvax to Merck KGaA is in the best
interest of both Oncothyreon and the development of this product,” said Robert L. Kirkman, M.D.,
President and Chief Executive Officer of Oncothyreon. “Merck KGaA will be able to bring its
resources and manufacturing expertise to the development of a commercial manufacturing process for
Stimuvax, which has become a key component of its oncology pipeline. At Oncothyreon we will be
able focus our resources on our proprietary pipeline of targeted small molecules in oncology, while
retaining our substantial economic upside if Stimuvax is commercialized.”

“We are also very pleased that EMD Serono Canada will offer employment to most of our Edmonton
employees,” continued Dr. Kirkman. “This group has worked with dedication and enthusiasm to
bring Stimuvax to its current stage, and we are grateful that Merck KGaA has recognized the
knowledge and expertise they will bring to the ongoing development of this exciting product.”

“Merck Serono’s acquisition of manufacturing rights for Stimuvax reflects our confidence in its
future role in the treatment of cancer and also our commitment to expanding our oncology portfolio
so that we can continue to provide oncologists and patients with innovative treatment options,”
said Hanns-Eberhard Erle, Executive Vice President Technical Operations, Merck

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

Serono, a division of Merck KGaA.

“In addition, with the Edmonton facility we are proud to be adding a group of experienced and
dedicated individuals to our workforce who will form a vital arm of the team that supports the
ongoing development of Stimuvax,” Erle continued.

About Stimuvax

Stimuvax is an investigational therapeutic cancer vaccine designed to induce an immune response to
cancer cells that express MUC1, a glycoprotein antigen widely expressed on common cancers. MUC1 is
over-expressed on many cancers such as lung cancer, breast cancer, prostate cancer and colorectal
cancer. Stimuvax is thought to work by stimulating the body’s immune system to identify and
destroy cancer cells expressing MUC1. Merck KGaA currently is conducting a global Phase 3 trial of
Stimuvax known as START (Stimulating Targeted Antigenic Responses To NSCLC). START is a
randomized, double-blind, placebo-controlled study that will evaluate patients with documented
unresectable stage III NSCLC who have had a response or stable disease after at least two cycles of
platinum-based chemo-radiotherapy. The Phase 3 trial is expected to enroll more than 1,300
patients in over 30 countries. For more information on the START trial, or to find a participating
center and eligibility criteria, log on to www.nsclcstudy.com or
www.clinicaltrials.gov.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic
products for the treatment of cancer. Oncothyreon’s goal is to develop and commercialize novel
synthetic vaccines and targeted small molecules that have the potential to improve the lives and
outcomes of cancer patients. For more information, visit www.oncothyreon.com.

Forward Looking Statements

In order to provide Oncothyreon’s investors with an understanding of its current intentions and
future prospects, this release contains statements that are forward looking, including statements
related to future manufacturing and commercial plans for Stimuvax and to future milestone and
royalty payments to Oncothyreon. These forward-looking statements represent Oncothyreon’s
intentions, plans, expectations and beliefs and are based on its management’s experience and
assessment of historical and future trends and the application of key assumptions relating to
future events and circumstances.

Forward-looking statements involve risks and uncertainties, including risks and uncertainties
related to Oncothyreon’s business and the general economic environment. Many of these risks and
uncertainties are beyond Oncothyreon ‘s control. These risks, uncertainties and other factors
could cause our actual results to differ materially from those projected in forward-looking
statements. Risks, uncertainties, and assumptions include those predicting the timing, duration
and results of clinical trials, the timing and results of regulatory reviews, the safety and
efficacy of Stimuvax, the size of the market, if any, for Stimuvax and the possibility of future

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-5-

 

payments to Oncothyreon as the result of the further development or commercialization of Stimuvax.
There can be no guarantee that the results of preclinical studies will be predictive of either
safety or efficacy in future clinical trials. These and other risks and uncertainties are
described in the reports and other documents filed by Oncothyreon Inc. with the SEC and/or Canadian
regulatory authorities.

Although Oncothyreon believes that any forward-looking statements contained herein are reasonable,
it can give no assurance that its expectations are correct. All forward-looking statements are
expressly qualified in their entirety by this cautionary statement. For a detailed description of
the risks and uncertainties associated with Oncothyreon, you are encouraged to review the official
corporate documents filed with the securities regulators in the United States on U.S. EDGAR and in
Canada on SEDAR. Oncothyreon is under no obligation to (and expressly disclaims any such
obligation to) update or alter its forward-looking statements whether as a result of new
information, future events, or otherwise.

###

Investor and Media Relations Contact:

Julie Rathbun

Rathbun Communications

206-769-9219

ir@oncothyreon.com

ONCOTHYREON INC. 2601 Fourth Avenue, Suite 500, Seattle, WA 98121

Tel: (206) 801-2100 Fax: (206) 801-2101

ONCOTHYREON CANADA INC. 2011 — 94 St., Suite 200, Edmonton, AB, Canada

T6N 1H1

Tel: (780)450-3761 Fax: (780)463-0871

http://www.oncothyreon.com

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

-6-

 

Schedule N

Disclosure Schedule

[+] [Redaction continues for 46 pages]

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

 

Schedule O

Excluded Assets

Oncothyreon Canada Inc

Asset Listing by Department

As of September 30, 2008

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Dept	 	 	 	 	 	 	 	 	Purch	 	Purch	 	 	Net Book	 	 	 	 	 	 	Serial	 	 	Model	 	 	 	 	 	 	 	 	 	 	Metrolog	 
	Code	 	 	Number	 	 	Description	 	Date	 	Price	 	 	Value	 	 	Manufacturer	 	 	Number	 	 	Number	 	 	AFE#	 	 	Location	 	 	y #	 
	 
	 	1030	 	 	 	1149	 	 	Abra HR recruiting system 500
	 	28-Aug-97	 	 	20,396.50	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	2050	 	 	 	1023	 	 	Control Manufacturing CincomSW
	 	30-Dec-95	 	 	35,302.00	 	 	 	 	 	 	CINCOM	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	2050	 	 	 	1037	 	 	Cincom Software
	 	21-Jan-96	 	 	16,151.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	2050	 	 	 	1098	 	 	Cincom Software
	 	9-Feb-97	 	 	65,036.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	95-2-012	 	 	 	 	 	 	 	 	 
	 	2050	 	 	 	1438	 	 	Adonix Software
	 	21-Sep-07	 	 	98,723.61	 	 	 	 	 	 	Adonix	 	 	 	 	 	 	 	 	 	 	20127	 	 	 	 	 	 	 	 	 
	 	2050	 	 	 	1439	 	 	HP Computer for Adonix ERP 

HP Computers — Finance (2)	 	21-Sep-07	 	 	15,963.12	 	 	 	 	 	 	HP	 	ZUX71 507XK 	 	 	 	 DL380	 	 	20127	 	 	SRVRM	 	 	 	 
	 	9030	 	 	 	1287	 	 	FT900 115V Immersion Cooler
	 	9-Jul-00	 	 	6,236.74	 	 	 	 	 	 	8103370002	 	 	 	 	 	 	 	00-9-019	 	 	 	B215	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Biotage
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Isolera
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Purification
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 Sytem
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Single
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Channel
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Detector,
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Standard
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Arm,
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Variable
	 	9030	 	 	 	1455	 	 	Biotage Isolera System-ISO-1SV
	 	 	39667	 	 	25,287.10	 	 	Biotage	 	IS 10826015	 	ISO-1SV	 	 	39333	 	 	Edmonton	 	see notes	 	Detector
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	15/9/2008
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	additional
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	cost for
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Asset #
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	1455-
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	installation
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	and
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	training =
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	698.44USD
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	   SI
	 	9030	 	 	 	1457	 	 	Biotage Isolera System-ISO-1SV
	 	 	39706	 	 	698.44	 	 	Biotage	 	 	 	 	 	ISO-1SV	 	 	39333	 	 	 	 	 	 	note: part of 1455	 	0803220
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	283,794.51	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

Schedule P

Specifications

[+] [Redaction continues for nine pages]

 

			
	+	 	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00156-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00156-of-00352.parquet"}]]